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ABSTRACT
Gastrointestinal infections are a major cause of mortality and morbidity especially in the
developing world. It is nearly a century since it was first observed that antibodies were
present in the gut and it is now clear that secreted antibodies in the gut mucosa are
crucial for host defence against pathogens. In addition, they may be important in the
interaction of the host with commensal bacteria and oral vaccines.
The development of a new clinical technique, whole gut lavage, has facilitated the
collection of large amounts of gut fluid containing antibodies for the study of immune
responses in the Gl tract in health and disease.
The aims and related hypotheses of this thesis were:
a) To develop an antibody test that could be used as a tool to examine the gut humoral
immune response to bacteria of the gut flora. In order to develop the antibody test,
various antigens were prepared from the bacterial cell wall and their biological
potentials were examined with human and murine cell lines. These tests could be
combined with studies of other facets of gut immunity for which methods were already
available, in order to explore active immunity and tolerance in the mucosal and systemic
compartments.
b) To examine and compare humoral immunity in the gut and serum of immunologically
normal people from Edinburgh and Dhaka, in order to establish and test the following
hypotheses:
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1. In view of the probable higher antigenic load from a potentially contaminated
environment, there would be evidence of gut damage and inflammation in the healthy
people of Dhaka, and thus high levels of IgA, compared to people in Edinburgh.
2. In the developing country, the drive for production of high levels of humoral
responses to bacteria would have the additional effect that antibodies to other gut
antigens, such as foods, would be absent or of low titre.
By studying patients with chronic colitis (inflammatory bowel disease), it might be
possible to investigate how chronic gut inflammation affects specific antibodies and to
identify the sources of gut antibodies, ie. serum- derived or locally produced. Prompted
by the case of a patient with hypereosinophilic syndrome, high gut IgA concentrations
and ulcerative colitis, the stimuli for eosinophil migration into the gut and eosinophil
activation were examined and possible interaction with the regulation of humoral
immunity investigated.
My literature review concentrates on a monograph on The gut as an immune organ' and
illustrates the important features of intestinal immunoglobulins and antibodies. In the
first chapter a section on bacterial structure and antigens has been included and the
current knowledge on the regulation of eosinophil migration has been discussed. There
is a small section on an appraisal of the whole gut lavage procedure that has been
used in this thesis. Chapter 2 includes characteristics of patients and healthy volunteers,
laboratory methods and technical development. A pilot study to confirm technical
competence and reproducibility of methods is presented in chapter 3. Chapter 4
describes various gut damage and immune parameters in people from Edinburgh and
Dhaka. Despite higher antigenic load, no evidence of gut damage, but high IgA, was
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found in the Dhaka groups. Results of anti-endotoxin and antibacterial antibodies,
including those to various core types of E.coli LPS are presented in chapter 5. A section
on the purity of the antigens and their biological potential by producing nitric oxide,
inducing various cytokines in murine and human cell line have been presented. For the
first time it has been found that IgA antibodies against various core types of LPS of
E.coli are present in the gut, and their potential in the therapy of sepsis syndrome and
for oral vaccine development has been discussed. Chapter 6 describes the of humoral
immunity, role of gut bacteria, and cytokines controlling local and systemic immunity and
pathogenicity in chronic inflammatory bowel disease. Evidence has been presented in
chapter 7 to support the view that the source of IgG antibody detected in the gut of
patients with active IBD is locally produced and not serum derived.
The drive for production of a high humoral response to bacteria may be responsible for
absent or low titre antibodies to other gut antigens, such as food. The antigen-driven
bystander suppression or recently described Th1/Th2 paradigm is the purported
mechanism for these results. The implications of these results in therapeutics and
strategies for oral vaccine against infectious disease have been discussed in chapter 8.
The stimuli of eosinophil migration in to the gut and their role in the mucosal
inflammation of IBD have been discussed in chapter 9. For the first time it has been
shown that the eosinophil specific chemoattractant, eotaxin, is secreted into the gut
lumen; this may help in our understanding of the diseases related to eosinophil
accumulation.
The final chapter is an overview with some speculation on the relationship of the
findings to future developments.
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General Introduction
Gastrointestinal infections are a major cause of disease and death, particularly in the
developing world. It has been estimated that about 5-10 million deaths annually are
related to gastrointestinal infections. The discovery of aetiological agents including
bacteria, viruses, and protozoa, and the appearance of new diseases such as AIDS
have illustrated the enormous burden of infectious diseases throughout the world.
Historically, the field of immunology, in particular the study of humoral immunity,
developed in the context of resistance to infectious disease. The humoral immune
system is compartmentalised; antibodies in mucosal secretions, such as in the
gastrointestinal tract, differ from those in the serum; this was recognised by Besredka
in the early part of the century. The local humoral immunity concept was much clarified
after the discovery of IgA in 1953 and its isolation and characterisation in 1959. It is
now clear that secreted antibodies are crucial to the host/bacterial interactions and
are as relevant to commensal bacteria as to pathogens and to the development of
vaccines. However, despite the existence of multiple mechanisms which control
microbial populations at mucosal surfaces, the mucous membranes remain the most
important portal of entry for microbial infections. Therefore the ability to enhance
mucosal resistance to infection has enormous clinical importance.
The development of a new clinical technique- whole gut lavage (WGL)-has made it
possible to collect large amounts of gut-secreted antibodies, and to study the mucosal
humoral responses of normal and diseased individuals.
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Since infectious disease continues to be a major source of mortality and morbidity
throughout the world and especially in economically less privileged areas, a better
understanding of mechanisms of immunity continues to be one of the most urgent
needs in medicine. There is no doubt that a better understanding of mucosal
immunobiology will not only help in the effective treatment and management of
infections that have a mucosal phase, but it will also help us to understand other
diseases such as inflammatory bowel disease, food allergy and mucosal
hypersensitivity.
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Aim of the Thesis
My long- term research objectives are to investigate the gut immune system in the
context of health and disease of people in the Developing World, especially in the field
of malnutrition and diarrhoeal diseases. This Ph.D. project has formed a foundation for
my future work.
My aims, and related hypotheses, were as follows :
1. To develop antibody tests that could be used as tools to examine the gut humoral
immune responses to bacteria of the gut flora. These methods were to be combined
with studies of other facets of gut immunity for which study methods were already
available, to explore active immunity and tolerance in the mucosal and systemic
compartments.
2. To examine humoral immunity in the gut and serum of immunologically normal
people from Edinburgh and Dhaka, and test the hypotheses:
a) that there would be evidence of gut damage and inflammation in the healthy
people of Dhaka, in view of a high antigenic load from the contaminated environment
and thus very high levels of IgA; and
b) that in the developing country, the drive for production of a high humoral response
to bacteria would have the additional effect that antibodies to other gut antigens, such
as foods, would be absent or of low titre.
3. By studying patients with Inflammatory bowel disease, to investigate how chronic
gut inflammation may affect specific antibody responses.
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4. To use the data obtained from the above studies and establish whether the source
of gut antibodies are serum-derived or locally produced.
5. A patient with hypereosinophilic syndrome and ulcerative colitis with a very high
level of gut IgA, prompted me to examine the stimuli for eosinophil migration into the
gut, and possible interaction with regulation of mucosal humoral immunity.
The literature review for this thesis has concentrated on ' The gut as an immune
organ' which has been written as a short monograph, and has illustrated the important
features of intestinal immunoglobulins and antibodies. A section has been included on
bacterial structure and antigens, and previously-known information on serum
antibodies against gut bacterial antigens. Current knowledge on the regulation of
eosinophil migration is also discussed, and there is an appraisal of the WGL
procedure which has been a critical tool in many of my studies.
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Chapter 1
Review of Literature
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Section 1
The Gut as an Immune Organ
Introduction
The mucosal surfaces of the body, such as the gastrointestinal, respiratory and
genitourinary tracts, provide an effective barrier to the entry of potentially harmful
substances and infectious agents (McGhee et al, 1992; Staats et at, 1994). In Man the
mucosal surface area is over 400 square metres, which is more than 200-fold greater
than the surface area of the skin (McGhee et al, 1989; Holmgren et al, 1992). It should
be noted that more than 80% of this large mucosal surface is occupied by the
gastrointestinal tissues (i.e., gut associated lymphoid tissue [GALT]) . Considerable
experimental evidence supports the existence of an elegantly integrated mucosal
immune system that is largely distinct from the systemic immune system (McGhee et
al, 1992; Kiyono and McGhee, 1994; Kraehenbuhl et al, 1992; Ferguson et al, 1994).
The mucosal immune system has often been ignored on the assumption that it is a
branch of the systemic immune systems. Moreover, the difficulties involved in the
isolation and characterization of mucosa-associated lymphoid tissue (MALT) and
measurement of secretory antibodies from mucosal secretions added further to
confuse and limit our understanding of the intricacies of the mucosal immune system.
Much research on GALT has been conducted in mice. It is likely that the general
principles derived from the results of such experimental work are also applicable in
humans, but this has been proven for only a few aspect of immunity. Good studies of
the physiology and regulation of the human GALT are urgently required.
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Organization of the Gl Immune System
Recent advances in the field of immunology and cell and molecular biology provide
convincing evidence for a unique and independently operated immune system
(Takahashi & Kiyono, 1999; Table 1).
Table 1: Unique features of the mucosal immune system
A. Common mucosal immune system (CMIS)
1. Inductive tissues: GALT, NALT (nasal-associated lymphoreticular tissue)
2. Effector tissues: lamina propria and epithelial layer of the intestinal, respiratory, and
genitourinary tract glandular tissues
3. NewT-cell nests for thymus-independent cells: cryptopatches
B. Secretory IgA (S-lgA)
1. Dimeric and polymeric form of IgA
2. Neutralization and immune exclusion
3. Presence of high frequency of S-lgA+ B cells in GALT and NALT
C. Mucosal internets and intranets
1. Formed by Th1 and Th2 cells, S-lgA + B cells, and epithelial cells for the production
of S-lgA
2. Cross-regulation between epithelial cells and intraepithelial y5 T cells
D. Essential cytokines for the induction of IgA responses
1. TGF-p: isotype switching.
2. IFN-y: enhancement of the secretory component (SC) production.
3. IL-5 & IL-10: differentiation of S-lgA+ B cells.
4. 1L-6: generation of IgA plasma cells.
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Induction and Expression of Immunity
Overall, mucosal immune functions can be separated into induction and effector
phases. For the induction of antigen-specific immune responses at the mucosal
barrier of the Gl tract, one must consider the common mucosal immune system
(CMIS), which is composed of IgA inductive effector tissues (McGhee et al, 1992). Oral
immunization has been shown to be an effective way to induce mucosal immune
responses, because this antigen deposition pathway can effectively prime and
stimulate immunocompetent cells in the mucosal inductive sites in the Gl tract (i.e.
GALT, which consists of organised lymphoid follicles [Peyer's patches and lymphoid
aggregates]). After antigen presentation, antigen-specific lymphocytes travel from the
inductive site (i.e. GALT) and migrate to distant mucosal effector tissues (e.g. the
lamina propria region of the intestinal tract) via the blood circulation using specific
mucosal homing receptors (Picker, 1994;Phillips-Quagliata and Lamm, 1994). This
dynamic cell trafficking between IgA inductive and effector tissues are essential for the
generation of antigen specific immunity after oral immunization.
Inductive Tissues in the Gl Tract
Peyer's patches (PP) are concentrated in the distal ileum in Man and contain all the
necessary immunocompetent cells including CD4+ T cells that become Th1 and Th2
type helper cells, CD8+ T cells with cytotoxic function, IgA committed B cells (surface
lgA+; SlgA+B cells), macrophages and dendritic cells (DC). The epithelium overlying
PP has been termed a follicle-associated epithelium (FAE), because it contains
specialized antigen-sampling cells, termed microfold (M) cells. One of the major
functions of M cells is to engulf and pass intact antigens from the apical membrane
exposed to the lumen of the Gl tract to the basolateral surface, where the antigen
can interact with adjacent follicle-derived lymphoreticular cells including antigen-
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presenting cells (APC), CD4+ T cells and SlgA+ B cells to give rise to an immune
response (Kraehenbuhl et al 1992). M cells have been shown to be the portal of entry
for a variety of bacterial and viral pathogens (Krahenbuhl et al, 1992).
T cells present in the parafollicular regions of PP are mature and more than 95%
express the ap T-cell receptor (TCR), while a small subset, which remains poorly
characterized, exhibits a yS TCR (McGhee et al, 1992), The CD3+ CD4+ CD8" Th cells
make up approximately 60% to 65% of ap T cells in PP, while the remaining are CD3+
CD4"CD8+ (cytotoxic /suppressor) T cells (25%) and CD3+CD4"CD8" T cells bearing y5
TCR (5%) (Takahashi and kiyono, 1999).
PP have distinct B cell zones (follicles), which have a germinal centre containing about
8 to 15% of SigA + B cells (McGhee et al, 1992). The tissue also contains biologically
active antigen-presenting cells (APC) including follicular dendritic cells within the
germinal centre, interdigitating cells in close contact with the lymphocytes of
parafollicular zones (McGhee et al, 1992; Kato and Owen, 1994). Taken together,
mucosal inductive tissues, such as GALT or PP, consist of all the essential epithelial
(i.e. M cells) and lymphoreticular cells for the induction and regulation of mucosal
immune responses.
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Effector Tissues in the Gl Tract
As mentioned briefly earlier, after the initial stimulation of immunocompetent cells in
the PP, antigen-specific CD4+ Th1 and Th2 type cells, CD8+ T cells and SlgA+ B cells
leave the tissue via the efferent lymphatics. They are transported to the systemic
circulation through the thoracic duct, ultimately entering mucosal effector sites such as
the lamina propria (LP) of the Gl tract. This circular loop for dissemination of antigen-
activated T and B cells from the inductive tissue to the mucosal effector sites is usually
termed common mucosal immune system (CMIS) (Takahashi and Kiyono,1999). One
of the hallmarks of the mucosal immune response is the presence of antigen-specific
secretory IgA (SlgA) antibodies in external secretions (Ferguson et al, 1994). At least 3
types of cells are required for the formation of SlgA, these are: IgA enhancing
cytokines (e.g. IL-5, IL-6 and IL-10) producing Th2-type CD4+ T cells, SlgA+ B cells,
and epithelial cells residing in the effector tissue (Takahashi and Kiyono, 1999). This
will be discussed further in the next section of the review of mucosal antibodies.
The LP of the Gl tract consists mainly of T cells (more than 60%) and B cells (= 20%,
including plasma cells), with macrophages (= 5%) and other cell types (McGhee et al,
1992; Kiyono and McGhee, 1994). Approximately 70% to 90% of these plasma cells
produce IgA in Man and are responsible for antigen-specific SlgA found at mucosal
surfaces of the Gl tract (McGhee et al, 1989). As already mentioned, macrophages
may represent the major APC in LP and eosinophils (1% to 2%), and mucosal mast
cells (1% to 2%) may mediate hypersensitivity reactions (Takahashi and Kiyono,
1999). It has been shown recently that mast cells may also play an important role in
bacterial immunity (Malaviva et al, 1996).
10
Intraepithelial Lymphocytes
The lymphocytes residing between intestinal epithelial cells (i.e. intraepithelial
lymphocytes [IEL]) are the first T cells to contact luminal antigens that cross the
mucosa via the columnar epithelial cells in the M cell-independent manner (Takahashi
and Kiyono, 1999). Most gut IEL from humans, mice and rats are T lymphocytes,
which are largely CD8+ T cells (70% to 85%) (Kiyono and McGhee,1994). In addition,
three other minor populations of CD4+ CD8+ (double positive) T cells, CD4+ CD8" T
cells (helper type; Th) and CD4" CD8" (double negative) T cells are also present in
lELs. Murine lELs contain high numbers ofyST cells (40% to 60%) in addition to ap T
cells. The frequency of y5 T cells in IEL of humans is lower than that of murine lELs,
but still approximately 15% T cells under normal conditions (Takahashi and Kiyono,
1999). The number of y5 T cells significantly increases in pathological conditions such
as coeliac disease (Halstensen et al, 1989)
The precise functions of IEL in vivo are not yet clear, however several functions for
these cells have been described, including antigen-specific delayed-type
hypersensitivity, and natural- killer cell-like function (Klein and Kagnoff, 1984; Cuff,
1994).
The actual function of y5 T cell in the induction and regulation of mucosal immune
responses is currently under extensive investigation. Recent observations suggest that
IEL y8 T cells and epithelial cells maintain interrelationships in order to regulate
reciprocally growth and function of both cell types. For example, y5 T cells have been
shown to modulate growth and differentiation of epithelial cells via the keratinocyte
growth factor (Boismenu and Harvan,1994). On the other hand, epithelial cells have
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been shown to produce IL-7 and stem cell factor (SCF) that can provide activation
signals via IL-7 R expressed on y5 T cells (Fujihashi et al, 1996). These new findings
suggest that an interdependence named as mucosal intranet ((Takahashi and Kiyono,
1999) exists between epithelial cells and intraepithelial T cells at the mucosal surface
barrier (Kiyono and McGhee,1994; Fujihashi et al, 1996), which is critical for the normal
development of both y5 T cells and epithelial cells.
Cryptopatch
The Gl mucosa may also provide a new nest for the development of thymus-
independent T cell precursors. Cryptopatches (CPs) have been defined as discrete
aggregates containing approximately 1000 CD3" CD4" CD8", Sig", IL-7R+ c-kit+
lymphoid cells enmeshed in a network of cells with the appearance of dendritic cells
(Kanamori et al, 1996). So far, they have only been found in mouse intestine. There
are several studies ongoing to find similar structures in human small intestine.
Obviously, it will solve some conceptual problems regarding T cell development as
these novel lymphoid structures (CPs) are present in both severe combined
immunodeficient (SCID) and recombinase activating gene (RAG) 1 knockout mice
(Kanamori et al, 1996). Recently, it has been shown that CPs are a source of T
lineage precursors that migrate to populate the intestinal epithelial layer to become IEL
(Saito et al, 1998). It seems that extrathymic T cells developed from CPs could be an
important subset of mucosal T cells that contribute to the induction and regulation of
unique immune responses associated with the Gl tract.
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Secretory IgA (SlgA): Basis of Specific Humoral Immunity in The Gut
SlgA is the most important humoral antibody/immune mechanism for the protection of
the intestinal tract. Considering its enormous importance in mucosal humoral
immunity, a whole section (section 2) of this thesis is devoted to a review of mucosal
immunoglobulins and most details of SlgA are discussed in that section.
The Concept of Oral Tolerance
Ingestion of food protein or bacterial, viral and chemical antigens can result in
subsequent inability to mount a systemic immune response to the same antigen
following parenteral immunization (Challacombe & Tomasi,1980). This state of
systemic unresponsiveness is known as 'oral tolerance'. While the phenomenon of
oral tolerance has been extensively and exhaustively studied in animals, there is very
limited information on this phenomenon in Man (So far, only two studies have been
conducted in Man, one is from Alabama, Birmingham [Husby et al, 1994], another is
from the Edinburgh Gl lab by Dr Robert Boulton-Jones [personal communication]).
The mechanisms by which oral tolerance is mediated include the generation of active
cellular suppression (regulatory cells), clonal anergy, or clonal deletion; the
determining factor is the dose of antigen fed (Strobel and Mowat,1998; Ferguson et
al, 1994). Low doses favour active suppression, whereas higher doses favour anergy
and deletion (Weiner and Mayer, 1996). It has been proposed that a breakdown in oral
tolerance may be involved in the pathogenesis of coeliac disease and inflammatory
bowel disease (Brandtzaeg et al, 1989). It is vital therefore, to determine the role of
oral tolerance in disease pathogenesis in Man.
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Section 2.
Mucosal Immunoglobulins
2.1 Immunoglobulin A (IgA)
Introduction
A little more than 30 years ago IgA was identified as predominantly a mucosal
immunoglobulin (Chodirker and Tomasi,1963). The interest in secretory immunity has
broadened considerably since that time, but the study of the structure and functions of
IgA and the role of other mucosally secreted immunoglobulins, is still under active
research.
The mucosal surface acts as an interface between the external environment and the
internal milieu of the body. This represents the largest area of exposure to pathogens,
400 m2 compared to only 1.8 m2 for the skin (Childers et al, 1989). IgA is the
immunoglobulin class primarily responsible for humoral immune protection at this
large exposed surface. On a daily basis, the body synthesises far more IgA, 66mg/kg
body weight, than all other immunoglobulin classes combined (Mestecky and
McGhee, 1987).
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Biological properties of IgA
IgA has several unique properties which enable it to carry out its specialised function
in mucosal defence. Firstly, IgA can associate intracellular^ with J chain via a
cysteine residue in the C terminal 'tail' to form dimeric IgA (dlgA) (Koshland,1985)
which can bind to the polymeric immunoglobulin receptor (plgAR). The complex is
transported across mucosal epithelia (Mostov, and Blobel, 1982; Mostov, 1994) to be
released as secretory IgA (slgA). The IgA thus transported acts in the first line of
humoral defence at mucosal surfaces (Underdown and Sciff; 1986). Accordingly, it is
also the target of specific receptors and proteases produced by a number of
pathogenic bacteria in an effort to escape from IgA mediated immunity (Kilan et al,
1988). Blood contains a large quantity (2mg/mL) (Mestecky and McGhee, 1987) of
predominantly monomeric IgA; this circulatory pool is largely independent of the
mucosal pool in Man ( Jonard et al 1984). Secondly, IgA is known to bind to Fca
receptor (mFcaR,CD 89), which has been cloned recently (Shen et al, 1989, Monteiro,
et al 1990, Maliezewski et al, 1990) on the surface of eosinophils ( Monteiro et al
1993), neutrophils (Kurita et al, 1986) and monocytes/ macrophages (Shen et al, 1989)
thereby triggering effector responses. Thirdly, B lymphocytes and T lymphocytes
possess surface receptors for Fca through which immunoregulatory signals are
thought to be transmitted (Weisbart et al 1988). Fourthly, a receptor specific for slgA
has been identified on eosinophils which may have a role in eosinophil activation and
degranulation during the inflammatory response (Lamkhioued et al, 1995). Finally, IgA
is thought to activate complement through the alternative pathway (Lucisano-Valim
and Lachmann, 1991; Carayannopoulos et al, 1994). Owing to these functional
properties, especially the ability to be transported through cells, IgA not only plays a
role in host defence against viruses and bacteria, but is also potentially critical for
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neutralisation of intracellular viruses in tissues expressing polymeric immunoglobulin
A (plgA) (Mazanec et at, 1992), and destruction of the helminths, protozoa and other
eukaryotic parasites ( Grzych et at, 1993).
Structure and function of IgA
IgA is a tetrameric protein comprising of two identical light chains (k or X) and two
identical heavy chains (a ) which give IgA its specific biological properties. In man,
there are two IgA isotypes, lgA1 and lgA2 - defined by the differences in the a chain,
mostly due to a deletion in the hinge region at the mid point of the a2 chain ( Kerr,
1990). Within the a chains of the lgA2 subclass there are two allotypic variants,
lgA2m(1), and lgA2m(2). As immunological mediators, however, no major functional
differences have been assigned to the two subclasses. However, their ratio can vary
in the local population of plasma cells in different parts of the body, in different body
fluids and secretions. There is also considerable variation in antibody response to
different kinds of antigens and in certain diseases (Mestecky et at, 1989). The lgA1
subclass is uniquely susceptible to proteolysis by IgA proteases, released by certain
pathogenic bacteria, that manifest unusual substrate specificity for the hinge region of
the a1 chain, but not lgA2 (Plaut, 1983; Kilian et at, 1988). The lgA2 subclass thus
appears to have some advantage in resisting infections by these pathogens.
Moreover, lgA2 is more glycosylated than lgA1 suggesting a role of glycosylation in
protection of this secreted antibody in the mucosal milieu (Tomana et at, 1976).
In contrast, IgA in serum, is mostly monomeric lgA1, compared to the IgA produced by
the mucosal plasma cells that enters the local secretions which is relatively enriched in
16
lgA2 (Kett et al, 1986) ( although the magnitude varies in different mucous
membranes). For example, the relative amount of lgA2 increases along the intestinal
tract with distance from the stomach (Mestecky et al, 1989). As mentioned, mucosal
IgA is mostly dimeric, i.e. composed of two of the basic four chain immunoglobulin
subunits, so that the dimer possesses 4 a and 4 L polypeptide chains. The two
subunits of the dimer are joined covalently by disulphide bridges from two of the a
chains and by a disulphide bridge from the other two a-chains C termini to a third type
of polypeptide chain, the 17-kDa J chain (Mestecky et al, 1974; Garcia-Pardo et
a/,1981; Bastain et al, 1992). J chains, like immunoglobulin heavy chains and light
chains, are synthesised by plasma cells. These J chains are present in all oligomeric
immunoglobulins, i.e., all antibody molecules having more than one basic four-chain
subunit, for example, dimeric IgA and pentameric IgM. The J chain is thought to play
a role in initiating or stabilising the oligomeric structure and in providing a conformation
for IgA that enhances binding to the plgAR, also know as transmembrane secretory
component (SC) (Brandtzaeg and Prydz ,1984) . The single most important
distinguishing feature of secretory IgA with respect to serum IgA is the presence of
SC. In addition to its crucial role in the transport of plgA to mucosal secretions, SC has
been shown to confer resistance to proteolysis on secretory IgA, presumably an added
advantage in the gut mucosal environment (Brown et al, 1970).
IgA in mucosal defence
It is generally agreed that the role of mucosal IgA antibodies is to protect against
infectious micro-organisms and other foreign materials, which gain access through to
the mucosal linings of the body. This concept of protection by IgA is supported by
17
studies of oral (Sabin) vaccination against poliomyelitis, which induces intestinal IgA
antibodies ( Ogra and Karzon , 1971), as well as by studies of resistance to a variety
of other mucosal infections. In all these studies, it has been found that resistance best
correlates with the content of IgA antibodies in the local secretions (Liew et al, 1984;
Offit and Clark , 1985). In addition, it is a well established fact that patients with IgA
deficiency manifest an increased incidence of mucosal infections as well as other
disorders related to mucous membranes (Hanson et al, 1983). This background
supported the modern efforts to develop oral immunisation for intestinal pathogens like
Vibrio cholerae (Clemens et al, 1986). The observation that IgA can neutralise
intracellular viruses ( Mazanec et al, 1992) in the epithelial cells during transcytosis,
generates a recently developed technique (Chen et al, 1994) of using intracellular
antibodies to fight disease or inhibit intracellular mechanisms causing disease. In this
method, a gene therapy approach has been used, where the antibody genes are
introduce into the cell. This method has the strength that expression of the antibody
can be directed to the appropriate subcellular compartment. Although there is a clear
limitation that only plgA-expressing cell types can be targeted it may still be worth
pursuing for epithelial cell specific viruses and tumours. Finally, it is now recognised
that mucosal IgA is functioning in three different tiers to protect the host (Mazanec et
al, 1992). The innermost tier is the lamina propria, into which abundant plasma cells
secrete dimeric IgA. If IgA antibody binds antigen in the lamina propria, the antigen-
antibody complex can be directly excreted. The middle tier is the epithelial lining of the
mucous membrane. If IgA antibody in transit to the secretion meets an infectious
pathogen inside an epithelial cell, it can neutralise or excrete it. The outer tier, is the
well known place for secretory IgA, e.g. intestinal lumen , where it can bind to
microbes or their toxins and prevent attachment to and penetration through the
mucosal epithelium.
18
2.2 Immunoglobulin M (IgM)
IgM accounts for approximately ten percent of the immunoglobulin pool. The molecule
is a pentamer of the basic antibody four-chain structure. The individual heavy chains
have a molecular weight of approximately 65 000 and the whole molecule has a
molecular weight of 970 000 (Roit et al, 1996). It is a largely poly-reactive, natural
antibody confined to the intravascular pool and considered as a 'primary' antibody as
frequently seen in the immune response to antigenically complex infectious organisms.
In 1970, it was pointed out that IgM also appears in exocrine fluids because of active
secretion. Secretory IgM (SlgM) was later shown to be associated with SC (secretory
component) and to follow the same intracellular route through glandular epithelia as
SlgA (Brandtzaeg, 1970 & 1974 ; Brown et al, 1976). However, the concentration of
secretory IgM is substantially lower than that of secretory IgA because of the lower
proportion of IgM producing cells in the mucosa. It has been shown in a study that the
number of IgA and IgM-producing cells in various segments of normal human gut
mucosa varies considerably; these are as follows: in the upper small bowel, about
18% cells are IgM producing cells compared to 80% of IgA, and in ileum and large
bowel , these are 11% vs 84% and 6% vs 90% respectively (Brandtzaeg, 1985). It
may also be possible that IgM is not transported as efficiently as plgA because of a
molecular weight restriction in SC-dependent transport (Schiff et al, 1984).
Interestingly, a compensatory increase of IgM is observed in mucosal tissue and
secretions of IgA-deficient individuals (Plebani et al, 1983).
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2.3 Immunoglobulin G (IgG)
Immunoglobulin G (IgG) is the major immunoglobulin in normal human serum,
accounting for 70-75% of the total immunoglobulin pool (Roit et al; 1996). IgG
consists of a single four-chain molecule with a sedimentation coefficient of 7S and a
molecular weight of 146000. In Man, there are four subclasses of IgG, lgG1-lgG4.
These subclasses differ only slightly in their amino acid sequences. Most of the
differences are clustered in the hinge region and give rise to differing patterns of
interchain disulphide bonds between the four proteins. The most significant
structural difference is the elongated hinge region of lgG3 which confers on it a higher
molecular weight and may possibly give some enhanced biological activity (Roit et al,
1996). Having two identical binding sites in a single IgG molecule allows the antibody
to bind with high avidity to antigens with repeating epitopes or to aggregates of
antigens (Janeway and Travers , 1996; Male et a,I 1996). The flexibility of the IgG
molecule, inherent within the elbow bend of the Fab (between V and C domians), and
particularly within the hinge region allows for the two binding sites to cope with
antigenic epitopes with a range of spacing and orientations (Pumphrey, 1990). The
binding of antigen can result in direct inactivation of infectious agents by blocking of
functional sites with enzymic or receptor-binding activity. Other important properties of
IgG is that even if it becomes aggregated by antigens it can still interact with other
components of the immune systems by either activating the complement cascade or
by binding to Fey receptors on various cell types (Janeway and Travers, 1996). Both of
these processes can assist in the opsonisation of antigen and in the triggering of
inflammation and the enhancement of an immune response against infectious agents.
However, any consideration of the interaction of IgG antibodies with Fc receptors
needs to take account of the different types of receptor. In humans, there are three
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different classes of Fc receptors for human IgG (FcyR). Human FcR1 (CD64) can
bind monomeric IgG with high affinity and is expressed constitutively on macrophage
and monocytes and can be induced on neutrophils and eosinophils.
Human FcyRII (CD32) binds IgG only in complexed or polymeric forms and is widely
expressed on a range of cell types including monocytes, macrophages,
basophils, eosinophils, Langerhans cells, B cells and platelets. Human Fc Rill (CD16)
is also a medium to low affinity receptor and is expressed on macrophages,
and some large granular lymphocytes, killer (K cells), some natural killer cells (NK
cells), and neutrophils . This also can be induced on eosinophils and monocytes (van
de Winkle and Capel ,1993).
Another important property of IgG that has been recognised for many years is that the
biological half-life (3-4 weeks) is much longer when compared to other plasma
proteins, including other immunoglobulins such as IgM and IgA (3-7 days) (Janeway
and Travers, 1996; and Male et al, 1996). It has also been noted that the half life is
dependent upon the total concentration of IgG in the plasma. Thus if the
concentration of IgG is raised as in a condition such as myeloma, the half life is greatly
reduced while if the IgG concentration is lowered as in agammaglobulinaemia, the
half-life of administered immunoglobulin is extended. This suggested a saturable
receptor-driven mechanism for the control of the catabolic rate of IgG (Brambell et al,
1964). Thus a relatively constant plasma concentration of IgG can be maintained over
a fairly wide range of synthetic rates. IgG antibody is also distributed evenly between
the intravascular and extravascular pool, and notably in humans, all the subclasses of
IgG can cross the placenta and thus maternal IgG confers immunity in neonates.
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IgG concentration in mucosal secretions is approximately the same as or somewhat
greater than that of IgM. IgG is thought to enter the mucosal secretions non-
specifically via para-cellular transport or fluid phase endocytosis ( Ogra et al, 1994).
However, IgG-producing cells constitute 3% -5% of the immunocyte population in the
normal intestinal mucosa but a considerably larger contribution (12%-14%) is found in
the gastric mucosa ( Brandtzaeg et a/, 1985). This gastric contribution may be
affected by low grade gastritis even in a healthy subject (Valnes et a/,1986). In
certain diseases such as inflammatory bowel disease, an increased concentration of
IgG is found in whole gut lavage fluid. It has been shown that increased IgG in lavage
can be used as an objective measure of disease activity in IBD (Choudari et al ,1993).
The source of the high IgG concentration in the gut lumen is currently a subject of
debate. It has been postulated that this high concentration of IgG is serum-derived
because there is no special mechanism for transportation of IgG in the gut lumen. It
has also been shown in some other studies that there is evidence of local production
of high IgG in the gut lumen suggested as a ' second line defence1 in the mucosa.
(Brandtzaeg et al 1985). Lately, a pathway involving FcRn within intestinal epithelia
which may mediate the bi-directional transport of IgG across intestinal epithelia, has
been reported (Christ et al, 1997).
However, it is worth knowing the source of this increased concentration of IgG as it is
not only beneficial as a second line defence in the mucosa but also has inflammatory
potential.
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2.4 Immunoglobulin E (IgE)
IgE is the immunoglobulin found in lowest levels. The concentration of IgE in the
serum of a normal individual is of the order of 100-300ng/mL (Ogra et al, 1994).
However, IgE antibodies have unique biological activities. The antibodies sensitise
mast cells and basophilic granulocytes of homologous species and the reaction to
antigen to cell bound IgE antibody induces the release of various mediators that cause
allergic reactions. In fact, it is now known that there are two different receptors for IgE
on cells. The high affinity receptor (FcsRI) is found on the mast cells and basophils
and is the 'classical' IgE receptor. This receptor is part of the immunoglobulin
supergene family and quite distinct from the low affinity receptor for IgE (FceRII) found
on leucocytes and lymphocytes. The importance of the high affinity IgE receptor for
IgE is that although the serum half life of free IgE is only a few days, mast cells may
remain sensitised by IgE for many months. This is due to the high affinity of binding to
the IgE receptor FcsRI, which protects IgE from serum proteases.
Normally, allergic diseases are induced by exposure to extrinsic antigens such as
allergen; therefore IgE mediated allergic diseases are induced most frequently in the
respiratory tract, gastrointestinal tract, and the skin. In the gastrointestinal tract, the
IgE positive mucosal mast cells are involved in the pathogenesis of certain
gastrointestinal diseases (Brandtzaeg,1986).
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Section 3.
Gut bacterial antigens
In this section, various antigens associated with bacteria are discussed. In particular,
attention is given to the Gram-negative Enterobacteriaceae which are one of the major
aerobic inhabitants of the human gut. The genus Escherichia includes Escherchia coli
a typical member of Enterobacteriaceae and is closely related to a number of other
members in the family. I will discuss this organism in detail as a model of
Enterobacteriaceae.
It is generally agreed that micro-organisms are broadly divided into three groups:
Archea, Prokaryota and Eukaryota. Prokaryotes have a simple structure and true
bacteria come under this classification. The features of Prokaryotes include: a single
chromosome, absence of nuclear membrane, mitochondria and other organelles; they
divide by binary fission. On the other hand algae, protozoa and fungi are classified as
Eukaryotes. The more sophisticated intracellular features which are essential for
Eukaryotes are: multiple numbers of chromosomes, presence of organelles such as
mitochondria and nuclear membrane, and multiplication by mitosis (Carlile and Skehl,
1974). The Archea represents very primitive bacteria that are found in extremes of
environment: none of these is pathogenic.
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3.1 General structural features of bacteria
Cell envelope
The prokaryotic envelope can be defined as the complex of membrane-associated
macromolecules which together form the boundary between the inside and outside of
the cell. Basically, the cell envelope has two components: an inner cytoplasmic
membrane and outer layer cell wall / outer membrane.
Essentially, the cell envelope is responsible for a number of important functions: it
confers the cell shape, supports other structures of its own and gives rigidity; and
thereby protects the cell from the external environment as well as from osmotic lysis.
It also acts as a selective barrier and maintains ionic balance between inside and
outside (Poxton, 1993). There are considerable differences in the structure of the cell
envelope between Gram-positives and Gram-negatives. These are described later.
The cytoplasmic membrane:
The cytoplasmic membrane is the site of many major cellular functions (Jawetz et al,
1987), which include: a) selective permeability and transport of solutions, b) electron
transport and oxidative phosphorylation, c) secretion of extracellular hydrolytic
enzymes (exoenzymes) and d) biosynthesis of phospholipids and proteins.
Bacterial cell wall
Bacterial cells have high intracellular concentrations of inorganic ions and thus have
high osmotic pressure (5-20 atmosphere) (Hancock and Poxton, 1988). This leads to
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fluid influx into bacterial cell. Therefore, the cell walls need to resist cell lysis. Bacterial
cell walls are described in more detail later in this section.
Bacterial capsule
It is a well known fact that many bacteria are surrounded with a large amount of
extracellular polysaccharide. This polysaccharide layer is described under different
names depending on its condensation; some times it is known as the 'slime layer'.
When this layer is condensed and well defined, it is called a 'capsule' and when it is a
loose meshwork, it is then called a 'glycocalyx'.
The capsule protects pathogenic bacteria against non-specific host defences, notably
the action of complement and phagocytes. Thus, encapsulated bacteria are often
virulent, and their capsules are the virulence factors. Some bacterial capsules mimic
host macromolecules and thus camouflage the underlying bacterial antigens from the
host immune systems.
The Nucleus
Bacteria lack true nuclei since there is no nuclear membrane or mitotic apparatus as
found in eukaryotic cells. The DNA of the bacterial 'nucleus' is a single circle of double
stranded DNA and it is thus regarded as a single chromosome of about 1 mm in
circumference and 2-3x10 9 molecular weight. Under the electron microscope this
DNA can be seen as fibrils within the cytoplasm. The nuclear DNA is associated with
a small amount of RNA and RNA polymerase. The DNA is folded around an RNA core
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which seems to keep the DNA in its condensed form ( PettiJohn, 1976; Kleppe et al,
1979).
Ribosomes
Ribosomes in a bacterial cell are distributed throughout the cytoplasm and are the
principal site of protein synthesis. The cytoplasmic RNA of bacterial cells is of three
types, separated according to function: ribosomal (rRNA), amino acid transfer or
transfer RNA (tRNA) and messenger RNA (mRNA). Bacterial ribosomes have a
sedimentation constant of 70S compared to that of the human (eukaryotic) ribosomes
which is 80S. The aggregates of the 70S particle are attached to a common strand of
mRNA to form polysomes. In these, the mRNA determines the order of amino acids in
the peptide chains formed i.e. functions as the template for protein synthesis. Despite
the fact that there are many similarities between bacterial ribosomes and those of
human cellular tissues, differences still exist which allow the use of antibacterial agents
such as streptomycin which interferes with bacterial metabolism at the ribosomal level
without unduly affecting human cell ribosomal function (Jawetz et al ,1987).
Flagella and Fimbriae (Pili)
Flagella: These are thread like appendages, about 12-30 nm in diameter composed
entirely of protein called 'flagellin'. They are the organ of locomotion of bacteria. If the
flagella are mechanically removed, new flagella are formed and the motility is restored
within 3-6 minutes (Macnab and Aizawa, 1984). Three types of arrangement are
known: monotrichous (single polar flagellum), lophotrichous (tuft of polar flagella), and
peritrichous (flagella distributed over the entire cell).
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Bacteria respond to change in the environment by a mechanism called sensory
transduction (Tayler, 1983). Sensory transduction may occur due to chemotaxis,
phototaxis (movement towards light) or aerotaxis (movement towards optimum oxygen
concentration) ( Boyd and Siman, 1980).
Fimbriae (Pili)
Many Gram-negative bacteria possess rigid surface appendages called 'pili' (Latin
'hairs') or fimbriae ( Latin 'fringes'). These are composed of a protein subunit called
'pilin'. There are two types of Pili : 1) sex pili which are responsible for transfer of
genes from a donor to a recipient cell during bacterial conjugation; 2) ordinary fimbriae
which are responsible for adherence of bacterial cells to host cells. In certain
pathogenic bacteria such as enterotoxigenic E.coli, these are, known as colonisation
factor antigens (Beachey, 1980).
Structure of bacterial cell walls
The bacterium owes its strength to a layer composed of a substance called
mucopeptide or peptidoglycan. This layer will be described in detail later in the
chapter. However, bacteria are classified as Gram-positive or Gram-negative
according to their response to the Gram-staining procedure. This procedure, named
after its inventor, was developed in an attempt to stain bacteria selectively in infected
tissue. Bacteria that retain the crystal violet stain are called Gram-positive, while
bacteria decolourized by washing with acetone or alcohol, which subsequently take up
a red counterstain are called Gram-negative. The difference between Gram-positive
and Gram-negative bacteria is in fact due to differences in the structure of the cell
walls which determine whether the gram stain is lost or retained. Although, there are a
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number of variations in bacterial cell structure, in a simplistic view this can divided into
two groups:
1) Gram-positive bacteria: The cell wall is composed of a thick, cross linked
peptidoglycan layer which is much thicker than that of the Gram-negative bacteria
(20-30 nm vs 3-5 nm respectively). These bacteria also contain teichoic acid which
consists of a water soluble polymer of ribitol phosphate or glycerol phosphate residue
(Schleifer and Kandler, 1972). 2) Gram-negative bacteria: The cell wall is composed
of a thin, cross linked, peptidoglycan layer (figure: 1.1). The outer layer of the cell wall
of Gram-negative bacteria contains, lipolpolysaccharide molecules which form
'endotoxins'.
Figure 1.1: Gram -negative bacterial cell wall (Courtesy, Professor Poxton)
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The peptidoglycans
The basic building block of peptidoglycan is a disaccharide of /V-acetyl-D-glucosamine
and A/-acetyl-D-muramic acid, p linked (1-4) in long chains. A peptide side chain is
attached through an amide linkage to the acyl group of A/-acetyl muramic acid, which
in turn is cross linked to side chains on adjacent glycan chains by peptide cross
bridges. Variation in structure occurs in any of these three components. The glycan
chain of alternating /V-acetyl muramic acid and A/-acetyl glucosamine is the least
variable and found in almost all species of Gram-positive and Gram-negative bacteria,
with a few exceptions such as Mycobacterium and Nocardia species in which N-
glycolyl groups are found instead of N-acetyl groups (Poxton, 1993).
The peptide side chains of peptidoglycans are also well conserved. The main type
consists of a tetrapeptide of alternating L and D form amino acids: usually L-alanine ,
D-glutamic acid, L- lysine (or another diamino acid) and D-alanine. The alternative to
L-lysine, is either an isomer of di-aminopimelic acid (commonly meso-) or ornithine.
This diamino acid is species-specific and often used in classification.
Chemical structure and special features of Gram-negative bacterial cell wall.
Gram-negative cell walls contain three polymers which lie outside the peptidoglycan
layer: lipoprotein, outer membrane, and lipopolysaccharide (LPS).
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Lipoprotein
Molecules of an unusual lipoprotein serve to cross-link the outer membrane and
peptidoglycan layer. The protein component contains 57 amino-acids, representing
repeats of a 15-amino-acid sequence ; it is peptide linked to di-aminopimelic acid
residues of the peptidoglycan tetrapeptide side chains. The lipid component is
noncovalently linked to the outer membrane (Jawetz et al, 1987).
Outer membrane
The outer membrane is a typical lipid bilayer with phospholipid in the inner leaflet and
LPS in the outer leaflet. It is relatively permeable to small molecules, both hydrophilic
and hydrophobic. Proteins of the outer membrane are individually named after the
genes that encode them. In E.coli and Salmonella typhlmurlum the porin proteins
OmpC, D and F penetrate both faces of the outer membrane and form relatively non¬
specific pores that allow diffusion of small hydrophilic solutes through the membrane.
In addition to its barrier preventing the leakage of the periplasmic proteins, the outer
membrane protects the bacterial cell from bile salts and hydrolytic enzymes especially
in enteric bacteria. The protein pores render the outer membrane permeable to low-
molecular weight solutes while higher molecular weight molecules, such as antibiotics,
cannot enter easily. This may explain the higher antibiotic resistance of Gram-
negative bacteria.
Lipopolysaccharide (LPS)
Lipopolysaccharide is an essential component of the outer membrane of all Gram-
negative bacteria. Structurally, most types of LPS are composed of three distinct
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regions: the lipid A, the core oligosaccharide and the O-polysaccharide consisting of
long chains of repeating oligosaccharide units (figure: 1.2). This general
Figure 1.2 DiagrammaticrepreseasiictisofSaopd^ccsharide
Smooth form LPS
Iipid A Core tL-j»H*s4Ct5widc
Rough form LPS (or iipoo^ncstonde)
lipid A Core
(courtesy Professor Poxton)
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structure is typical of the LPS of E.coli and related enterobacteria and is often referred
to as the smooth or S-form chemotype. Mutants of enterobacteria that have lost the O-
polysaccharide region of their LPS molecule are described as rough and produce an
LPS molecule of R-form chemotype (Poxton ,1995). The O-specific chain (O antigen)
determines the O-serotype of the strain and in E.coli there are over 160 different
known serotypes.
The core oligosaccharide structurally and serologically is divided into two regions:
inner and outer core. In E.coli, there are five recognised core structures which show
great similarity to each other and to that of Salmonella species. The outer cores
consist of five hexoses (D-glucose, D-galactose and D-glucosamine in different
arrangements and configurations), but showing an overall degree of similarity and
cross-reactivity. These can be differentiated serologically by monoclonal antibodies
(Gibb et al, 1992). The inner part of the core is much more conserved, and it contains
the unique sugar called KDO (2-keto-3-deoxy-D-manno-octonate) and heptose
trisaccharide as well as phosphate substituents . There is little variation between
closely related species (figure: 1.3).
Safmoneffa Ra
E. coli R1
E. caff R2
E. coH R3
E, COM R4-
£ coii K-12
Figure 1.3: Chemical composition of various core types of LPS ( courtesy Professor
Poxton)
The lipid A region is much more conserved and has a unique fatty acid called (3-
hydroxymyristic acid. Lipid A is often highly toxic and it is the biologically active part of
the lipopolysaccharide. The minimum structure of the LPS molecule, which is
essential for the viability of the bacteria is equivalent to the Re-form LPS (Rietschel et
at, 1990).
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The role of lipid A and inner core regions of lipopolysaccharide in pathogenesis
of sepsis
Different parts of the LPS molecule have got different biological activities and thus
pathogenic potentials. The roles of these parts of LPS are described in detail.
The Endotoxin
The signs and symptoms seen in patients suffering from Gram-negative sepsis can
be reproduced in animals by the injection of a suspension of killed E.coli or
Salmonella bacteria; cultured suspension is less effective in reproducing the
symptoms of shock (Raetz, 1991). This observation coined the term 'endotoxin'
because it was found that a portion of the bacterium itself, rather than a secreted
'exotoxin' was responsible for the pathological process. Bacterial endotoxic shock
(septic shock ) is a serious medical condition associated with high mortality. Studies
have identified the bacterial product responsible for producing fever and shock
associated with Gram-negative bacteria. The lipid A-KDO portion of LPS is necessary
to reproduce the signs and symptoms of sepsis (Young et al 1991). It was recognised
that infections with a variety of gram-negative organisms produce very similar
symptoms as they have very similar Lipid A . On the other hand, the action of an
'exotoxin' is quite specific.
The effects of endotoxin administration are numerous and include, fever, myocardial
depression, coagulopathy, hypotension, acute respiratory distress and multi-organ
failure (Shenep, 1992). It is well known that the capacity of LPS to produce such a
variety of symptoms is due to release of cytokines and other mediators, which in turn
are responsible for the activation of the acute phase response. In acute phase
35
responses there are a number of processes, e.g, haematological, metabolic and
immunological, which become activated (Glauser et al, 1991). Interestingly, in health
as well as disease, the host is constantly exposed to endotoxin; the symptoms related
to the endotoxin insult depend upon the dose of LPS and the immune status of the
host. In fact, several mechanisms have evolved for scavenging and detoxifying LPS in
small amounts as well as responding to major insults of toxin. Great progress has
been made in the last decade in the understanding of how endotoxins react with
various components of the immune system.
Stimulation of mammalian cells and production of proinflammatory mediators
by endotoxin
Endotoxin binds to a number of surface receptors on macrophages, monocytes and
neutrophils, and also with plasma and intracellular proteins (Morrision, 1990; Lei and
Chen, 1992). The binding of LPS to macrophages is greatly increased if the LPS forms
a complex with a large acute phase protein; the LPS-binding protein (LBP) (Tobias et
al, 1993). These LPS-LBS complexes then bind to the macrophage CD14 molecule
(Wright et al, 1990), which stimulates macrophages to produce the powerful
proinflammatory mediators, like nitric oxide (NO), tumour necrosis factor (TNF),
interleukin-1 (IL-1) and interleukin-6 (IL-6). Overstimulation of these cytokines,
together with LPS induced effect on the clotting and complement cascades, results in
the clinical symptoms of 'endotoxic shock' which is synonymous with 'sepsis'. Severe
sepsis causes disseminated intravascular coagulation and multiple organ failure
(MOF) leading to death (Bone, 1993).
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Anti-LPS antibodies
Antibodies produced to the various domains of the LPS molecule have different
specificity. For instance, antibodies to lipid A and the inner core are likely to be cross-
reactive with LPS molecules from several different species of Gram-negative bacteria,
because the lipid A-inner core region of LPS is conserved. Conversely, antibodies to
the O-polysaccharide may only react with the LPS of specific serotypes (Poxton,
1995).
The major impetus of LPS antibody research, was to find an immunotherapeutic agent
to treat Gram-negative sepsis or endotoxaemia. This was prompted by an elegant
report of Zeigler and colleagues in 1982 showing that passive administration of
plasma from donors immunised with the 'J5' mutant of E. coli (which possesses an
LPS of Rc like chemotype) had a beneficial effect on patients with sepsis (Ziegler et
al, 1982).
For the last decade, there has been considerable research on anti-LPS antibodies.
Various methods and a vast range of immunisation protocols have been used to
produce a wide range of antibodies. These vary from broadly cross-reactive to
recognition of a single antigen. It has also been shown that it is possible to produce
monoclonal antibodies of the IgM and IgG classes with differing proportions of all the
isotypes of IgG (depending on the study). It has also been recognised that it is
possible to demonstrate cross-species protection in a range of in vitro and in vivo
assays (Di Padova et al, 1993). Conversely, it has not been possible to demonstrate
conclusively an antibody which binds to all LPS molecules and is also cross-reactive
between species (Poxton, 1995). Several techniques have been tested to measure
antibodies binding to LPS over the last couple of years. Also improvements have been
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made in antibody production against LPS, by structural integration and thereby
enhanced antigenicity.
Serology of anti-LPS antibodies
The 'Widal' reaction is a typical serological test for enteric fever caused by Salmonella
typhi and S. paratyphi. The test measures antibodies to the Salmonella O-antigen, Vi
antigen and H antigen by an agglutination technique. Many more serological studies
for the detection of antibodies to LPS or O-antigens of a wide range of Gram-negative
bacteria have been developed over the last two decades. Most of them employ the
ELISA technique but few of them have been exploited commercially (Poxton, 1995).
It has been found that the measurement of 'anti-endotoxin antibodies' is important in
various clinical settings. Some studies have suggested that high levels of antibodies to
endotoxin are good prognostic indicators in sepsis patients and that levels of passively
administered antibodies should be monitored ( McCabe et al, 1972; Pollack et al,
1983). There has been a great deal of interest in Edinburgh in LPS antibody research,
especially to find an anti-endotoxin antibody from blood donor plasma for therapeutic
use ( Barclay, 1990; Barclay and Scott, 1987).
Anti-LPS core (EndoCAb) ELISA - antibody to endotoxin
An ELISA technique for the measurement of cross-reactive, anti-LPS/endotoxin
antibodies has been developed by Barclay and colleagues. This is used for screening
blood donors for high levels of these antibodies, with a view to manufacture of
therapeutic hyper- immune intravenous IgG. This technique has now been used in a
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variety of situations for the indirect measurement of endotoxaemia (Barclay ,1990).
Basically, the method employs a mixture of four 'rough' mutant LPS in a polymyxin
ELISA. The hypothesis is that exposure to systemic endotoxin will result in a decrease
in systemic antibody due to complexing of LPS with endotoxin and clearance.
Subsequent to this decrease, levels can recover and rise to exceptionally high values.
By observing the dynamics of the antibody levels it is possible to use them as a
prognostic indicator e.g. depressed IgG and /or absence of the characteristic rise
indicates a poor prognosis in septic patient. This method can also be used for
monitoring levels during administration of therapeutic antibody (Poxton, 1995). Barclay
and his group investigated this anti-endotoxin antibody technique in a variety of
clinical settings. These include: patients with pancreatitis ( Windsor et at, 1989), gut
mucosal hypoperfusion in surgical patients (Mythen et at, 1993), patients with sepsis
syndrome (Barclay et at, 1989), a patient with HUS (haemolytic uraemic syndrome;
(Heyderman et at, 1994) and in victims of sudden infant death syndrome (Oppenheim
et at, 1994). Poxton and his colleagues also attempted to measure antibody to LPS of
a colonic Bacteroides species, Gram negative-anaerobic organisms making up a
major part of the gut flora. The idea behind this approach was that Bacteroides LPS is
more relevant than enterobacterial LPS, as much of the systemic endotoxin originating
in the gut (large bowel rather than small bowel) has been translocated during periods
of shock-induced gut ischaemia (Allan et at, 1995). This promising area needs further
research.
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Intestinal immune response to E. coli
As was mentioned earlier, the close relationship between E.coli and other
Enterobacteriaceae, especially Shigella and Salmonella spp, suggests that the
immune responses to these organisms may have much in common. It is worthwhile
knowing the details of the host immune response to these organisms. Moreover, as
E.coli is a major pathogen of neonates and young children, an understanding of these
immune mechanisms may offer potential strategies for the protection of those at risk.
The nature of exposure to E.coli ranges from superficial gastro-intestinal colonisation
to a pathological systemic infection. The range of immune responses is equally wide.
It is important to know the antigenic and virulence factors of E. coli bacteria.
The antigens of E.coli
Like other Gram-negative bacteria, E.coli has antigens and virulence factors in the cell
envelope, LPS and capsules. In E.coli, many of the strains produce polysaccharide
capsules (capsular antigen K) that are important virulence factors which help the
bacteria to evade or resist non-specific host defence during the early phase of
infection. Specific anti-K antibodies are necessary for optimal opsonization of K
antigen bearing strains. K-antigens, particularly K1, have relatively low
immunogenicity, because they share partial homology with certain host structures
(Silver et al, 1988).
O- polysaccharide (O-antigen)
As has already been mentioned the structure of the lipid A-inner core region of LPS is
extremely constant while the outer core and O-polysaccharide chains vary
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considerably. The variation may occur even within the same species. However, the
combination of 0-, H-(flagellar) and K- (capsular) antigens defines the serotype of
E.coli. Apart from its five outer core structures, E.coli has 170 different O-antigens.
These O-antigens can be differentiated by their reaction with polyclonal rabbit antisera
(Orskov & Orskov, 1977). Precise chemical analysis of the O-polysaccharide from
E.coli of the same O-serogroup shows heterogeneity. For example, three different
chemotypes have been classified as 01 and the 170 different O-antigens may be an
underestimate of the true variation (Gupta, 1992; Jann et al, 1992).
There is a curious relationship between the pathogenicity of various E.coli strains and
their O-serogroups. In spite of the large number of O-antigens, a few appear to
predominate among isolates recovered from specific diseases, as compared with
those isolated from the faeces of normal individuals (Robert et al, 1975). Thus, a very
limited number of O-serotypes are associated with E.coli that cause diarrhoea and
these do not in general overlap with those frequently associated with urinary tract
infection and sepsis (Orskov & Orskov, 1977; Orskov et al, 1982). It has been noted
that the O-antigens of enteroinvasive E.coli, which cause a dysentery-like disease, are
chemically similar to those of Shigella, classical agents of bacillary dysentery (Jann &
Jann,1984).
It seems that there is a constant relationship between various O-antigens with
particular diseases. These associations have given rise to the clonal theory of the
pathogenicity of E.coli. This postulates that pathogenic strains of E.coli are the
descendants of a few ancestral lines that somehow acquired pathogenic traits (Orskov
& Orskov, 1977; Orskov et al, 1982). The ability of these strains of E.coli to cause
certain diseases is not necessarily due to their particular O-antigens, but rather the
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genes they carry for other traits that enhance their pathogenicity, such as enterotoxins
and colonisation factors. Whether the specific O-antigens of these strains have a role
in the disease process has not been determined.
Fimbrial antigens
There is a clear correlation between bacterial adhesion and pathogenesis (Krogfelt,
1991). About 70 per cent of wild E. coli express mannose-sensitive type-1 fimbriae.
Fimbriae such as K88, K99 and colonising factor antigen (CFA) are associated with
diarrhoeal diseases.
Other antigens
E.coli, like other Gram-negative bacteria has outer membrane proteins, enterobacterial
common antigens, lipoprotein and a-haemolysin. a -haemolysin is secreted by the
most haemolytic strains of E.coli. Production of a-haemolysin is an important virulence
factor and anti-a-haemolysin antibody titre correlates closely with the degree of
invasiveness of infection (Emody et al, 1982).
The antibody response in enteric Escherichia coli infections
Enterotoxin-producing Escherichia coli
Enterotoxin-producing E.coli (ETEC) is one of the major causes of infant and
childhood diarrhoea in developing countries. Studies conducted in a large diarrhoeal
diseases hospital in urban Bangladesh, showed that ETEC is responsible for diarrhoea
in about 15 percent of cases of children under five (Hoque et al, 1994). This
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organism is the commonest cause of traveller's diarrhoea. The diarrhoea is due to
production of heat labile enterotoxin (LT) and/or heat stable enterotoxin (ST). The ST
is poorly immunogenic. In order to produce diarrhoea, ETEC must also adhere to small
intestinal mucosa and in humans various fimbrial (CFA) antigens have been described.
Most patients with diarrhoea due to LT-producing ETEC can be shown to develop
serum and local antibody response to LT, CFA and LPS, which confers homologous
immunity, while asymptomatic acquisition of the organism is generally not associated
with an immune response (Stoll et a/, 1986). Studies in Bangladesh, showed that in
paired samples from convalescents, an eight to nine fold rise in anti-CFA and a four
fold rise in anti-LT can be demonstrated (Clemens et al, 1990). Immunity appears to
be primarily directed towards CFA-type fimbrial antigens, and heterologous protection
is not conferred where the only common antigen is LT (Levin et al 1979). Antibodies to
LT and CFA appear to afford synergistic protection from diarrhoea.
Vero-cytotoxin-producing Escherichia coli
Vero-cytotoxin-producing E.coli (VTEC) are an important cause of diarrhoea in some
areas and can cause severe life-threatening complications. Most important are:
haemolytic-uraemic syndrome (HUS), and haemorrhagic colitis. At least two Vero
toxins, VT1, and VT2, are associated with disease in humans and VTEC isolates may
produce either or both of these toxins (Karmali,1989). Antibodies to bacterial
components and to Vero cytotoxin can be detected in infection with VTEC. These
antibodies, however, are either not found, or found in low titre, in healthy individuals
(Kishore et al, 1992). The main immune response in VTEC infection is an IgM
response to 0157 LPS, and detection of such antibodies is useful in providing
evidence of infection where faecal VTEC or Vero cytotoxin cannot be demonstrated
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(Chart et al, 1989). Antibodies to both VT1 and VT2 can be detected by ELISA.
However, most patients with E.coli 0157:H7 infection develop a response to VT1.
Enteroinvasive Escherichia coli
Enteroinvasive E.coli (EIEC) causes dysentery similar to shigellosis by an invasive
mechanism that depends on the presence of certain outer membrane proteins (Gross,
1991). There is a paucity of data in human studies. However, in animal models, the
intestinal secretory IgA (SlgA) response is the principal component of the immune
response which confers immunity to reinfection.
Enteropathogenic Escherichia coli
Enteropathogenic E.coli (EPEC) is one of the common causes of diarrhoea in the
young and children in developing countries. The diarrhoea is due to the capacity of
EPEC to adhere and efface the microvillous surface structure of intestinal epithelial
cells. In a considerable number of strains localised adhesion is associated with the
presence of a plasmid-encoded 94-kDa OMP, EPEC adherence factor (EAF). Studies
show that recipients of EAF-positive strains develop both serum and breast milk
antibody to this protein. The antibodies have been shown to inhibit bacterial
attachment in vitro, and to protect individuals from diarrhoea after challenge with EAF-
positive strains (Gray, 1997).
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Cell-mediated immunity in Escherichia coli infections
The humoral response to E.coli has been studied extensively while cell-mediated
immunity has received less attention. However, the gastrointestinal tract contains
numerous immune effector and regulatory cells of lymphoid and myeloid origin that are
thought to play a critical role in host defence against enteric infection. Studies have
shown that lysates of enteropathogenic Escherichia coli (EPEC) inhibit lymphokine
production by mitogen-activated human peripheral blood and lamina propria
mononuclear cells (Klapproth et al, 1995 and 1996). Recently, a further study by the
same group has delineated the mechanisms of the alteration of the cytokine
production (Malstrom and James, 1998). They showed that pre-exposure to EPEC
lysates inhibited mitogen-stimulated interleukin-2 (IL-2), IL-4, and gamma interferon
(IFN-y) production by the murine spleen cells, but IL-10 production was increased. The
inhibition was not due to increased apoptosis and was not also blocked by neutralizing
antibodies against IL-10 or transforming growth factor (3 (TGF-p). They went on to do
further experiments with other toxin-producing E.coli and related strains of bacteria
and noted their effect on various human cell lines. They conclude that EPEC and
certain related strains of bacteria have the potential to regulate cytokine production
selectively by peripheral lymphocytes and gut-associated lymphoid tissue in both
human and murine cells by mechanisms that appear to act directly on lymphocytes
without increasing apoptosis.
Finally, infection and colonisation by E.coli is associated with a variety of host immune
responses. These responses have broad significance for an understanding of the host
-microbe interaction. There is a great deal of literature about E.coli and the antibody
responses against it, but in most of the studies there is poor or no real quantitation of
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the data. However, there are limited data on intestinal antibody responses against
E.coli and other gut bacteria, mainly from Dhaka ( Stoll et al, 1986), from Sweden
(Holmgren & Svennerholm, 1992), and from Edinburgh (Ferguson, et al, 1994). This
area will be discussed further later in the thesis and related to my research findings.
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Section 3
Cell migration and Eosinophils
Cell migration
The circulatory and migratory properties of white blood cells have evolved to allow
efficient surveillance of tissues of the body for infectious agents and rapid
accumulation at sites of tissue injury and infection. Among the white blood cells,
lymphocytes continually patrol the body for foreign antigens. They re-circulate from
blood through tissue, into lymph, and back to blood. Granulocytes and monocytes,
also emigrate from the blood stream in response to molecular changes on the surface
of the blood vessels that signal injury or infection. However, unlike lymphocytes they
cannot re-circulate. The nature of the stimulus determines whether lymphocytes,
monocytes, neutrophils, or eosinophils will be recruited and predominate. The stimulus
also exercises specificity in the molecular signals that control traffic of particular
leukocyte classes (Springer, 1994).
General morphologic features of eosinophils
Eosinophils, like neutrophils and basophils are a type of granulocyte derived from
bone marrow. This group of cells has some unique features which
distinguish them from others by their morphological features, intracellular constituents,
products, and association with specific diseases. They comprise 2-5% of blood
leucocytes in healthy, non-allergic individuals. Eosinophils are similar in size to
neutrophils but have bi-lobed nuclei and distinctive cytoplasmic granules. The
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numerous specific granules, with their content and structured packaging of cationic
proteins, are the distinguising marker of these cells. Although eosinophils
in the blood are easily available for quantitation and investigative studies, they are in
fact predominantly tissue-dwelling cells; several hundred times as many as in blood
(Weller, 1991). These cells are abundant in the tissues with an epithelial interface with
exterior, eg. G-l tract, respiratory tract etc. The actual life span of eosinophils is not
known, but they live longer than neutrophils and may survive for weeks within tissues
(Spry,1988).
Intracellular constituents
The specific granules of eosinophils contain lysosomal hydrolyses as well as most of
the cationic proteins unique to eosinophils. The crystalloid core of the granule is
composed of major basic proteins (MBP), and the non-core matrix contains eosinophil
cationic protein (ECP), eosinphil-derived neurotoxin (EDN), and eosinophil
peroxidase(EPO) (Weller,1991).
The MBP is the most abundant cationic protein in eosinophil granules; it is a 14,000-
dalton protein rich in arginine residues. It has no recognised enzymatic activity, but is
toxic to helminthic parasites, tumour cells and host cells (Butterworth et al, 1979;
Gleich et al, 1986). The ECP is a markedly cationic polypeptide of between 18,000 and
21,000 daltons with bactericidal (Lehrer et al, 1989), and helminthotoxic activities
(Ackerman et al, 1985). Like MBP, it is also toxic to the host cells.
Eosinophil derived neurotoxin (EDN), a protein of 18,600 dalton, has some homology
with the peptide sequence of ECP. As its name indicates, it is capable of damaging
human nerves (Gleich et al, 1986). Unlike, myeloperoxidase of neutrophils and
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monocytes, eosinophil peroxidase (EPO) consists of two polypeptides of about 15,000
and 55,000 daltons. It is toxic to helminthic and protozoan parasites, bacteria, tumour
cells and host cells (Jong & Klebanoff, 1980).
In addition to the preformed granule proteins, eosinophils synthesise and release
bioactive mediators in response to stimulation. These include platelet-activating factors
and eicosanoids, particularly leukotriene C4 (Weller,1991).
Cell surface receptors
Eosinophils, like other granulocytes, express receptors and ligands on their cell
surfaces. The eosinophil receptors for immunoglobulin G (IgG) is the low affinity Fc
receptor FcyRII (CD32) in contrast to neutrophils and monocytes which bear Fc
receptor FcyRII and FcyRIII (CD 16), and FcyRI (CD64) and FcyRII respectively
(Weller, 1991). Eosinophils also have receptors for IgE, which are of the low affinity
type, quite different from the high affinity classical receptors (FcsRI) expressed on
mast cells and basophiles (Capron et a/, 1981). The eosinophil receptor for IgA binds
secretory IgA preferentially and more potently rather than the monomeric form of IgA
(Abu-Ghazaleh et at, 1989). Because eosinophils localise to the mucosal surfaces of
the respiratory and gastrointestinal and genito-urinary tract, their IgA receptors can
engage secretory IgA at these sites.
Eosinophil receptors for complement components include those for C1q,
C3b/C4b(CR1), iC3b(CR3), and C5a. The structure and affinity of the eosinophil C5a
receptor differ from those of the C5a receptor on neutrophils (Gerard et at, 1989).
There are receptors identified on eosinophils for cytokines which are very important for
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eosinophil maturation and chemo-attraction. These are: interleukin-3, (IL-3),
interleukin-5 (IL-5), and granulocyte-macrophage colony stimulating factors (GM-CSF).
Recently, an eosinophil-specific chemokine was identified, this protein molecule not
only causes chemotaxis but also is involved in eosinophil-mediated tumour killing
(Rothenberg et al 1995).
Eosinophils also have receptors for lipid mediators like platelet-activating factors and
leukotriene C4. The later are also chemoattractants for eosinophils and they can
stimulate the degranulation of eosinophils, as well as the formation of superoxide
anions and other oxygen derivatives. Eosinophils also have receptors for
glucocorticoid and oestrogen (Weller,1991). Mature eosinophils retain the ability to
synthesize proteins, including both the cell surface glycoprotein CD4 and class II
protein of the major histocompatibility complex (HLA-DR) (Weller, 1991). They have not
only the capability to take part in immune responses but also to synthesize and
elaborate cytokines (Wong et al, 1990). In addition, eosinophils also express other cell
surface molecules involved in cell-cell interactions, such as adhesion molecules;
these integrins and cell adhesion molecules enable eosinophils to migrate from blood
to inflamed tissues. Eosinophils express intercellular adhesion molecule-1 (ICAM-1),
vascular adhesion molecule-1 (VCAM-1), a4pi,a4p7, and a6pi (Wardlaw et a/,1996).
These adhesion molecules play important roles in the migration and expression of
functional responses of eosinophils. However, some of the adhesion molecules as yet
have only been described in animal models. The presence and the importance of
these adhesion molecules in eosinophil function in humans remains to be defined.
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Production and activation of eosinophils
The development and differentiation of eosinophils occurs in bone marrow and is
prompted by three important cytokines. These are GM-CSF, IL-3 and IL-5. The GM-
CSF and IL-3 also stimulate other leukocytes whereas IL-5 acts more specifically on
eosinophils. Studies showed that IL-5 is the principal cytokine responsible for
increased eosinophil production (Weller,1991). Eosinophils, like lymphocytes are
subject to processes of cellular activation. Several morphological, biochemical and
functional studies demonstrated that there are significant differences in normal
eosinophils from those from patients with eosinophil related disease. Eosinophils from
patients with eosinophilia are morphologically distinct. They have cytoplasmic
vacuoles, altered in size and number in granules and loss of granule core containing
major basic proteins (Dvorak et al, 1990). They are also less dense than normal
eosinophils when separated by density gradient centrifugation. These hypodense
eosinophils have been found in the blood of patients with asthma, helminthic
infections, neoplasia and idiopathic hypereosinophilia (Gleich and Adolphson,1986).
Role of eosinophils in health and disease
It is recognised that eosinophils have specialised roles in host defence against non-
phagocytable multicellular parasites. They contribute to antiparasitic host defence by
several means, including the release of their cationic granule protein which is highly
toxic to mammalian cells. Some of the mechanisms employed in host defence,
especially by releasing toxic proteins, are sometimes detrimental to the host's own
cells.
The potential role of these cells in inflammation of the respiratory tract as well as in
the gut is well recognised. The role of these cells in inflammatory bowel disease and
coeliac disease is less clear (Sarin et al, 1987; Dvorak, 1980; Talley et al, 1992). The
pathogenic role of eosinophils and their pro-inflammatory protein in disease has not
been established firmly, because of the paucity of studies in this area. There are some
questions still un-answered, for instance, how do eosinophils accumulate selectively in
allergic diseases and how do they accumulate in high numbers despite being a
minority cell type in the circulation? This area will be discussed later in the chapter in
relation to my findings.
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Section 4
An Appraisal of the Whole Gut Lavage (WGL)Procedure for Diagnosis of
Mucosal Inflammation and Protein/Blood loss from the Gut
The WGL procedure which is routinely carried out as a bowel preparation prior to
clinical investigations (e.g. colonoscopy, barium enema) has provided a novel
opportunity for investigating gut mucosal inflammation and protein or blood loss from
the gut. I have used this 'clinical tool' for my research work. It has already been shown
from this Laboratory (Gl Lab) that this procedure is highly relevant to patient
management and has potential for further research in clinical gastroenterology. This
procedure has many advantages when compared with the more traditional
investigative methods, such as those involving invasive traumatic procedures (i.e.
endoscopy and biopsy) or faecal collection, but there are also some disadvantages.
The WGL procedure involves the administration of an isotonic solution which is not
absorbed from the gut. It is safe and well tolerated by patients and it clears the gut of
faecal debris and leads to the production of a clear fluid per rectum within 3-4 hours.
This procedure is non-invasive and in occasional cases involves passing a nasogastric
tube for patients who cannot tolerate the oral lavage procedure. There are no gas-
producing substrates in the lavage solution (previously mannitol solution was used for
bowel preparation, which is fermented and produces hydrogen), so, subsequent
patient investigations or therapeutic procedures such as diathermy are completely
safe. Moreover, the WGL procedure is commonly used prior to colonic examination.
The collection, processing and analysis of the resultant fluid does not require further
patient involvement or inconvenience. The fluid can be processed, for example, as
serum and urine are processed; thus filtration, centrifugation, or direct addition of
53
preservative into solution are all easily accomplished. These procedures are much less
easily done with faecal specimens, which cannot be immediately dealt with in these
ways. After adequate treatment with protease inhibitors, WGL fluid can yield valuable
information in both healthy and diseased subjects by measurement of endogenous
secretions present in the WGLF. Since the whole gut is perfused during the procedure,
inflammatory lesions in areas which are difficult to investigate by direct access (for
example, any pathology in the ileum) yield products that can be detected.
It has been confirmed by sequential analysis of WGL samples for different proteins
that there is a steady state perfusion once the clear fluid is obtained (Brydon, 1993;
Sallam,1994, Ferguson et al, 1995 ;Croft, 1996). This however, does require
monitoring of the patient by trained nursing staff to maintain the correct fluid intake.
Measurement of fluid intake rate and concentration of analyte in WGLF can allow
quantitative determination of the daily output. Moreover, additional knowledge of blood
or serum concentration of the substance permits calculation of blood or serum
clearance of the analyte. This eliminates the need for 24 hour faecal collections.
Quantitative faecal measurements are not easily made, because the discipline
required of the patient and staff and necessary facilities of an investigative metabolic
unit are not generally available. Moreover, it has been shown very convincingly that
data based on the analysis of faeces are highly misleading, and despite the apparent
ease of specimen collection, such studies should be discouraged (Ferguson et al,
1995).
Furthermore, in the vast majority of studies where pathological faecal samples are
compared with controls, the pathological samples may be of a different form (for
example, diarrhoea) from the control and this itself may introduce a physiological
difference as highlighted by Strygler et al (1990). Since a standard WGL procedure is
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used for controls and patients any such sample differences are eliminated when
WGLF samples are studied. A further advantage of WGLF compared with faeces in
investigative work is the elimination of dietary interference by substances that may
give false readings. For example, a dietary component such as red meat can make a
significant contribution to the measurement of faecal haemoglobin, thus reducing the
sensitivity and specificity of the assay.
The WGL procedure is very well tolerated and has been successfully used in a wide
range of subjects from children to the elderly. Flowever, the potential disadvantages of
WGL procedure merit consideration:
a) Since the whole gut is perfused, pathological areas are not specifically located as in
closed loop studies. Accordingly it is not possible to link protein measured in WGLF to
intestinal cells or tissue type and so such investigations require to be combined with
studies of biopsies or imaging. However, WGL here provides an extra dimension
similar to the dual sugar permeability tests which give diagnostic information
complementary to that of jejunal biopsy in patients with malabsorption.
b) Some proteins such as albumin are labile and still degraded to some extent during
the lavage procedure, despite the prompt addition of protease inhibitors when the fluid
is collected. The amount of degradation will depend on the site of protein secretion
and activity of the patient's proteases, with more proximal protein secretion being more
affected (Brydon,1993).
c) Patients on average pass samples every 10-20 minutes once clear lavage fluid is
being produced per rectum, so gut losses are measured only during this time period;
i.e. only continuous loss of protein or blood is measured by this procedure.
Occasionally patients with active ulcerative colitis have been observed to pass fresh
blood per rectum, have subsequently undergone the WGL procedure, and have been
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found to have a normal WGL haemoglobin. This highlights the difference between
continuous ooze and acute intermittent bleeding which may stop completely between
episodes. Little is known about intermittency of protein loss although,reassuringly,
sequential samples show little variation (Brydon,1993; Sallam, 1994; Croft, 1996).
Despite, certain limitations, the WGL procedure is a safe, non-invasive, well tolerated
'clinical tool' that has added a new dimension to the study of mucosal humoral
immunity.
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Chapter: 2
Materials and Methods
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Section 1:
Patients
The patients were those who visited the Gl unit who had had gut lavage for clinical
diagnostic purpose. As a routine, their clinical materials and serum samples are stored
and their lavage 'intake and output' were carefully recorded. For my research, I have
taken three groups of patients, whose diagnosis and disease severity were confirmed
by Professor Anne Ferguson.
2.1 A Cohort of Patients with a Spectrum of Diseases:
For my pilot study, which I will discuss in chapter 3, a total of 32 patients with a
spectrum of diseases were studied. The clinical characteristics of these patients are
presented in Table 2.1
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Table 2.1 Clinical Characteristics of Patients Studied
Patient
groups
No: of
Patients
(n)
Sex
(M/F)
Age
median
(range)
Treatment
received
IBD(UC+CD)* 10
4/6 46 (29-75) Salazopyrine/
Prednisolone
Coeliac
disease
2
1/1 41(40-42) Gluten-free
diet
Possible
infection
10
2/8 30 (27-86) Antibiotics
Miscellaneous
(e.g. Polyp,
anaemia,
Ca** colon
etc.)
10
8/2 76 (32-85) Polypectomy/
Iron and
vitamine
supplement
*UC= Ulcerative colitis, CD= Crohn's disease, **Ca= Carcinoma
2.2. A Cohort of Patients with Inflammatory Bowel Disease:
A small cohort of patients with moderate to severe active inflammatory bowel disease
( 12 Crohn's disease and 11 Ulcerative colitis) were carefully selected and studied.
The severity of the diseases were assessed by clinical and by total IgG in WGLF [IgG
>10 pg/mL = moderate to severe disease (O'Mahony et al 1991; Chaudari et al 1993).
Patients characteristics are given in table 2.2.
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Table: 2.2: Clinical Characteristics of Patients with IBD
Patient
group
n Age
median
(range)
Sex
M/F
Median
Duration
(yrs)
of Diseases
Disease
anatomy
Treatment
received
UC 11 29 (19-66) 6/5 5 5 LS*, 2R, 4 S*,3,5asa +SE
3 LS+ Tr, 3,5asa+OS,1az+
1 Pan C OS
CD 12 27 (18-70) 4/8 4.5 4 Tl*,5 IC,
3 C
4 S+OS, 4, 5asa
+ OS, 2 az+ OS,
2 antibio**+ ED
*
( LS= left sided colitis, R= rectum, Tr= transverse colon, Pan C= pancolitis,
S=salazopyrin, 5asa= 5-amino salicylic acid, SE= steroid enema, OS= oral steroid, az=
azathioprine, **antibio= antibacterial agents, especially metronidazole + Ciprofloxacin,
ED= elemental diet)
2.3 A Group of Patients with Ileal Pouch- Anal Anastomosis (IPAA)
Ileal pouch anal-anastomosis (IPAA) is the operation of first choice following
proctocolectomy in patients with ulcerative colitis. A small cohort of patients with IPAA
who had had gut lavage for diagnosis of pouchitis were studied ( Patients' clinical
information and WGLF from these patient were a kind gift from Mr. Nikos Evganikos, a
surgical colleague in the Gl Unit). Patients' characteristics are provided in Table 2.3
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Table 2.3: Clinical Characteristics of IPAA Patients
IPAA n Age Sex Duration of Indication for
median (M/F) disease before operation
(range) operation median
(range)
Normal 10 39 (28-73) 6/4 6 (1-28) years Ulcerative
colitis
Pouchitis 9 36 (28-74) 4/5 9 (3-16) years Ulcerative
colitis
2.4. Healthy Controls:
a. Edinburgh Controls:
Those people were immunologically normal and had no protein-losing enteropathy, no
evidence of gut damage or bleeding, and were clinically normal, only functional bowel
disease, e.g. irritable bowel disease or constipation came out as final diagnosis were
studied. A cohort of such patients was considered as a healthy control group from
Edinburgh (Table 2.4).
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b. Dhaka Controls:
I have studied a group of healthy volunteers from Dhaka, Bangladesh. All the
volunteers were local residents of Dhaka city. Characteristics of these healthy controls
are given in Table 2.4.
Table 2.4: Characteristics of Healthy Controls.
Healthy n Age Sex Weight (kg) Height (cm)
Controls median (range) (M/F) mean (+SD) mean (±SD)
Dhaka 11 24 (18-32) 11 M 46 (± 5) 159 (±7)
Edinburgh 12 39 (23-48) 4/8 60 (±6.3) 166 (± 5.6)
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General Standard Methods:
2.1 Whole gut Lavage (WGL) technique
This non-invasive clinical technique has been used throughout the world for bowel
cleansing before barium enema, colonoscopy, and colorectal surgery. Recently it has
been established as a clinical tool for studying various humoral immune functions and
inflammatory parameters in the gut (Gaspari et al 1988; Brydon et al 1993). Briefly,
after an overnight fast, patients or healthy volunteers drink the lavage solution
(available commercially as Klean-prep from Norgine Ltd Oxford,UK. one sachet
dissolved in one litre of tap water), supervised. They were monitored and 'intake/
output' were recorded by an experienced research nurse in Edinburgh (by myself for
volunteer studies in Dhaka), aiming for a rate of 200 mL every 12 minutes. After a
period ranging from 30 minutes to 3.5 h, several formed or semi-liquid stools are
passed, followed by faecal-stained fluid. These are discarded until clear fluid
resembling urine is being passed per rectum.
2.2. Processing of whole gut lavage fluid
Clear fluid (20 mL) is filtered through GF/A (Whatman) glass fibre filters. To 10 mL of
the filtered fluid the following reagents are added (see details in appendix).
• Soya bean trypsin inhibitor in phosphate-buffered saline (PBS) (80pg/mL)
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• Sodium ethylenediaminetetracetate(15 mM) in PBS ( chelating agent for calcium
and magnesium ions which are required for the activation of protease enzymes)
• Phenylmethylsulphonyl fluoride in 95% ethanol (2 mM) (protease inhibitor)
• Sodium azide (1mM) (bactericidal agent)
• New born calf serum (5% v/v ) (to provide an alternative substrate for any remaining
enzyme)
Aliquots of processed WGLF were stored at -70 °C for later analysis.
2.3 WGLF samples labelling:
It has been a routine practice in the G.I. Lab ( also for the assay used in the thesis)
that samples are labelled as follows to indicate different treatments of the samples.
UF/UP: Unfiltered and unprocessed (without any treatment)
UF/P: Unfiltered but processed (unfiltered but processing reagent added)
F/UP: Filtered but unprocessed (only filtered but no processing reagent added)
F/P : Filtered and Processed (both filtered and processing reagent added)
2.4 Analytical Methods
2.4.1 Enzyme linked Immunosorbent Assays (ELISA) for Total Immunoglobulins
and antibodies-
Principle of the Method: Immunoglobulins are absorbed by class-specific antibodies
bound to the solid phase (ELISA Plate). Then an enzyme-labelled antiglobulin
conjugate (alkaline phosphate) is added and binds to the specific immunoglobulin
required. A double antibody 'sandwich' technique was used for the total
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immunoglobulin A, G, and M quantification using purified secondary standard material
(Gaspari et al, 1988; O'Mahony et at, 1991, O'Mahony et al, 1990).
An indirect technique was used for estimation of antigen specific immunoglobulins
measured against a known high-titre human sample. Antibodies studied included those
against ovalbumin and cholera-toxin B subunit (Gaspari et al, 1988).
Essentially the methodology of the assays is identical except for the initial coating of
the solid plate.
General Procedure
• Class specific antihuman immunoglobulin or pure antigen is bound in excess to a
solid phase overnight at 4°C in a moist box and then washed. Standard 96-well ELISA
plates were used as solid phase. Different plate types were used as they have
different binding characteristics.
• After washing, the plates are incubated with a protein- containing solution, usually
the ELISA diluent, to 'block' non-specific binding sites.
• Standards and samples for total immunoglobulin and antigen-specific antibody
quantitation are added to the plate in serial doubling dilutions, in order to cover the
wide concentration range.
• Samples are incubated and then washed. Binding takes place between the
antihuman globulin and the immunoglobulin quantified or between the specific antigen
and corresponding anti-antigen immunoglobulin.
• A class-specific antihuman antibody conjugate with alkaline phosphatase is added
to the plate, incubated then washed . This conjugate antibody binds to the complex
bound to the solid phase.
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• The substrate for the alkaline phosphatase is p-nitrophenyl phosphate in a
diethanolamine buffer at pH 9.8. The substrate is added to the plate and the reaction
is indicated by the change of colour (p-nitrophenyl phosphate which is colourless
changes to p-nitrophenol which is yellow in colour).
• The colour development takes place usually within 30 minutes and the optical density
at 405 nm is read on a dedicated ELISA reader (Dynatech MR 5000) when the top
standard or reference standard has reached 1.0.
• For the total immunoglobulin determination a standard curve is plotted (using the
'Inplot 4 program' in computer) with the concentration on the x-axis against the optical
density on the y-axis. A straight line section of the curve (r>0.99) is used as the
standard line by including at least 4 consecutive dilutions of the standard.
• The concentration of the specimen is calculated by averaging two of the doubly
diluted concentrations that lie within the standard line.
• Semi- quantitative antibody assays were performed by expressing the result as a
percentage of the concentration of a single dilution of the standard (the same dilution
as the top standard in the quantitative assays).
• Reagents and instrumentation are detailed in the appendix .
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Test Procedure
1. Coat plates with appropriate antigens
Using an 8 channel multichannel pipette, 125 pi of appropriate coating solution
including the antigen were dispensed to each well of the ELISA plate.
For total immunoglbulins
Immulon 1, flat bottomed 96 well plates (Dynatech) were used
Coating antibody Dilution
anti-human IgA 1/2500
anti-human IgG 1/5000
anti-human IgM 1/5000
For specific Antibodies
Immulon 2 ( which adsorbs coating antigens more strongly than 'Immulon 1' plates),
flat bottomed 96 well plates were used.
The following antigens in coating buffer were made up:
for ovalbumin assay, 5 jug/mL of ovalbumin (sigma A-5503) was coated for anti-ova
(IgA and IgG) and 10 pg/mL of ovalbumin for anti-ova IgM antibody.
2. Incubation
Each plate was covered with a plastic lid, placed in a moist box and incubated at 4°C
overnight.
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3. Blocking plate
The plate was washed x3 and then 250pL of ELISA diluent added (Appendix 1). It was
left for a minimum of 1 hour.
4. Samples and standards
All were assayed in duplicate.
Standard Material
Standards were all made up in ELISA diluent.
1. Total Immunoglobulins:
Total IgG and IgM
• SPS-01 - standard material for quantifying IgG and IgM. It was purchased from
the Dept. of Immunology, P O Box 894, Sheffield S5 7YT.
Total IgA
• Human IgA -purified immunoglobulin from colostrum (Sigma Chemical Co)
Top standard for IgA assay = 1000 ng/mL.
2. Specific Antibodies:
Quantitative Assays: For food antibodies a serum sample from a patient (Main,
Sample no. 1548 preserved in the Gl Lab) with high levels of specific food antibodies
was used . For calculation, arbitrary units have been allocated to this
standard.
Standard no. 1548 diluted 1:264, which is equivalent to the 1:50 dilution of Main
(patients serum) and this equals 2 units.
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Samples
Total immunoglbulins A,M, and G
The samples were made up as follows in ELISA diluent for the top row to start at the
dilution:
WGF/ELISA diluent
Total IgA 1/100
Total IgM 1/25
Total IgG 1/25
Specific Antibodies
samples (125 pL) were added to 125 pLdiluent (1/2 dilution) in the top row.
The samples and standards were then serially diluted down the columns using a 12
channel pipette.
5. Incubation
The plates were incubated at 4°C overnight.
6. Conjugates
Alkaline phosphate conjugated anti-sera dilution were prepared in ELISA diluent
following the dilution scheme in appendix 1.
The plates were washed as above, then using a multichannel pipette 125 pL conjugate
were dispensed to each well of the ELISA plate.
7. Incubation
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The plates were covered with a plastic lid, placed in a moist box and left at room
temperature for 3 hours.
8. Colour development
Alkaline phosphate substrate was prepared 30 minutes before it was required.
The plate was washed as above, then using a 12 channel pipette 125 pL of substrate
dispensed to each well of the ELISA plate. They were left on the bench for 5 minutes
as the colour starts to develop, then shaken on a Denley Wellmix 1.
9. Reading
The colour development was monitored manually on the Dynatech MR5000 Microplate
reader until the top standard reached its endpoint of approximately 1.00 (read with the
filter set at 405 nm and the reference filter set to 630nm).
10. Calculation
The concentration of the samples was calculated as described above. The results
were accepted if the co-efficient of variation (CV) was less than 15% and 5% in intra
assay and inter assay respectively.
2.4.2 Haemoglobin in Whole gut lavage fluid
(Reference: Brydon & Ferguson 1992).
Principle of Method:
Haemoglobin is converted to porphyrin with the removal of ferrous iron by the
commensal flora. Porphyrin is extracted with solvent and then detected by
fluorescence spectrophotometry. A three step purification procedure eliminates other
interfering fluorescent materials which may be present.
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Gastrointestinal blood loss is routinely assessed in the Gl laboratory using this
method. The healthy volunteer samples from Dhaka were assessed by Mr. John
Bode. Reference values for lavage haemoglobin in adults were obtained by studying
healthy volunteers. The normal range is 0-5 pg/mL ( Brydon & Ferguson, 1992).
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2.4.3 Albumin and a-1 Anti-trypsin in Whole gut lavage fluid
Reference ( Brydon et al, 1993)
Principle of the method:
Albumin and a-1 anti-trypsin in WGLF are measured by simple manual procedures
based on immunoturbidimetry. Turbidimetry involves the measurement of light-
scattering particles in solution by means of the decrease in intensity of an incident
beam as it passes through the sample. The light has been lost due to absorption,
reflection and scatter. Turbidimetric measurement can be made with a
spectrophotometer.
Albumin and a-1 anti-trypsin in WGLF are routinely tested as measures of gastro¬
intestinal protein loss. The test was done by Mr. John Bode in the Gl lab. Reference
normal values for lavage albumin and a-1 anti-trypsin were obtained by studying
healthy controls. These values were <26 pg/mL and 19 pg/mL for albumin and a-1
anti-trypsin respectively.
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3. Cytokines assays in WGLF and serum
The cytokine assays are commercially available ELISA kits that have been adapted for
analysis of WGLF.
Principle
These kits use the 'sandwich' type ELISA similar in principle to that described for the
total immunoglobulin and antibody assays. Monoclonal antibody to a particular
cytokine [(for example, interleukin (IL) -1(3 and IL-8)] is coated onto the microtitre plate
provided. Standards and samples are added and any particular cytokine that is present
is bound to the solid phase. After washing, an enzyme -linked polyclonal antibody is
added to the well to attach to the chemokine previously bound. Following a further
wash a substrate solution is added to the wells and the colour develops in proportion
to the amount of the substance bound initially. The colour development is stopped and
the intensity of the colour is measured.
In order to attempt to replicate as closely as possible the environment for both
standards and specimens the following solutions were used as diluents.
1. Standard diluent: PBS, 0.02% Tween 20, and 1% ABS
2. Processed Klean-Prep (Peg +) - Klean-prep (Norgine, Oxford UK) + processing
agents for WGLF.
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3.1 Interleukin - 8 (IL-8)
IL-8 concentrations in WGLF were assayed using a commercially available sandwich
ELISA kit (Quantikine, R&D Systems, Minneapolis, USA).
Methods:
Samples and Standard
Standard:
Seven tubes were labelled: 240, 96, 38.4, 15.4, 6.1, 2.5, and 1 pg/mL.
Volume (610 pL) of 50:50 working strength diluting buffer: Peg+ was pipetted into the
240 pg/mL tube and 300 pi into each of the other tubes. IL-8 standard (15 pL of the
10ng/mL) was put into the 240 pg/mL tube, mixed and then transfered 200 pL into the
96pg/mL tube followed by , mixing. This procedure was repeated through to the last
tube. Each standard (100 pL) was added to the appropriate duplicate wells.
WGLF samples
UF/P samples were used in cytokine assays. These samples were not diluted prior to
addition to the microtitre plate where they were diluted 1/2 in the standard diluent (e.g.
100 pi samples added to 100 pi processed Klean-prep already in the wells).
Assay Procedure
Day 0
1. The plate and coating antibody was brought to room temperature
2. The coating antibody was centrifuged at 3000g for 1 minute
3. The coating buffer was prepared.
4. Coating antibody was diluted 1:100 in coating buffer, i.e. 120 pL of antibody was
added to 12 mL of buffer.
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5. 100 pl_ was added to all wells.
6. The plate was covered and incubated overnight at room temperature.
Day 1
1. All reagents (except streptavidin-HRP) were brought to room temperature. Vials
were centrifused at 3000g for 1 minute.
2. Blocking buffer was prepared.
3. The plate was washed x5 with PBS alone.
4. (200 pL) blocking buffer was added to each well and incubated for 1 hour at room
temperature.
5. Standards were prepared and samples were diluted.
6. The plates were washed x5 with washing buffer (PBS+Tween 20)
7. Each standard (100 pl_) was added to appropriate duplicate wells.
8. Assay diluent (50 pl_) was added to all sample wells. Blanks= 100 p
I of 50:50 diluting buffer: Peg+
9. Pre-diluted samples (50 pL) were added to duplicate sample wells. The plates were
covered and incubated at room temperature for 1 hour.
10. The biotinylated antibody 1:100 in dilution buffer was prepared just before use.
11. The plate was washed x5 with wash buffer.
12. Biotin conjugate (100 pL) was added to each well, the plate was covered and
incubated (after tapping to mix) at room temperature for 1 hour.
13. Streptavidin-HRP conjugate was stored at -20°C until use. The conjugate was
centrifuged at 3000g for 1 minute before use. Then, just prior to use, 3 pL streptavidin
was added to 30 mL working strength dilution buffer.
14. The plate was washed x5 with wash buffer.
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15. Streptavidin-HRP (100 pL) was added to all wells, tap to mix, then covered and
incubated for 30 minutes at room temperature.
16. K-blue substrate (15 pL) was brought to room temperature.
17. Plate was washed X5.
18. Substrate (100 pL) was added to all wells. Incubated for (although the kit suggest
30 minutes, I have found less than 15 minutes was necessary.
19. Stop solution (100 pL) was added to all wells, tapped and mixed.
20. The plate was read at 405nm within 30 minutes.
21. Calculation of results:
Using a curve fitting program in Revelation software installed in Dynex (The microtitre
Company) ELISA reader, an ' r' value of >0.99 including all points required in the
standard curve. Concentration of the samples were then extrapolated from their optical
densities.
Sensitivity: The sensitivity of this assay is 1-3 pg/mL.
3.2 lnterleukin-1p (IL-ip)
High sensitivity lnterleukin-1 p ELISA kit -CISTRON BIOTECHNOLOGY, New Jersey,
USA). The principle is the same as the 'sandwich' ELISA described for
immunoglobulins, specific antibodies and IL-8.
Standard and Specimens
Standards: The standard was prepared in 50:50, Peg+ PBS Tween 20, 0.02%
The kit standard was reconstitute with 500 pL of distilled water and left for 15 minutes.
This gives a stock solution of 50,000 pg/mL; this was diluted then to gave 300, 150,
100, 50, 20, 10, 5 pg/mL
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Samples:
UF/PP of WGLF have been used . Samples were diluted 1/2 by adding 50 pi of
PBS/Tween 20 to each wells prior to adding 50 pi of lavage.
Assay procedure:
1. To a prepared coated plate 100 pL of each standard concentration was added to
duplicate wells.
2. To sample wells 50 pL of PBS/Tween 20 was added followed by 50 pL of lavage
samples. Blanks wells = 100 pL of 50:50.
3. The plates were covered with adhesive strip and incubated at 37° C for 1 hour.
4. The contents were aspirated and washed x3 with wash buffer.
5. Polyclonal IL-1p (50 pL) of mature anti-serum (rabbit) was added to each well. The
plate was covered and incubated at 37 °C for 20 minutes followed by washing x3 .
6. Diluted anti-rabbit IgG-HRP conjugate (100 pL) was added to each well.
7. The wells were covered and incubated at room temperature for 20 minutes
8. Substrate was prepared 5 minutes prior to use by mixing equal amounts of A
(supplied) and B followed by washing x3
9. Substrate (100 pL) was added to all wells and incubated uncovered at room
temperature (although the supplied kit suggests 20 minutes incubation time, I found
that less than 10 minutes is necessary).
10. Sulphuric acid (50pL of 2M) was added to stop the reaction.
11. The plate was read within 15 minutes at 450nm.
12. A standard curve was constituted and calculation of values were by extrapolating
optic density readings.
Sensitivity: The sensitivity of this test is 2 pg/mL.
Precision: The intra-assay coefficient of variation of this test as coated is <5%.
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3.3 Interleukin-5 (IL-5)
High sensitivity Human IL-5 ELISA kit -R&D systems (D5000). The principles is the
same as the 'sandwich' ELISA described for immunoglobulins, specific antibodies and
IL-8 and IL-ip .
Standard and Specimens
Standards: Standard was prepared in 50:50, Peg+ PBS Tween 20, 0.02%
The IL-5 stock standard was reconstituted by adding 5 mL of Peg+. The stock
standard was allowed to sit for a minimum of 15 minutes with gentle agitation prior to
making dilutions of 500, 250, 125, 62.5, 31.2, 15.6,7.8 pg/mL
Samples:
Unfiltered and processed (UF/PP) of WGLF have been used . Samples were 1/2 by
adding 50 pi of PBS/Tween 20 to each wells prior to adding 50 pi of lavage.
Assay procedure:
1. To a ready coated plate 50 pL of assay diluent was added to each wells
2. Each standard dilution (200 pL) was added to appropriate wells.
3. PBS/Tween 20/ABS (100 pL) was added to sample wells. Blanks contained 200 pL
of 50:50.
4. Samples (100 pL) were added to duplicate wells. These were then tapped and
mixed and cover with adhesive strip and incubated at room temperature for 2 hours.
5. The wells were aspirated and washed x4 with wash buffer.
6. Substrate solution (200 pL) was added to each well and incubated at room
temperature for 20 minutes ( we observed that only 10 minutes was required).
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7. Stop solution (50 pl_) was added to each well.
8. Results were read at 450 nm (with correction at 570).
9. The concentrations of the samples were then extrapolated from their optical
densities, using the curve fitting program in Revelation software installed in Dynex
(The microtitre company).
Sensitivity: The minimum detectable dose of IL-5 as mentioned in the kit was
<3pg/mL.
Precision: According to the Kit the coefficient of variation in intra assay and inter
assay was around 4% and 7 % respectively.
3.4 lnterleukin-6 (IL-6)
High sensitivity IL-6 ELISA kit-Millennia (MKL61). The principle is the same as the
'sandwich' ELISA described for immunoglobulins, specific antibodies and other
cytokines.
Standard and Specimens:
Standard: Six tubes were labelled: G (500 pg/mL), F (250 pg/mL), E (125 pg/mL), D
(61.5 pg/mL), C (31.3pg/mL), B (15.6 pg/mL). samples of 0.5 mL of IL-6
Calibrator/Sample Diluent were pipetted into each tube, pipette 0.5 mL of the
reconstituted Master Calibrator was pipetted in to the tube G (500 pg/mL) and mixed
thoroughly. A volume of 0.5 mL was transferred from tube G to F (250 pg/mL) and
mixed thoroughly. This process was repeated successively to complete the 2-fold
dilution series. The reconstituted Master Calibrator H served as the highest calibrator
(1,000 pg/mL). IL-6 calibrator/Sample diluent was used as the zero calibrator A (0
pg/mL).
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Samples: 100 pi of serum sample (frozen at -20 0 C) was used for the assay.
Assay Procedure:
1. A single microplate was prepared with enough 8-well strips to accommodate
calibrators (A to H), controls and patients' samples in duplicate.
2. Each standard, control and patients samples (100 pL) was pipetted in the wells
prepared (pipetted directly to the bottom of the plate).
3. IL-6 Sample buffer (150 pL) was added to every well. The plate was covered and
rotated for 2 hours on a plate mixer.
4. The plate was decanted and washed x4 with Micro Wash, each time with 300 pi
Buffered Wash Solution
5. Enzyme-Labelled Anti-IL-6 antibody (200 pL) was added to every well.
6. The plate was covered and rotated for 2 hours on a plate mixer.
7. The plate was decanted and washed as described above.
8. TMB/Substrate (200 pL) was added to every well.
9. The plates were incubated without shaking for 30 minutes in the dark.
10. Stop solution (50 pL) was added to every well.
11. The plate was read at 450nm within 15 minutes of adding the stop solution.
12. The concentrations of samples were then extrapolated from their optical densities,
using the curve fitting program in Revelation software installed in Dynex.
Sensitivity: The detection limit of the of the assay, according to the kit is 4 pg/mL.
Precision: The coefficient of variation within run is <4% and in run-to-run is <6.5%.
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4. Total Granulocyte Elastase (GE) Assay:
Principle of Method: The elastase activity of a sample is determined by its amidolytic
effect on the substrate pyroglu-pro-val-pNA.
< Glu-Pro-Val-pNA + H20 Granulocyte Elastase -> <Glu-Pro-Val-OH +pNA
The rate at which p-nitroaniline (pNA) is released is measured photometrically at 405
nm. This can be read after stopping the reaction with acetic acid. The correlation
between the absorbance and the granulocyte elastase activity is linear in the 0.1- 1.5
pkat/l. The amidolytic activity does not necessarily parallel the elastolytic activity for
different elastase preparations.
Reference: (Kramps et al, 1983)
Reagents:
1. Triton X100 (Sigma Chemical Co.,)
2. Dimethyl sulphoxide (DMSO, Sigma Chemical Co,)
3. Substrate (S-2484, from KabiVitrum AB, Sweden): The substrate (25 mg) is
dissolved in 7 mL of DMSO. One volume of this stock solution is diluted with 3
volumes of distilled water.
4. Buffer pH 8.3 (25° C): The composition of this elastase buffer is: Tris 12.1g (100
mmol/l), NaCI 56.2 g (960 mmo/l), Distilled water 800 mL. Adjust the pH to 8.3 at 25
°C by adding approximately 50 mL of 1 mol/l HCI. Fill up to 1000 mL with distilled
water.
5. Acetic acid 20% : Acetic acid is used in the acid-stopped method.
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Control Material
Positive control was a sonicated preparation of granulocytes isolated from the blood of
a normal volunteer. The control concentration was adjusted to give a GE activity value
of approximately 1.0-1.3 pkat/l.
Sample: Unfiltered and Unprocessed (UF/UP) lavage samples were used for this
assay.
Assay procedure:
1. Trion X -100 (1pL) was added in a microcentrifuge tube for each sample to be
tested
2. UF/UP lavage sample (600 pl_) was added to each tube and mixed.
4. A 2 mmol/L working substrate (S-2484) solution was prepared and placed in a
waterbath at 37°C.
5. Two plastic round bottom tubes were labelled for each sample to be tested one for
test and one for the blank.
6. Elastase buffer (250 pL) was placed into each tube.
7. The rack of tubes was placed in waterbath and allowed to warm (2-3 minutes).
8. UF/UP sample (200 pL) was added to both the test and blank tubes, and mixed and
allowed to warm.
9. Acetic acid (200 pL) was added to the blank tubes only and mixed.
10. The digital timer was set at 3 minutes and after the starting timer 200 pL of pre-
warmed substrate was immediately into all tubes keeping to a regular rhythm while
pipetting (test tubes should take priority). They were mixed well.
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11. After exactly 3 minutes, 200 pl_ of acetic acid was added to all of the tubes in the
same rhythm and mixed.
12. The tubes were read in a spectrophotometer at 450 nm.
Calculation of the results:
The amount of GE activity present in each sample was calculated as follows
( Average test'A' reading - Average blank'A'reading) X 2.31 jukat/l.
Acceptance of Results:
If positive controls gave an appropriate value ( co-efficient of variation has always
been less than 5%), samples results were acceptable, providing duplicate wells gave
similar values and blanks were not exceptionally higher than test values.
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Software Used in this Thesis
Data were stored using Access version 2.0 (Microsoft).
The word-processing package used in this thesis was Word for Windows V 6.0
(Microsoft). Statistics were calculated using Minitab for Windows V10.2 (minitab
statistical software). Graphs were produced using Prism V 1.03 (GraphPad) or Excel v
5.0 (Microsoft).
Statistical Analyses Used in this Thesis:
Minitab for Windows was used for the statistical analysis. For non-parametric data,
results were expressed as medians and interquartile ranges. Mann-Whitney U-test
was used for independent sets of data. Spearman's rank correlation coefficient was
used to study the relationship between two variables. However, where data were
normally distributed, Student's 't'-test was used to compare two independent
groups. The Pearson correlation coefficient 'r' was used to examine the relationship
between two variables.
Ethics of WGL for Research in Volunteer:
The Lothian Health Board of Scotland approved the WGL study on volunteers in 1992.
The volunteer study at Dhaka was approved by the ethical committee of the
International Centre for Diarrhoeal Diseases Research, Bangladesh (ICDDR.B).
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SECTION 2
Methods for Quantification of Anti-bacterial antibodies Including Technical
Developments:
1. Anti-LPS core (EndoCAb) ELISA:
As has already been discussed in the literature review, a semi-quatitative ELISA
method to detect antibody to endotoxin has been developed by Dr. G.R. Barclay. I
adapted Barclay's original method for the measurement of IgG antibody responses in
blood donor sera (Barclay and Scott, 1987). The method has been modified and
optimised for detecting the antibody response to endotoxin in WGLF (e.g. IgA
antibody).
Principle of the method: The principle is the same as that discussed in the general
method for 'Sandwich' ELISA. Microplates were coated with 'endotoxin' core antigen
cocktail ( Rough mutant LPS from Escherichia coli, Klebsiella pneumoniae,
Pseudomonas aeruginosa and Salmonella minnesota complexed with polymyxin B,
these plates were a kind gift from Dr. Barclay).
Reagent: Endotoxin-free buffer is needed for plate washing and sample dilution,
composition of which is given in the appendix .
Standards and Samples:
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Standard:
Human standard serum was used as a reference (Courtesy Dr. Barclay)
IgG, IgM and IgA values (MU) in the standard serum after reconstitution were:
IgG 7.84 IgG MU
IgM 3.30 IgM MU
IgA 9.04 IgA MU
Where MU= "median unit". The units are based on the median of the normal healthy
Scottish adult range of EndoCAb IgG, IgM, and IgA antibodies, where the median of
each immunoglobulin range is 100 MU. The units for the different immunoglobulin
classes (G,M and A) are not equivalent. The "normal" range usually employed for
each class is the 10 th to 90th percentile, which is approximately 35 (10th centile) to
250 (90thcentile) for each immunoglobulin class when median units are used.
Top Standard Dilution: ( optimised and modified)
IgG 1:250
IgM 1: 50
IgA 1: 25
Sample: Filtered and Processed (F/P) WGLF was used for EndoCAb assay
Dilution: For lavage 1:1, for serum samples 1:100.
Assay Procedure:
1. All reagents were brought to room temperature before use.
2. The samples and standards were put onto ready coated plate and kept in a dry
box.
3. The plates were incubated at 37° C for 90 minutes (instead of 1 hour suggested by
Dr. Barclay)
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4. After incubation the plates were washed x3 with ELISA wash.
5. The alkaline phospatase conjugate diluted 1: 1000 dilution (for A,G,and M) Sigma
chemical Co.
6. The plates were incubated in a box at 22°C for 3 hour, (instead of 90 minutes by
Dr. Barclay).
7. After 3 hour incubation, the plate were washed x3 and substrate (DEA buffer +
PNP) added in all well.
8. The colour development takes place usually within 3-5 minutes and the optical
density at 405 nm was read on a dedicated ELISA reader (Dynatech MR 5000) when
the top standard or reference standard had reached 1.0.
A standard curve was plotted (using Inplot 4 programme in computer) with
concentration on the x-axis against the optical density on the y-axis. A straight line
section of the curve (r>0.99) was used as the standard line by including at least 4
consecutive dilutions of the standards.
Precision: In between run and run-to-run coefficient of variation was observed as
<4% and < 12% respectively.
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Using different incubation period and
conjujugate concentration for same
samples
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i— Previous Method
Figure 2.1: Comparison of Dr. Barclay's method and modified method
(Nine samples were analysed following Barclay's method and the optimised method to
detect antibody in WGLF)
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2. Anti-cholera toxin antibody-ELISA:
The principle and Methods was the same as already described in general
methodology for detection of specific antibody by ELISA. However, for the cholera
toxin assay there was a two stage coating phase, the first coats with
monosialoganglioside (GM1, Sigma Chemical Co....G7641) to the well. This is a
constituent of enterocyte cell walls to which cholera toxin (CT) [List Biological lab.CVX-
20] binds strongly:
Stage 1 : Monosialoganglioside (GMi), 10 pg/mL in coating buffer. Plates were coated
with this solution of 100 pL/we11 follwed by incubating over night at 4°C.
The plates were washed x3
Stage 2: Cholera toxin, 5pg/mL in coating buffer. Plates were coated with this
solution (100 pL/ well) followed by incubation overnight at 4°C.
the plates were washed X3, followed by blocking with blocking solution (200 pL/well)
and incubation at room temperature for 2 hours.
For the cholera toxin antibodies, the standards were used from volunteers. Lavage
sample was donated by Martha Falconer for CT-A with serum sample from Dr Croft
for CT-M and CT-G.
Top Standard Dilution
Arbitrary Units Dilution of Top Cone, of Top Standard
(Units/mL of Undiluted standard) Standard (units/mL)
CT-A 100,000 Falconer 1/100 1000
CT-M 100,000 Croft 1/100 1000
CT-G 100,000 Croft 1/100 1000
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Standards and samples diluted as necessary in diluent solution were applied and then
incubated overnight at 4°C
The plates were washed x3
Conjugate (1/1,000 dilution for IgA, IgG and IgM) was applied and then incubated for
3 hours at room temperature,
plates were wash x3.
Other steps of ELISA development and calculation of the results were as for the
specific antibody ELISA already discussed in the general methodology section.
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3. An ELISA for quantification of mucosal IgA response against LPS core types
(R1, R2, R3 and R4) of Escherichia coli and surface antigens of Bacteroides
fragHis.
I adapted the methods described by Dr. A.P. Gibb ( Gibb et al, 1992) and Dr. I.R.
Poxton (Poxton et al, 1995). However, I have optimised the method for studying
antibody in the specimen of WGLF. This ELISA method is similar to EndoCAb ELISA
except for the preparation of LPS and coating on ELISA strips.
LPS preparation and coating onto ELISA strips
a) Growth of the organisms
four strains of E.coli were taken.
E.coli (R1) MPRL 2316
E.coli (R2) MPRL 2317
E.coli (R3) MPRL 2318
E.coli (R4) MPRL 2431
The above strains were provided lyophilised in ampoules. Each was reconstituted with
nutrient broth (NB) and used to inoculate nutrient agar (NA) plates as a purity check.
The following method was used for each of the above strains:
Day 1. 20 mL NB was incubated overnight (ON) at 37°C as a sterility check.
Day 2. The broth was then inoculated from the stock culture and incubated statically
ON at 37°C (inoculum). 10x1 litre of NB was incubated ON at 37°C (sterility check)
Day 3. Each of 10x1 litre of NB was inoculated with 2 mL of the inoculum culture and
incubated aerobically ON at 37°C in an orbital shaker.
91
Day 4. The cells were harvested by centrifugation at 14,000 g (9K rpm) for 10 minutes
(4°C). The pellets were pooled and washed twice in PBS pH 7.4 (9K rpm for 10
minutes at 4° C). The final pellet was frozen. The frozen pellet of harvested cells from
all of the above strains were then lyophilised and ready for LPS extraction.
b) Extraction of LPS with phenol/chloroform/petroleum (PCP).
( Reagents detail in appendix )
1. One part by weight of freeze-dried bacterial cell was suspended in 4 parts by
volume of PCP reagent and stired for 2 minutes at room temperature using a glass
rod.
2. The mixture was transferred to DuPont 'Corex' glass centrifuge tubes and
centrifuged in an enclosed rotor (Sorvall SS34) at 10,000 g for 15 minutes at 4°C.
3. The supernate was filtered through Whatman No.1 paper into a round-bottom flask.
4. The pellet was re-extracted with another volume of PCP (equal to the original
volume used), and the filter supernate collected as in step 1 to 3 above. The pooled
supernates were filtered.
5. The chloroform and petroleum was removed by rotary evaporation.
6. The dry material was taken up in 3-5 mL of water using a 26-gauge needle and
syringe (the aim was to solubilize all the LPS thus making a translucent solution).
7. LPS was sedimented by ultracentrifugation 100,000g (35k rpm) for 3 h (4°C).
8. The LPS was taken up in pyrogen-free water and lyophilised.
[ From step 5, LPS can be precipitated by another method (e.g. aqueous phenol
method), the choice of which depends on the organism being extracted (e.g.
Bacteroides)].
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c. Coating on to ELISA plates:
Lyophilised LPS of Bactericides fragilis (MPRL no 1669) [prepared by the aqueous
phenol method of Westphal and Luderitz (Westphal and Luderitz, 1954)] as described
by Hancock and Poxton (Hancock and Poxton, 1988)] and E.coli R1, R2, R3 and R4
were complexed with polymyxin B after the modification of the method developed by
Scott and Barclay ( Scott and Barclay,1987). LPS (1mL of a 1mg/mL solution) was
mixed with polymyxin B sulphate (1mg/mL of solution) in a Reactivial (Pierce), and
sonicated in a short burst for 30 second in an ultrasonicator (MSE Soniprep) set at
10p.lt was stirred at room temperature for 2 hours, sonicated and then dialysed in
2000 MWCO Spectrapor membrane overnight against distilled water to remove excess
polymyxin. After removal from dialysis bags, it was resonicated , diluted 1 in 50 in the
ELISA coating buffer (0.05 M carbonate /bicarbonate, pH 9.6, containing 0.02%
sodium azide). ELISA strips (Immunomodule polysorp F8 Nunc, Intermed) were
coated at 100 pl/well and incubated at room temperature overnight. LPS-coated strips
were washed four times with PBS containing 0.05% Tween 20 and 0.05% sodium
azide, and then post coated with 100 pi volumes of PBS containing 5% w/v bovine
serum albumin (ICN-Flow) and 0.02% sodium azide and incubated overnight followed
by washing and stored at -20 0 C until use.
Standards and samples:
Standard: A top standard was identified by studying healthy and patient populations.
An arbitrary unit was assigned to that standard to study the different populations by
antibody profiles.
Top standard dilution:
Serum sample no 2215/95 diluted 1 in 50 would give 1000 SAMI Unit (arbitrary).
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Samples: WGLF was diluted 1:1 with ELISA diluent (must be endotoxin-free).
Assay procedure:
All the reagent should be at room temperature.
1. The sample and standard were added in duplicate on the ELISA strips.
2. They were incubated in a dry box at 37 °C for 90 minutes
3. The plates were washed x3 in ELISA wash
4. Alkaline phosphatase conjugate was added (for IgA 1: 1000, Sigma chemical Co).
5 They were re-incubate at 22 °C for 3 hours
6. The plates were washed x3 after incubation
7. The substrate (DEA buffer +PNP) was added.
8. The colour development takes place usually within 10-15 minutes and the optical
density at 405 nm was read on a dedicated ELISA reader (Dynatech MR 5000) when
the top standard or reference standard has reached 1.0.
A standard curve was plotted (using Inplot 4 program in computer) with concentration
on the x-axis against the optical density on the y-axis. A straight line section of the
curve (r>0.99) is used as the standard line by including at least 4 consecutive dilution
of the standards.
Precision: In between run and run-to-run coefficient of variation was observed as
4.5% and 14% respectively.
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method and optimised method
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Fig: 2.2 Comparison between previous and optimised method.
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4. An ELISA to measure mucosal IgA response against LPS of E.coli 0157:H7
The method for the estimation of IgA antibody against LPS of E.coli 0157:H7 is similar
as described earlier for EndoCAb and various core types of E.coli, except for coating
ELISA plates with the LPS of E.coli 0157:H7 (MPRL No: 4252). The coating of ELISA
plates was done by Carol Currie (a research associate of Professor Poxton), who is
currently studying mucosal and serum antibody responses against E.coli 0157:H7.
5. Polyacrylamide Gel Electrophoresis (PAGE)
( Reagents detail in appendix)
1. Glass plates, spacers and comb were degreased with Mediwipes wetted with
methylated spirits.
2. Plates were wiped with distilled water and gently wiped dry.
3. Vaseline was melted in a universal bottle, in a boiling bath.
4. The cassette was constructed, without touching any surfaces that will make contact
with the gel. The bottom (long) spacer was placed onto the bottom edge and a side
spacer onto each side edge of one of cleaned surfaces on one of the plates, and then
covered with the other plate, ensuring that the cleaned surfaces face each other. The
2 plates were lined up and the spacers pushed up to leave a 1- 2 mm gap from the
edge. The cassette assembly was clamped together using two Bulldog clips per
spacer, leaving a gap between the clip and the edges of the plates. The comb was
inserted and checked that it is a good sliding fit. Lines 1cm and 8.5 cm from the base
of the comb were marked on to the glass plates. The comb was removed and then the
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cassette sealed with molten Vaseline by running it (via a Pasteur pipette) into the small
trough between the glass edges and the spacers.
5. The cassette was placed upright in a tray or on a section of 'Benchcote' with the
plain glass facing front and notched glass to the rear. The cassette was pushed down,
so that the base edge was in contact with the clips, in order to level it.
6. The separating gel solution and 4% stacking gel solution were prepared using SDS-
containing or SDS-free buffers as required, in clean, filtration flask as follows:
Ingredient Separating gel concentration Stacking gel
Distilled water 6.95 mL (10%) 5.2 mL (12%) 3.45 mL(14%) 3.5 mL(4%)
Separating gel buffer 17.5 mL for all concentration
Stacking gel buffer - - - 5 mL
Acrylamide (40%) 8.75 mL (10%) 10.5 mL (12%) 12.25 mL (14%) 1mL
7. The solution was de-gassed by applying a controlled negative pressure to the flask
via vacuum pump.
8. A syringe was loaded with 1mL water-saturated butan-2- ol, and pipettors adjusted
to deliver 875 pL and 50 pL. 1.75 mL of ammonium persulphate solution (15 mg/mL
APS) and 50 pL TEMED were added to the separating gel solution and mixed gently
but thoroughly. The gel solution was injected into the cassette up to the mark (i.e. 1
cm below the comb level), then air sucked up into the syringe and placed into the flask
that contained the gel solution. The gel in the cassette was carefully overlayed with
about 1 mL of butanol. The gel was left to polymerize (about 1-2 minutes).
9. A 10 mL syringe (plunger removed) fitted with a wide bore needle, and adjust
pipettors to 500 pL and 20 pL were got ready. When the separating gel had
polymerized, the butanol was removed and washed away with tap water. The gel
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assembly was replaced into the tray and the comb inserted so that one end was fully
inserted and the other end slightly raised. The syringe barrel was inserted into the
cassette. 500 p.L APS and 20 pL TEMED were added to stacking solution and mixed
gently but thoroughly. Whist holding the syringe to keep the whole cassette assembly
upright, the gel solution was poured into the syringe barrel and the plunger replaced.
The gel solution was run into the cassette as an overlay onto the separating gel
ensuring that no bubbles were trapped on the comb. The gel was left to polymerize
(about 2 minutes).
10. When polymerized, the cassette was layed horizontally and the wells numbered
(i.e. 1-20), writing the number in the centre of each well and about halfway up the well.
The 2 clamps at the base of the cassette and the bottom spacer were removed.
11. The "U"-shaped seal on the electrophoresis tank was lightly smeared with
Vaseline. The final 2 clamps were removed and used to fix the cassette into the tank,
making sure that there was a gap between the base of the cassette and floor of the gel
apparatus. The comb was slowly removed and placed it into the discard tray. The
PAGE electrode buffer was poured into the top tank to 2-3 mm above the tops of the
wells and into the bottom tank to 2-3 mm above the base of the gel. Any bubble was
removed from the base of the gel via syringe and curved needle.
12. Dry samples were dissolved in single-strength sample buffer to selected
concentration. Liquid samples were mixed with an equal volume of double strength
sample buffer. The sample (s) in SDS PAGE sample buffer were held in sealed
Eppendorf tubes in a boiling bath for 3 minutes, and then allowed to cool to room
temperature. The samples were mixed thoroughly without frothing and appropriate
volumes added to appropriate wells in the gel. Single strength sample buffer was
added to the outer wells and to any wells that did not contain samples.
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13. The gel was run at constant 60 volts until samples had just entered the separating
gel (about 1.5 h) and then increased to 150 volts. The gel was run until the dye front
reached the mark 7.5 cm below the stacking gel (about 1.5 h).
14. The power pack was switched off, the lid removed from the electrophoresis tank,
and the gel cassette removed, allowing buffer to drain into the gel tank.
15. The cassette was layed horizontally, numbered side up, on a piece of Benchcote
or a paper towel, then the 2 side spacers were slid out. A spatula was inserted about
10-12 mm into the bottom right hand corner between the two glass plates. By levering
upwards the plates could be separated.
16. If the gel required cutting, a sharp scalpel was used and vertical cutting motion
(rather than a slicing action), and the line previously drawn on the glass plates used as
a guide. The gel was then ready for the next process (e.g. silver staining,
immunoblotting etc.)
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6. Silver Stain for LPS
(Reagents are listed in the appendix)
1. The gel was transfered to a box and fixed in 200 mL fixative overnight.
2. The fixative was discarded and the gel oxidised in 154 mL oxidizer solution for 5-15
minutes.
3. The oxidizer was discarded and washed 4 times in distilled water, 200 mL/wash
and 1 hour/wash.
4. Fresh ammonical silver nitrate solution was prepared. The final wash water was
discarded and the silver stain added and left for 15 minutes (recipe in the appendix).
5. Silver stain was discarded and washed in at least 4x 200mL changes of distilled
water and 10 minutes /wash
6. The freshly prepared developer was warmed to 25° C. The water discarded and
200 mL developer added, maintaining the 25° C temperature. The gel was left until
required staining intensity was achieved.
7. The developer was discarded and the gel briefly washed (2-3 minutes/ wash) in
several changes of 200 mL of distilled water.
8. The gel was stored in distilled water in the dark.
7. Comassie blue stain for PAGE gel
(Reagents are listed in the appendix)
1. The gel was tranferred to a box or staining tray containing solution 1 and left
overnight at room temperature on a flat surface.
2. Solution 1 was poured off and solution 2 added and agitated on a rocker platform at
10 to 20 tilts/minutes for 1 hour.
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3. As 2, but solution 3 added
4. As 3, but solution 4 added
5. As 4, but solution 5 added. Gel should be stored in solution 5 until discarding.
[ Molecular weight marker can be added to the gel prior to running and then stained up
using the above technique]
8. Immunoblot (Dot Blot)
1. The Nitrocellulose (NC) was pre-soaked in Tween TBS (Tris-buffer saline) and
dried.
2. Samples (2-5 pl_) were loaded and dried.
3. Monoclonal antibody (mAb) reagent was prepared in 1:10 dilution and added.
4. Allow to incubate for 3 hours
5. The conjugate (I in 1000 dilution) was prepared.
6. The conjugate was added and incubate for 31/2 hour
7. The NC was washed x2 in TTBS
8. The NC was rinsed briefly in 3 changes of pyrogen-free water.
9. Colour was developed with the following solutions.
Solution A (in a glass universal). 30 mg of 4 chloro-1-naphthol and 10 mL methanol
(Analar grade)
Solution B (100mL flask). 50mL of TBS and 30 pl_ hydrogen peroxide (30% solution)
10. Solution A was added to solution B just prior to using
11. The developer was poured onto the NC and development of colour was observed
over 15-30 minutes, Stopping the reaction by washing in tap water.
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Section 3
Methods of Studying Eosinophil Migration.
Prompted by a case, I looked into the importance and mechanisms of eosinophils
causing disease in gastro-intestinal mucosa. I have set up some assays in WGLF
which had not previously been done. Dr.Croft (Croft, 1996) had done the pioneer work
in setting up an ECP assay in this lab. I have reproduced his method to detect ECP in
WGLF as well as set up the eotaxin assay in WGLF.
1. Eosinophil Cationic Protein (ECP) Assay:
ECP radioimmunoassay (RIA), Kabi Pharmacia
Principle
This kit is a double antibody radio-immunoassay where ECP in the sample competes
with a fixed amount of 125l labelled ECP for the binding sites of specific antibodies.
Bound and free ECP are separated by addition of a second antibody immunosorbent
followed by centrifugation and decanting. The radioactivity in the pellet is then
measured and is inversely proportional to the quantity of ECP in the sample.
Methods:
Standards samples
Standards and samples were all assayed in duplicate.
Standard:
As included in the kit in a range of dilution
Samples:
UF/P WGLF, no pre-dilution necessary.
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Procedure:
1. Standards and samples (50 pl_) were added to polystyrene centrifuge tubes.
2. 50 pi ECP 125l (blue in colour) was added.
3. 50 pi anti-ECP (yellow in colour) was added.
Now (all the tubes were then green).
4. Tubes were mixed, covered and incubated for 3 hours at room temperature.
5. 2 mL of decanting fluid (well mix the decanting fluid before use) was added.
6. Incubation was for 30 minutes at room temperature.
7. All tubes were centrifuged for 10 minutes at 1500g. Tubes were carefully replaced
into rack and immediately decanted and let stand for 30 seconds upside down on
absorbent paper.
8. The radioactivity in the tubes were determined in Gamma counter..
9. Calculation of the results was follows:
• The mean count (B) for the standards and samples expressed as a percentage of
the mean counts of the zero standard (B0)
:=> % activity bound= 100xB/B0.
• The percentage values obtained were plotted for the standards against the
concentration on a linear-log paper and a standard curve was constructed.
• The concentration of the unknown samples was read from the standard curve
Precision: According to the kit, the detection limit is <2 pg/l and recovery 103±3%
(mean±2SD). The recovery experiment in WGLF done by Croft found 100% recovery
(Croft, 1996)
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2. An Eosinophil Specific Chemokine (eotaxin) Assay:
High sensitive human eotaxin immunoassay kit - R&D systems (DTXOO).
Principle is the same as the 'sandwich' ELISA described for immunoglobulins, specific
antibodies and other cytokines.
Standard and Specimens
Standards: Standard is prepared in PBS Tween 20 (0.02%)/ABS (1%)
Reconstitute Eotaxin standard with 1 ml_ of distilled water=10,000 pg/mL. Place 900 pi
of PBS/ Tween 20/ ABS into 1000 pg/mL tube, place 500 pi into remaining tubes.
Carry out dilution series which would give 1000,500, 250, 125, 62.5, 31.2, 15.6 pg/mL.
To produce standard and samples in same final matrix it is necessary to prepare a
'standard plate diluent' and a 'sample plate diluent'.
Sample Diluent:
10 mL (75% PBS/Tween 20/ABS) by 5 mL PBS/Tween 20/ABS + 5mL 50:50,
(PBS/Tween 20/ABS : PEG+) was prepared.
Standard Diluent:
4 mL (75% PEG+) by adding 2 mL PEG+ to 2 mLs 50:50 (PBS/Tween 20/ABS :
PEG+ was prepared.
Blanks= PBS/Tween 20/ABS 50 pi + 100 pi of Standard diluent.
Procedure
1. All reagents, working standards, and samples were prepared.
2. 100 pL of 'standard plate diluent' was added to standard wells
3. 100 pL of 'sample diluent' was added to sample well
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4. Standard or Sample (50 pL) was added to appropriate wells and cover the
microplate at room temperature for 2 hours
5. The plates were aspirated and washedx3 with wash buffer.
6. 200 pL of eotaxin conjugate was added to each well, cover the plate and hold at
room temperature for 1 hour. Substrate was prepared.
7. The plate was aspirated and washed x3
8. 200 pi of substrate solution was added to each well and hold for 30 minutes at room
temperature.
9. 50 pi of stop solution was added to each well.
10. Read within 30 minutes at 450 nm wave length correction at 540 or 570nm.
Precision : According to the kit, the minimal detectable dose of Eotaxin is <5 pg/mL.
The intra assay and inter assay co-efficient of variation is <6 and <12 % respectively.
Effect of filtering on eotaxin assay in WGLF,
I looked at the effect of filtering on the level of Eotaxin in WGLF by analysing filtered
and unfiltered specimens.
Figure 2.3, shows that there is no significant variation in the measured eotaxin in the
filtered and unfiltered specimen.
It is possible that eotaxin, which is an 8.3 KDa, 74 amino acid residue, non-
glycosylated polypeptide is easily filtered out through the 1 micron pore size of the
filter paper.
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Effect of Filtering on Eotaxin
Concentration in WGLF
onm UF/PP
i i F/PP
Figure 2.3: Eotaxin concentration in
filtered and unfiltered samples of
WGLF
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Section 4:
Methods for studying biological potentials (nitric oxide and cytokine production)
of LPS, using mouse and human colonic carcinoma cell lines.
1. Determination of TNF- a secretion by L929 bioassay.
1. The L929 mouse fibroblast cell line, which is sensitive to TNF, was cultured in
growth medium; DMEM [Dulbecco Modified Eagle's Medium (Sigma, D-5546)]
containing 5% FCS (Foetal calf serum) supplemented with penicillin (100 U/mL),
streptomycin (100 pg/mL) and 1 mM L-glutamine, and maintained by splitting 1:10
twice weekly. Cells were subcultured once weekly by splitting 1:20.
2. Cells were dislodged by 0.005% trypsin/0.02% EDTA to avoid cell clumping, washed
and resuspended in DMEM to 2x10 5 cells/mL.
3. Cells were dispensed in flat bottomed microplate (Cellstar, Greiner) at 100 pL/well
and incubated at 37°C, 5% C02 overnight.
4. The growth medium was then aspirated, discarded and replaced with 100 pL/well of
assay medium: DMEM containing 5% FCS supplemented with 1mM glutamine and 2
pg/mL actinomycin-D (to stop further cell growth without killing the cells).
5. To experimental wells, 100 pL of test supernatants which had been diluted 1:5 in
assay medium, was added.
6. A standard of recombinant TNF (National Institute for Biological Standards and
Controls, UK) diluted serially 1:5 at a starting concentration 1000 lU/mL and a well
without TNF were included. Plates were covered and incubated at 37°C, 5% C02over
night. The medium was then discarded and replaced with 100 pL/well of filtered (0.22
pL) crystal violet solution [0.5% crystal violet in 20% (v/v) methanol in distilled water)
which stains surviving cells. After 2 minutes the plates were washed vigorously under
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tap water and dried. The crystal violet was dissolved by addition of 100 pL of 20% (v/v)
acetic acid to each well.
7. The plate was read at 590 nm.
2. Nitric oxide (NO) assay
Mouse monocyte cell line (J774) and human colonic carcinoma cell line (CaCo2) were
used.
1. Cells were plated (24 well tissue culture plate) at 1X10 6 cells/well
2. Plates were left for 1 hour.
3. Different concentration of various core types of LPS were added.
2. The cells were centrifuged at 300g for 7 minutes.
3. 100 pL of supernatant were added in triplicate.
4. 25 pL 1mM NaN02 to 175 pL RPMI medium (Sigma, R-5886) were added to first
well.
5. Greiss reagent (100 pL) was added to each well.
6. Plates were left for 10 minutes.
7. The plates were read at 540 nm.
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Results Section
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Chapter: 3
Pilot Study
Introduction
Before starting well designed in-depth studies I did a small study using specimens
collected from patients with a spectrum of diseases. The aim of the study was two¬
fold: (I) To establish whether the research findings using the WGL technique from the
Gl lab were reproducible. (II) to test my competence at reproducing those findings
using the same, as well as some new techniques.
Patients
A small cohort of patients is presented in Table 2.1 in chapter 2.
The patients studied were heterogeneous in disease distribution and their previous
and current treatment. Among the 10 inflammatory bowel disease (IBD) cases, 7 had
Crohn's disease (3 active, 4 inactive disease on the basis of lavage total IgG) and 3
had inactive ulcerative colitis. The IBD cases were relatively older compared to other
groups. The possible infection group, on the other hand, is relatively younger
(Table2.1, chapter 2). This group comprises Idiopathic diarrhoea (n=2), Travellers'
diarrhoea (n=1), giardiasis (n=2), diverticulosis (n=1) and transient diarrhoea (n=4).
From the miscellaneous group, two patients (1 Ca Colon, 1 anaemia/cirrhosis) have
been excluded from the analysis as they have extremely high total lavage IgA and IgG
values respectively.
Assays Performed
• Total immunoglobulin in WGLF (IgA, IgM and IgG)
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• Specific antibody in WGLF(lgA, IgM and IgG EndoCAb and anti-Ova IgA).
Methods are described in chapter 2.
Results:
1, Technical:
Five WGLF samples were analysed independently, in parallel by two technically
expert research technicians (KH and NA) in the Gl Lab and by myself (SAMI).
Sample no. SAMI KH NA
94/062 117 114 109
94/256 63 52 56
94/375 97 86 82
94/802 122 113 127
94/802 87 91 85
Table 3.1: Comparison of Total IgA pg/mL estimation in WGLF by different personnel
Table 3.1 shows that there is an excellent agreement (correlation coefficient r= 0.96)
between my results (SAMI) and the results from others (KH & NA), who are
technically expert in ELISA method and doing routine ELISA in this laboratory.
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Table 3.2: Estimation of different antibodies in WGLF in a patient on 3 different occasions
Lavage no/ Total IgA Total IgG IgA Endo IgA Ova IgM Endo
Date pg/mL pg/mL MU/mL Unit/mL MU/mL
1702:3/6/93 25 1 7.7 0.71 0.04
1733:9/8/93 30 5 4.6 0.91 0.00
1763:2/9/93 26 2 3.8 0.50 0.02
Antibody levels in WGLF taken on three different occasions from a patient with
constipation (otherwise healthy) showed very consistent results (albeit with a slight
scatter, Table3. 2).
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2. Laboratory Methods
Lavage total IgG
Figure 3.1 records the total IgG in WGLF from the different patient groups.
In the miscellaneous group, an 85 year old female patient diagnosed with
anaemia/cirrhosis had a very high lavage total IgG (excluded from the analysis).
Another 84 year old female patient who had been diagnosed with a rectal adenoma,
also had a very high IgG value (67pg/mL). In the IBD group, 3 Crohn's patients had
lavage IgG >10 pg/mL. These patients had active disease and were on therapy
consisting of Prednisolone and Salazopyrin. One case of giardiasis also had a high
lavage IgG level(16 pg/mL).
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Figure: 3.1 TotallgG in WGLF from different groups of patients.
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Lavage Total IgA
Figure 3.2 shows the total IgA in WGLF . There were no significant differences in
lavage total IgA between patient groups. Total IgA values ranged from 9-175 pg/mL
Flowever, higher values of IgA were observed in coeliacs. A 72 year old male, who
was admitted with unexplained anaemia and altered bowel habit, and was diagnosed
with colonic carcinoma, had high IgA values. Another patient, a 29 year old female,
diagnosed with Travellers diarrhoea had a very low total IgA in lavage. This may be a
case of IgA deficiency. It would merit checking her serum level of IgA antibody.
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Figure: 3.2 Total IgA in WGLF from different groups of patients
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IgA EndoCAb
Specific secretory IgA antibody against bacterial antigens was detected in all 35 cases.
The values ranged from 1.3-19.9 MU/mL and are shown in figure 3.3.
There were no significant differences between the groups. However, again there was
increased values observed in patients with coeliac disease. It is noteworthy that the
lowest value of IgA EndoCAb (1.3 MU/mL) was in the patient who was suspected to
have IgA deficiency. This finding lends support to her diagnosis.
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Figure: 3.3 IgA EndoCAb in WGLF from different groups of patients.
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One interesting phenomenon was observed in the IBD cases. There was a significant
correlation between the total IgA and IgA EndoCAb titre in lavage (figure:3.4).
There were also increased IgA EndoCab responses observed in two cases, one with
giardiasis and another with diverticulosis.
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Figure: 3.4 Correlation between total IgA and IgA EndoCAb in WGLF from patients
with IBD
r=0.8
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IqM EndoCAb
Figure 3.5, illustrates the IgM antibodies against 'Endotoxin' core antigens in different
patient groups. There were significant differences in the expression of IgM EndoCAb
response in coeliacs compared with IBD (p<0.05), possible infection (P<0.05), and
various (p<0.04) groups.
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Figure: 3.5 IgM EndoCAb in WGLF from different groups of patients
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Discussion
By comparing my results with the results from others it shows that I am technically
competent in this laboratory work. Information from the patient with constipation
confirms that antibody tests in WGLF provide a relatively reproducible test. Therefore,
it is reasonable to expect to find a meaningful difference between patients groups as
there really are differences in gut immunopathogenicity. This was also shown
previously by other investigators from this laboratory (e.g. Sallam, 1995).
As discussed in chapter 2. Total IgG in WGLF has been shown to be a useful
objective parameter of Gl protein loss as well as disease activity in IBD (Chouduri et
al, 1993). Higher values of total IgG in WGLF were also observed in this study.
However, statistical significance was not reached due to small groups of patients.
In this study, high total IgA values were observed in patients with coeliac disease
(although only in 2 cases). This finding is in agreement with those of others ( Colombel
et al, 1990; Wood et al, 1987; Crabtree et al, 1989) who showed enhanced local
secretion of IgA and IgM antibodies and increased Ig- synthesising plasma cells in the
lamina propria.
IgA-specific antibody responses against 'Endotoxin' core antigens were also higher in
patients with coeliac diseases. In a similar fashion, to total IgA, this increased
response may be due to generalised immune up-regulation in the gut in coeliac
disease. Alternatively, these results may suggest a selective contribution by
antibacterial antibody responses to the increase in intestinal Ig content.
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The increased levels of IgA EndoCAb paralleled the increase in total IgA in patients
with IBD probably due to increased non-specific response to gut bacterial antigens.
This may indicate a breakdown of gut immune tolerance to resident intestinal flora.
This result may reinforce the finding of Dunhmann and colleagues (Dunhmann et al,
1995) who showed that tolerance exists towards resident intestinal flora but is
broken down in active IBD.
Over-expression of total IgM antibody levels in intestinal secretions from coeliacs has
been previously shown in this laboratory ( O'Mahony et at, 1991). It was also
postulated that plasma leakage (coeliac disease is also a protein-losing enteropathy)
could be partially responsible for this high IgM value. However, an increase in the
intestinal fluid immunoglobulin content was not accompanied by equivalent changes in
serum immunoglobulins . In addition, several in vitro studies (Falchuk et al, 1974;
Ciclitera et al, 1986) assessed the relative contribution of specific antigliadin
antibodies to the increase in total intestinal immunoglobulin content in coeliac disease.
They found a variable contribution (from 12 to almost 50%) of antigliadin IgM
antibody to the total concentration of IgM antibody.
I am not aware of any in vivo studies that have assessed the contribution of antibodies
against gut bacterial antigens to the increased total immunoglobulin in intestinal
secretions in coeliac disease. These immunoglobulins may have a significant
contribution to the enhanced intestinal antibody production in this disease.
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Conclusions:
From this pilot work, a number of useful pieces of information have already emerged.
However, further studies will be needed using carefully selected patients along with
healthy controls to confirm and expand on these findings. Similar range assays could
be done on lavage and paired sera from the patients which may yield important
results. However, a colleague in the Gl lab, who has interests in coeliac disease
wanted to take this issue further.
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Chapter:4
Studies of Healthy Controls from Dhaka and Edinburgh
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Section 1 Studies of Gut Damage Parameters
Introduction
Gastrointestinal infections and parasitic diseases are highly prevalent in developing
countries, like Bangladesh ( Baqui et al, 1992). This is not the case in Western
societies. The resultant question is therefore whether any alteration or fundamental
differences exist in gut mucosal immunity between these two heterogeneous
population groups.
Various immunological parameters in the gut mucosa of patients and healthy
volunteers have been well studied in Edinburgh (Mahony et al, 1990, Croft, 1996,
Sallam, 1994). The significance of these immunological parameters in relation to
diseases (for example, Coeliac disease, Inflammatory bowel disease) has been
described in publications originating from this gastrointestinal unit (Mahony et al, 1990
& 1991; Brydon et al, 1992 & 1993, Choudari et a/,1993, Ferguson et al, 1992 & 1994,
Croft, 1996). For example, in all of these studies WGLF total IgG has been shown to be
an excellent objective marker of gut inflammation or damage.
In the following two sections, I have compared various immunological and gut damage
parameters in WGLF from healthy volunteers and controls from Dhaka and Edinburgh.
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Results:
Table 4.1 summarises the findings in the two control groups of various factors that are
indicators of mucosal damage and inflammation in the gastrointestinal mucosal
system.
Table 4.1: Comparison of Gut Damage Parameters among Healthy Controls
from Dhaka and Edinburgh
Gut damage Substances Dhaka(N=11) Edinburgh (N=12) P
parameters analysed Median (range) Median (range) value
Gl Bleeding Haemoglobin 4 (2-11) pg/mL 3(1-9) 0.37
Mucosal Total IgG pg/mL 0.9 (0.2- 4) 1 (0-1) 0.47
Inflammation and Albumin pg/mL 15 (11-22) 1.5 (0-13) 0.0001
Protein loss a-1 Anti-trypsin 4 (2-10) 2 (0-7) 0.123
pg/mL
Gastrointestinal Blood Loss
Gastrointestinal blood loss is indicated by measurement of haemoglobin
concentrations in WGLF. The normal range for adults (between 0 and 5 pg/mL) has
been established in Scotland (Brydon & Ferguson, 1992). All the controls from Dhaka
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have normal lavage haemoglobin, except one volunteer. This was a 32 year old (Mr.
N), healthy man whose lavage haemoglobin was 11. No obvious reason was found
for this high value. He might have had a parasitic infestation. Parasitic infestation is
quite common in developing countries. Similarly, all the controls from Edinburgh had
values within the normal range, apart from one: a 29 year old female (PL) who had a
lavage haemoglobin of 9 . She was constipated and occasionally had problems with
haemorrhoids. Thus, with the exception of these two cases there was no evidence
of gastrointestinal blood loss in either control group.
Mucosal Inflammation and Protein loss
Total IgG in WGLF
The normal range for healthy control adults was studied in this unit (Sallam,1995). All
had total IgG of less than 5 pg/mL. However, the normal range in adults is considered
to be up to 10 pg/mL (Brydon et al, 1993). All the healthy controls both from Dhaka
and Edinburgh had lavage IgG < 5 pg/mL . Thus there was no evidence of mucosal
inflammation.
Albumin
The normal range for adults is up to 26 pg/mL (Brydon et al, 1993). The median and
range in both control groups were within the normal range. However, there were
significant differences in lavage albumin values between the control groups. Healthy
volunteers from Dhaka have a significantly higher selective (no evidences of other
protein loss) albumin loss through the gut compared with Edinburgh controls
(P<0.001).
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g-1 Anti- trypsin
The normal range in Scottish adults is up to 19 jig/mL (Brydon et al, 1993). The
healthy controls both from Dhaka and Edinburgh both had values <10 pg/mL.
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Section 2 Studies of Gut Mucosal Immunity Parameters
I will now discuss the results of different immunological parameters for the healthy
volunteers from Dhaka. These results will be compared with the normal ranges
previously established in adults from Edinburgh ( summarised in table 4.2)
Table 4.2: Comparison of Gut Immunity Parameters Among Healthy Controls
from Dhaka and Edinburgh
Immunity Substances Dhaka Edinburgh P values
Parameters Analysed (N=11) (N=12)
Median Median
(range) (range)
Secretory Total IgA pg/mL 51 (33-138) 36.5 (18-55) 0.0242
Immunoglobulins Total IgM pg/mL 9 (4- 34) 7 (0.34-23) 0.23
Cytokines IL-1 (3 pg/mL 0 (0- 20) 0(0-13) 0.83
IL-8 pg/mL 0(0- 18) 0(0-23) 0.503
Cellular ECP ng/mL 70(12- 98) 11.4(4-29.2) 0.0023
Mediators GE pkat/mL 0 (0- 0.194) 0 (0-9) 0.14
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Secretory Immunoglobulins
Immunoglobulin A (IgA)
In a previous study of healthy Scottish adult volunteers, the total IgA in WGLF was
found to have a median concentration of 73 pg/mL (10-173 pg/mL) (Saliam,1995)
The median (and range ) concentration of total IgA in WGLF from healthy volunteers
from Dhaka and Edinburgh were 51 pg/mL (33-138) and 36.5 pg/mL (18-55)
respectively. It is noticeable that the concentration of total IgA in WGLF from these
controls was less than that found in the previous study. The reason for this apparent
discrepancy in concentration of total IgA in healthy adult Scottish controls is not clear.
However, there was a problem with the IgA standard in the previous study (Mr.
Norman Anderson, personal communication ) which may have caused higher values in
comparison to my studies (which have been verified and confirmed by two
independent expert research technicians in the Gl lab)
There is a significant difference in total IgA in WGLF between healthy controls of
Dhaka and Edinburgh (p<0.0243). In the Edinburgh control group, some patients
were constipated, which leads to the question of whether constipation can cause
lower levels of IgA in WGLF. I will discuss this more fully later in the chapter.
Immunoglobulin M (IgM)
The median concentration of total IgM in WGLF from both Dhaka and Edinburgh
control are 9 pg/mL (4-34 pg) and 7 pg/mL (0.34- 23 pg) respectively. These values
are higher than total IgM in healthy adult volunteers studied previously (Sallam, 1995).
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Cytokines
lnterleukin-1(3
Healthy adult controls have concentrations up to 18 pg/mL. Virtually no IL-10 was
detected in WGLF in either control group. However, there was one exception in each
group: a 26 year old man (Mr.S) from Dhaka group had an IL-1 (3 level of 20 pg/mL.
Similarly, a 38 year old female (CS) from Edinburgh group had an IL-1 (3 level of 13
pg/mL
lnterleukin-8 (IL-8)
The normal adult range for IL-8 is less than 4 pg/mL. The median value and range in
Dhaka and Edinburgh groups were 0 pg/mL (0-18 pg/mL) and 0 pg/mL (0-23 pg/mL)
respectively. Three out of eleven volunteers from the Dhaka group had IL-8 levels of
more than 10 pg/mL in WGLF no IL-8 was detected in the remainder. No IL-8 in
WGLF was detected in the Edinburgh control group with the exception of one case: a
29 year old female (PL, her lavage Hb was 9) whose WGLF IL-8 was 23 pg/mL. No
obvious reason was found for the slight increase in IL-8 concentration in these 4 cases
Cellular mediators
Granulocyte Elastase (GE)
The normal range in adults is <100 pkat/mL (Ferguson et al, 1994). There was no GE
detected in either of the control groups, except in three cases, whose values were <10
pkat/mL. This suggests there was no evidence of active inflammation in either group.
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Eosinophil Cationic protein (ECP)
There is no available adult reference range for ECP in WGLF. The median value and
range in healthy adults from Edinburgh was 11.4 ng/mL ( 4 - 29.2 ng/mL). The ECP
concentration in WGLF in healthy controls from Dhaka was higher, with a median
value and range of 70 ng/mL (12-98 ng/mL). This value is significantly different from
the Edinburgh control group (p<0.0024). Higher incidence of parasitic disease in
developing countries, like Bangladesh (Baqui et al, 1992) may explain this difference.
Total serum IgG and IL-6
In view of the higher concentration of total IgA in WGLF in controls from Dhaka, I
decided to investigate the possibility that the higher IgA response could be due to
non-specific immune activation resulting from a high bacterial antigenic load from the
contaminated environment ( Stoll et al 1986; Baqui et al, 1992). I measured total
serum IgG and IL-6. These are good indicator of non-specific and recurrent infection.
The values are significantly different from those for the Edinburgh control groups,
p<0.0006 and p<0.0026 respectively (Figures 4.1 & 4.2). It is worth mentioning that
due to unknown reasons several cytokines, e.g. IL-6, IL-5, IL-10, and TNFa could not
be measured in WGLF (Hazel Drummond, personal communication).
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Figure: 4.1 IgG concentration in serum from healthy controls from Dhaka and
Edinburgh.
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Figure: 4.2 IL-6 concentration in serum from healthy controls from Dhaka and
Edinburgh
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Discussion
Despite significant environmental and geographical differences, there is no evidence
of gut damage or inflammation (as assessed by WGLF total IgG) in either of these
two healthy control groups. As far as lavage albumin is concerned, all the values from
both control groups were within normal adult ranges, according to a previous study
(Brydon,1993). However, the WGL albumin level was significantly higher in the control
group from Dhaka compared with Edinburgh. It is quite plausible that repeated enteric
infections in controls from Dhaka may lead to increased permeability, which results in
significant enteric protein loss. A study conducted at the International Centre for
Diarrhoeal Diseases Research, Bangladesh (ICDDR.B) has clearly shown that enteric
infection can lead to significant protein loss which could occur even in the recovery
period of the disease. Alteration in intestinal permeability is the cause of the protein
loss following enteric infection (Alam et al, 1994). However, the serum protein loss is
quite selective (albumin but not a-1 antitrypsin or IgG) . In spite of there being
significantly higher serum IgG levels in the Dhaka controls (Figure 4.1), an
insignificant amount of total IgG was detected in WGLF. This result may contradict
the currently held belief that total IgG in WGLF, which has a good correlation with
disease activity in IBD, is merely a 'seepage' from serum (Choudari et al, 1993).
However, I will discuss the origin of WGLF IgG further in chapter 7.
The total IgA result in WGLF is interesting. The significant difference between the
Dhaka and Edinburgh control groups needs further clarification. It could be due to the
incidence of constipation in the Edinburgh control groups which may result in lower
values of total IgA in WGLF, due to slower intestinal transit time in constipation. This
may result in intraluminal degradation of total IgA or dilution of intestinal secretion by
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the WGL solution. However, Croft (1996) examined these issues in his study as
causes for lower detection of total IgA in constipated children. He clearly showed that
intraluminal degradation or dilution of intestinal secretions by lavage solution are not
the cause of low IgA levels in constipation. The reason for the increased total IgA in
WGLF in the Dhaka control may be due to non-specific immune activation. In view of
the high bacterial antigenic load from a highly contaminated environment (Albert et
al, 1991), it is probable that there may be an increased drive for the production of
secretory IgA to prevent inflammation and bacterial translocation. It has been shown
that T cells 'armed' with secretory IgA antibodies are capable of direct killing of
bacteria (Tagliabue et al, 1986). In addition, a study conducted by Kett et al showed
that enteric bacteria enhance secretion of the protease-resistant form of IgA i.e. lgA2
( Kett et al, 1995). Furthermore, significantly higher non-specific IgG and IL-6
responses in serum (Figures 4.1 and 4.2) from the Dhaka controls lend further
support to the hypothesis of increased non-specific immune activation in the gut
mucosa. It should be noted here that I have measured neither the specific lgA2 levels
in WGLF nor the activity of serum IL-6. The activity of serum IL-6 by bio-assay and
measurement of specific lgA2 in WGLF would be helpful to reveal the mechanisms of
this non-specific immune activation. It would be worth doing further study in this area.
Cellular mediators, especially, ECP, (which is significantly higher in Dhaka controls
than Edinburgh controls), will be discused further in relation to 'cell migration' in
Chapter 9.
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Chapter 5
Studies of anti-Endotoxin and specific antibacterial antibodies
in healthy controls from Edinburgh and Dhaka
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Section 1 : Anti-Endotoxin and other antibacterial antibodies
Introduction
In a previous chapter, evidence has been presented to suggest that higher IgA
responses in healthy controls from Dhaka are due to non-defined gut mucosal immune
activation. This immune activation may be due to a higher microbial antigen load in
the gut from the contaminated environment. Therefore, I decided to look at anti-
endotoxin (using 'cocktail antigens, which have been described in the method
development section of chapter 2) antibody responses as well as specific anti bacterial
antibodies in these two population groups. I will describe these findings in the following
two sections of this chapter.
Results
The concentrations of IgA [median and (range)] in WGLF against endotoxin core
'cocktail' antigens in Dhaka and Edinburgh were detected as 7 (3-18) MU and 1.02
(0.51-4.14) MU respectively. The Dhaka control group had a significantly higher IgA
response against these antigens compared to the Edinburgh control group, p<0.0001
(figure:5.1).
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Figure: 5.1 IgA EndoCAb in WGLF from healthy controls
The higher IgA EndoCAb response in the Dhaka control group is well correlated with
their total IgA in WGLF, r=0.78, p<0.02 (figure:5.2). Conversely, no correlation was
found between IgA EndoCAb and total IgA in WGLF in the Edinburgh group (data not
shown).
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Figure: 5.2 Correlation between total IgA and IgA EndoCAb in WGLF from Dhaka
control groups.
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The IgM EndoCAb in WGLF in both Dhaka and Edinburgh groups are similar, these
values are 0.18 (0.04 - 3.67) MU, and 0.18 (0.02 - 0.29) MU respectively.
No significant differences were found in serum EndoCAb antibodies (IgG, IgM and
IgA) in these two population groups (figure:5.3). Their serum concentrations were
similar. These values were ( median and range): for IgG, 201.5 (103 - 523) MU, and
205 (105 - 999) MU; for IgM, 132 (70 - 251) MU and 104 (58 -234) MU; and for IgA,
170 (95 - 537) MU and 199 (125-522) MU in Edinburgh and Dhaka control groups
respectively.
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Figure: 5.3 Serum EndoCAb antibodies (IgG,IgM and IgA) in two control groups
Anti-cholera antibodies
The results of the specific anti-bacteria antibodies were quite surprising. There were
no significant differences observed in anti-cholera toxin (CT) antibodies (IgA and IgM)
in WGLF between Dhaka and Edinburgh control groups (figure:5.4).
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Figure: 5.4 Anti-cholera toxin antibodies (IgA and IgM) in WGLF in two control groups.
The median (range) values of these antibodies were : IgA, 7488 (1200 - 43456)
units/mL and 9570.5 (1870 -59243) units/mL; and IgM, 12604 (836 -211488) units/mL
and 8177.5 (0 - 36088) units/mL for Dhaka and Edinburgh control groups respectively.
The anti-cholera toxin antibody responses in serum were also similar in these control
groups with an exception of anti-CT IgG antibody. The serum anti-CT IgG response
was significantly higher in Dhaka control compared to the Edinburgh control group,
p<0.001 (figure:5.5).
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Figure: 5.5 Anti-cholera toxin antibodies (igG, IgM and IgA) in serum from two control
groups.
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To check the purity of cholera toxin antigen, I have run the cholera toxin B in SDS
PAGE gel, which was also stained with Comassie blue to rule out any other protein
contamination (figure: 5.6)
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Figure 5.6: SDS PAGE of cholera toxin B with Comassie blue stain
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Discussion
These data demonstrate that the higher IgA response in WGLF in Dhaka control
groups is likely to be due to a higher level of Gram-negative enteric bacterial antigens
in the gut. These enteric bacterial antigens may be responsible for the non-specific
immune activation seen in these control groups. The specific IgA antibody responses
against a representative number of Gram-negative enteric bacteria ('cocktail' antigens)
is well correlated with their total IgA antibody in the WGL. This was not observed in the
Edinburgh control group.
As far as serum antibodies are concerned, no real difference exists in specific
antibody responses against the 'cocktail' antigens. This result suggests that
differences exist between the systemic and mucosal immune compartments and
support the statement that 'these two compartments are completely distinct' (Ferguson
et at, 1994). Furthermore, this result also supports the recommendation that for the
study of intestinal immunopathology, direct investigation of the gut is mandatory
(O'Mahony et al, 1991).
The results of anti-cholera toxin (CT) antibodies were surprising for at least for two
reasons: why should these occur in Edinburgh controls who have never had clinical
cholera or been exposed to cholera vaccine? In some cases, primary antibody IgM is
not detectable. However, some of the healthy volunteers from Edinburgh who said that
they have had a history of a 'tummy upset' while they were on holiday or at home
appear to have high levels of specific intestinal antibodies. Secondly, why should
Dhaka controls have relatively lower levels of anti-CT intestinal antibodies ? A possible
explanation for the first query is that these are antibodies to the heat-labile (LT)
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enterotoxin of E.coli, which is antigenically (81% sequence homology) very similar to
cholera toxin (Clements and Fikelstein, 1978; Takeda et al, 1983; O' Mahony et al,
1991 Ferguson et al, 1996). It has been shown that the LT from E.coli is
immunologically related to both subunits, A and B, of cholera enterotoxin as
demonstrated by neutralization and immunodiffusion (Clements and Finkelstein, 1978;
Takeda et al, 1983). In addition, It has also been shown that cholera like-enterotoxin
can be produced by some strains of Camplybacter jejuni. The toxin activity was
blocked by cholera anti-toxin (Ruiz-Palacios et al, 1983). Flowever, the possibility of
Edinburgh people having recent exposure to LT is unlikely.
From previous studies in the Gl lab, it has been shown that anti-cholera toxin antibody
could be apparently detected in some patients from Edinburgh (O'Mahony et al, 1991).
The antigen used by O'Mahony was from the List Biological Laboratories, Inc. USA
(Batch No: 103). I used antigen from a different batch (No: 569B) but from the same
company. According to the company, the purity of the antigen was checked by disc gel
electrophoresis (non denaturing condition), which gives a sharp immunoprecipitin band
against cholera toxin antiserum. I have checked the purity of the antigen by running in
SDS PAGE (figure 5.6). As it can be seen, there is also a sharp band in the gel which
clearly suggests a single molecule. Cholera toxin is a protein molecule, composed of
two distinct subunits. The A subunit (28,000 Da) is noncovalently bound to an
aggregate of five B subunits (11,600 Da) (Reid et al ,1995). Ideally, in a SDS PAGE
the B subunit should come out as either 11,6 00 Da or 57,500 Da. After comparing
with molecular weight markers, it shows that the antigen did not reach 57,500 Da or
11,600 Da but was at around 28,000 Da. This is the correct molecular weight of the A
subunit. Following inquiry, the company mentioned that B subunit came up as single
molecule but they quoted the published molecular weight. It is therefore, reasonable to
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conclude that the anti-cholera toxin results should be interpreted against all these
backgrounds and obviously warrants further study before any firm conclusion can be
made..
In explanation of the second query, it seems reasonable to postulate that the down-
regulation of anti-CT antibody production could be due to 'oral tolerance' (Strobel &
Mowat, 1998). This is possibly due to repeated exposure of individuals in a 'cholera
endemic' area, like Dhaka. However, this statement contradicts the previous anti-
endotoxin results and hypothesis. Nevertheless, it would seem unreasonable to
postulate that 'oral tolerance' may be developed against generalised Gram-negative
enteric bacteria.
In a recent murine study it was shown that mice orally immunised with killed
Salmonella dublin in conjunction with a suitable adjuvant were protected against a
lethal oral challenge compared to mice orally immunised with killed S.dublin alone,
which were not protected. The protected group showed a four-fold increase in serum
anti-LPS IgG but not in faecal anti-LPS IgA. There was a correlation between serum
anti-LPS IgG antibody response and adjuvant-induced protection in orally induced
mice (Chong, 1998). The significantly higher anti-CT IgG response in the Dhaka
control groups compared to the Edinburgh groups may lend support to the theory that
Dhaka controls are relatively immunised. A study done in the late sixties showed that
the degree of protection against cholera is directly related to the level of serum
vibriocidal IgG antibody (McCormack et al, 1969).
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Section 2: Anti-Lipolysaccharide (LPS) Core Types (R1,R2,R3 and R4) of
Escherichia coli, IgA antibody
Introduction
As described in the literature review section of chapter 1 (figure: 1.1),
lipopolysaccharide (LPS) is an essential component of the outer membrane of all
Gram-negative bacteria. Structurally, most types of LPS are composed of three
distinct regions: the lipid A, the core oligosaccharide and the O-polysaccharide (O
antigen) consisting of long chains of repeating oligosaccharide units (figure: 1.2). The
LPS core region of E.coli has a conserved overall structure, with an inner 2-keto-3-
deoxy-octonate-heptose region and an outer hexose/hexosamine region. Most of the
variation that does occur is in the outer part of the core, furthest from lipid A. In wild-
type smooth E.coli, the core region can be typed into at least five different
chemotypes, known as R1,R2, R3, R4 and K-12, the geneticists strain (Schmidt et
al, 1969; 1970).
The O antigen of smooth LPS may mask some of the epitopes and phage attachment
sites in the core region. The chemical, serological and phage methods that have been
used to define the different core types of E.coli are therefore not directly applicable to
wild-type smooth strains (Gibb et al, 1992). However, it is now well recognised that
certain O-serotypes are associated with certain diseases, especially within E.coli
(Orskov and Orskov,1992), and can be useful in epidemiology. Dr Gibb demonstrated
that O serotypes of E.coli can be further analysed by core typing using monoclonal
antibodies (Gibb et al, 1992). Certain O-serotypes appear to be always associated with
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a single core type, while others may be associated with more than one core type. Very
little is known about the frequency with which these different core types occur in wild-
type E.coli serotypes. Similarly, the relationship of core type with various diseases
caused by E.coli is unknown.
E.coli diarrhoea is common in Bangladesh (Hoque et al, 1994). In view of the recent
enterohaemorrhagic E.coli outbreak in Scotland (Douglas and Kurien, 1997), I was
prompted to look at whether there is a gut mucosal immune response against the
different chemo-types of E.coli in these two population groups. It is a well known fact
that gut mucosa is an interface between 'exterior' and 'interior', and acts as a barrier
against infectious organisms or their products gaining access to the systemic
circulation. In the field of sepsis, the source of LPS/ Endotoxin, whether of gut origin or
due to bacteraemia, is debated (Poxton,1995). It is recognised that mucosal immunity
is quite separate from systemic immunity. It is, therefore, essential to examine the
mucosal antibody responses to core LPS types of E.coli. Knowledge of this area would
have potential in the development of the oral E.coli vaccines. The comparative
distribution of responses to core types of E.coli in these two geographically different
population group was an important aim of this study.
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Results
LPS extracts were run in PAGE gel and subsequently silver stained to check the purity
of the LPS. Figure 5.7 shows the silver-stained PAGE profile of R1-R4 core types of
E.coli. The purity of LPS were also checked by immunoblot (figure, 5.8) with core
specific monoclonal antibodies [VN2 483.10 (R1 specific), H4361.23 (R2 specific), W4
434.07 (R3 specific) and WN1 222-5 (cross-reactive with all core types)], as described
by Gibb (Gibb et al, 1992). These monoclonal antibodies were supernatants of
hybridoma cell cultures grown in RPMI 1640 supplemented with 5% FCS. (These
antibodies were a kind gift from Dr.Barclay). The R4 core LPS was not totally pure,
some 'ladder pattern' of bands is visible corresponding to O- polysaccharides (track 4
in figure 5.7). This is typical of the R4 core type LPS. It is rather heterogeneous and
has been observed previously (Professor Poxton and Robert Brown, personal
communication).
*3 ^
Figure 5.7 Silver stained PAGE profiles of core types of LPS E.coli
Track 1= R1, Track 2= R2, Track 3= R3 and Track 4= R4.
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Figure 5.8 'Dot blot' of various core types of LPS with specific monoclonal antibodies
aR1, aR2 and aR3= monoclonal antibodies specific for R1, R2, and R3 respectively.
Xrt= cross-reactive with all E.coli R cores. CNTRh control.
Figure 5.9 depicts the findings of WGLF IgA responses against LPS core types of
E.coli. As can be seen in the figure, there were IgA antibody responses against the
whole range of available core types (R1 ,R2,R3 & R4) of E.coli. In the Edinburgh
control groups, the antibody responses were in descending order of magnitude:
R1>R2>R3>R4. On the other hand, in the Dhaka control groups, the order was:
R1>R3>R2>R4.
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Figure: 5.9 Anti-LPS core types (R1 ,R2,R3 & R4 of E.coli) IgA antibody in WGLF in
healthy controls.
There were significant differences in the IgA antibody response against core types of
E.coli between Dhaka and Edinburgh. The IgA antibody responses against R1, R3
and R4 in Dhaka controls were higher and significantly different from the Edinburgh
controls, p<0.02, p<0.03 and p<0.01 respectively. IgA antibody response against R2 in
the Dhaka controls were also higher but not significantly different from the Edinburgh
controls (p=0.30).
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Discussion
This study has shown for the first time that there are mucosal IgA antibody
responses present against the specific LPS core types of E.coli in the gut. In view of
the fact that the core epitopes may not be readily accessible to antibodies, the
mechanism of antigen expression and induction of antibody response is brought into
question. In an excellent study done by Gibb et al, it has been shown that the LPS
core types can be differentiated serologically by monoclonal antibodies ( Gibb et al,
1992). These antibodies are selective for the LPS core of E.coli. They do not bind to
a range of other Gram-negative bacilli, indicating that their binding observed is
specific. However, most of the antibodies bind to Salmonella and Shigella species as
these share E.coli core structure, and are in fact closely related to E.coli in many other
respects..
Unsubstituted LPS core is present in smooth bacterial cells but may not be easily
accessible to monoclonal antibodies in standard laboratory cultures (Nelson et
al, 1990). However, core epitopes are more accessible on bacterial cells grown in
serum or magnesium-depleted medium, which is thought to mimic conditions in the
infected host (Nelson et al, 1991). However, the environment of the gut lumen for the
growth of E.coli and other members of the Enterobacteriaceae is completely different.
We do not know the mechanisms of expressivity and induction of IgA mucosal immune
responses to core epitopes within the Gl tract. It is known that enterocytes (the
absorptive cells in the intestinal mucosa) can function as antigen-presenting cells
(APCs), i.e. are able to take up and complete endosomal degradation, processing
and presentation of antigen to immunocompetent cells (such as T cells and
macrophages) (Kato & Owen, 1994). It is probable that the LPS core types of E.coli
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may exploit the efficient antigen-processing system operated by enterocytes for the
following reasons: firstly, enterocytes are the first point of contact for enteric bacterial
LPS like other luminal constituents; secondly, the transcellular route through
enterocytes has been recognised as the route of uptake of non-nutrients (Kato &
Owen, 1994). The route of uptake of non-nutrients was believed previously to be only
paracellular. Moreover, normal absorptive cells in humans express MHC class II
proteins on their surfaces ( Mayer et a/, 1991) which is a prerequisite for a APC to
initiate the process of antigen presentation.
Uptake mechanisms are separated into receptor-mediated and non-receptor-
mediated pathways (Kato & Owen, 1994). The core epitopes of LPS may use either or
both pathways. Another important route of transportation of antigens is via M cells. M
cells play an important role in antigen sampling, taking up particles from the intestinal
lumen and transporting them to lymphocytes and macrophages enfolded in pockets in
the basolateral surfaces of M cells ( Trier, 1991). In general, antigen uptake and
transport are determined by the nature, polarity and capacity of the intracellular
pathways to take up antigens. The core types of LPS of E.coli may use any of these
antigen transport systems to reach the inductive arm of the mucosal immune system.
Gibb et al found in their study of 180 wild-type E.coli isolated from clinical samples
(blood and urine specimens) and from the faeces of asymtomatic individuals, that 123
were assigned to R1 core type, 14 to R2 and 18 to R3. Due to lack of suitable specific
monoclonal antibody, they could not positively identify the R4 groups (heterogeneous,
not purely extracted as seen in figure 5.7). They did have a group of 25 strains,
assigned as RNC (R not classified), which may include isolates with R4 core with
other as-yet unidentified core types (Gibb et al, 1992). Our data suggest a similar
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pattern of distribution of the core types viewed by the mucosal IgA response in both
Edinburgh and Dhaka control groups. However, we do not know the incidence of R
cores in the Dhaka population. The mucosal IgA data suggest that R3 may be more
common in Dhaka compared to Edinburgh.
As far as O-serotypes are concerned, Gibb et al found R1 core type was associated
with O types 1,4, 6,8, 18 and 75 whereas R2 with only 075. R3 core type was
associated with 015. There were some apparently constant associations between O
types and core types: all 26 06 isolates in his study were R1 and all 3 015 isolates
were R3. In contrast, 075 isolates were found among both R1 and R2 core types
(Gibb et al, 1992). They also found that the proportion of R1 that belongs to one of the
common O types was greater among blood culture isolates. The relationship between
core types and O serotypes of E.coli and their pathogenicity in man is not yet
established. Significantly higher IgA responses against R1 core types in the Dhaka
control groups, may be due to the fact that E.coli is not only a common diarrhoeal
pathogen (Hoque et al, 1994), but also a common isolate in Gram-negative
septicaemia in Bangladesh (Strulence et al, 1985). It is possible that there may be a
relationship between core types and pathogenicity.
The IgA response against R3 core types in the gut is fascinating, in view of the fact
that all isolates of E.coli 0157:H7 as well as other vero-toxin producing E. coli (VTEC)
strains investigated in Scotland are R3 positive (Curie and Poxton,1999). Significantly
higher IgA responses against R3 in the Dhaka control groups may be due to higher
incidence of infections caused by Shigella and E.coli in Bangladesh (Hoque et al,
1992; 1994). These organisms share closely related LPS cores (Gibb et al, 1992;
Heinrichs et al, 1998). Gibb et al showed that Shigella sonnei strains reacted with the
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R1-specific monoclonal antibody (mAb) while Shigella flexneri strains reacted with the
R3-specific mAb. It is difficult to comment on R4 core types because this group is not
yet well characterised. Salmonella shows homology with the R2 group.
This study suggests that the LPS core types of E.coli are expressed and capable of
producing IgA antibody responses in the intestinal mucosa. Information concerning
the LPS core epitopes that evoke protective immunity could be useful in the future
design of oral vaccines. However, further studies are needed to investigate how these
core type antigens are presented to the inductive arm of mucosal immune systems,
especially the role of T cells and immunological memory. It is also necessary to
establish the relationship between the LPS core types and O types and pathogenicity.
It would be interesting to investigate specific monoclonal IgA antibodies and their
relative protective capabilities, especially whether antibodies recognising a single
epitope on the target organism can provide protection against colonisation or invasion
of the intestinal mucosa.
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Section 3: Biological potentials of core types of LPS of E.coli
Introduction
Septic shock syndrome is a serious problem associated with high morbidity and
mortality. It is well recognised (already discussed in the literature review section ) that
the effect of excessive release of proinflammatory mediators -including reactive
oxygen intermediates and nitrogen compound, such as nitric oxide (NO) and cytokines
(notably,TNF a and IL-1 p) induced by the LPS of gram-negative bacteria is the
mechanism of this syndrome. It is also possible that inflammatory responses in the Gl
tract may be caused or exacerbated by LPS and some LPSs may be more biologically
active than others. In an earlier section, it has been found that the IgA antibody
response against core types of LPS of E.coli is quite variable. Furthermore, it is also
known that several virulent pathogenic enteric bacteria (eg. Shigella, E.coli 0157 )
possess R3 core types in their LPS. The following section tested the hypothesis that
some core types, e.g. R1 or R3, are more active in terms of inducing proinflammatory
mediators than that of other core types ( R4 was omitted as it was not purely isolated
and it is uncommon) Accordingly, I have measured induction of NO, TNF-a and IL-ip
using the mouse monocyte cell line (J774) and human colonic carcinoma cell lines
(Caco2).
Results:
Figure 5.10 depicts the effect of various core types of LPS on mouse monocyte cell
line (J774) NO secretion. It shows that R1 is more potent in inducing NO secretion
than other core types (R1>R2 & R3).
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Figure 5.10: Effect of various LPS R core types in induction of NO secretion in
mouse monocytes
Figure 5.11 illustrates the TNF-a secretion in response to different concentration of
various core types of LPS. Apparently it shows that the R3 core type is much more
potent in inducing TNF-a secretion than other core types (R3>R1>R2). Statistical
analysis was not done in view of the small sample size.
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Figure: 10.11 Effect of LPS R core types on J774 mouse monocyte cells in induction of
TNF-a secretion.
No IL-ip was produced by the mouse cells J774 in response to LPS core types (in
different concentration, upto 100 ng/mL)
Core types of LPS in concentrations up to 100 ng/mL used had no effect on human
colonic carcinoma cell line in producing NO, TNF-a or IL-1 (3.
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Discussion:
The single layer of epithelial cells that lines the intestinal mucosa is the initial site of
interaction between host and microbial pathogens. Intestinal epithelial cells respond to
bacterial invasion by up-regulating the expression of an inflammatory gene programme
(Kagnoff and Eckman, 1997). Characteristic features of this programme include the
increased production of chemokines that can act as early signals to activate an acute
mucosal inflammatory responses ( Eckmann et al, 1993; Jung et al, 1995; Yang et al,
1997).
Nitric oxide (NO) is generated by the conversion of L-arginine to L-citrulline by NO
synthase (NOS), which exists in three isoforms, each encoded by a separate gene
(Nathan and Xie, 1994). The expression of inducible NOS (iNOS) is regulated in
various cell types and can be increased by stimulation of cells with several cytokines or
with bacterial LPS (Nathan and Xie, 1994; Witthoft et al, 1998). NO can mediate an
array of physiological effects in the intestine. It has been shown that blocking
endogenous nitric oxide synthesis led to increased intestinal permeability; i.e.
endogenous production of NO is essential for maintenance of the normal barrier
function of the gut (Fink, 1999). On the other hand, it has been shown that excessive
release of NO compromises the viability of intestinal and colonic epithelial cells in
endotoxin-challenged rats (Tepperman et al, 1994). Thus, under some conditions, NO
does not protect the gut,but rather injures the mucosa.
Initial experiments with the mouse monocyte cell line J774 reveal that LPS at
concentrations as low as 0.01 ng/mL can induce NO production. However, the 100
ng/mL concentration was found to induce maximum NO production in a dose-
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dependent manner but without killing the cells (C. Erridge, unpublished). In the present
study, R1 core was found to be more potent in inducing NO production compared to
other core types. Gibb et al found that most of the blood or urinary isolates of
pathogenic E.coli are R1 core positive(Gibb et al, 1992). It may be possible that the
LPS which induces much more NO has a predilection for systemic pathogenicity. It
should be noted that some Shigella spp have an R core.
Tumour necrosis factor-a (TNF-a) and IL-1(3 are produced primarily by macrophages
and fibroblasts in inflamed tissue. IL-1 p and TNF-a appear to contribute directly to
tissue damage through induction of the release of tissue-damaging enzymes (e.g.
matrix metalloproteinase) (Tissi et al, 1999; Monteleone et al, 1999). In this study, R3
core produced huge amounts of TNF-a compared to other core types. Several
enteroinvasive pathogens (e.g. other Shigella spp and E.coli 0157) are R3 positive. It
is quite possible that mucosal pathogens induce more TNF-a production compared to
others who have predilection towards systemic pathogenicity. No core types (up to 100
ng/mL concentration ) were able to induce IL-1 p production from either J774 or Caco2
monolayer cells upto 24 hour post challenge. The reasons for not detecting IL-1 p
could have been due to the fact that IL-1 p takes a longer time to synthesize or a
larger dosage of LPS might have been needed for stimulation. Alternatively, J774 is
not a suitable model at all for studying IL-1 p. Similarly, Caco2 monolayer cells were
found to be fairly resistant to the core types LPS (up to to 100 ng/mL) challenge.
Normally, colon (large bowel) harbours the highest concentration of bacterial load in
the human body (10 12 bacteria/gm of colonic content). This may suggest that the
colonic cell line is constitutively resistant to smaller dosages of LPS (inadequate
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dosage for stimulation). Alternatively, interspecies difference may have been
responsible for the discrepancy observed.
The further assessment of the biological potential of LPS in inducing inflammatory
mediators is essential, especially for the development of a vaccine against septic
shock syndrome or for the prevention or management of diarrhoea.
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Section 4: Mucosal IgA antibody against LPS of E.coli 0157
Introduction
Vero cytotoxin (VT)-producing Escherichia coli isolates (VTEC isolates, also called
Shiga-like toxin [SLT]- producing E.coli isolates) are associated with a spectrum of
illnesses that include diarrhoea (Pai et al, 1988), haemorrhagic colitis (Riley et al,
1983), and haemolytic-uraemic syndrome (Karmali, 1985; 1992). Whereas VTEC
isolates belong to many different serotypes, 0157:H7 is the most common serotype
associated with human illness (Griffin and Tauxe, 1991).
The recent E.coli outbreak in Scotland caused major public concern regarding food
safety and sparked several studies in this field (Douglas and Kurien, 1997). Despite
the enormous burden of diarrhoeal disease with a wide range of infectious agents
(including multiple agents) in Bangladesh, the isolation of E.coli 0157:H7 is virtually
non-existent there. (Hoque et al, 1994; 1998). All E.coli 0157:H7 strains possess the
R3 core type in their LPS (Currie and Poxton, 1999) and in an earlier section I noted
that IgA antibody in intestinal secretions against R3 core type was significantly higher
in healthy volunteers from Dhaka compared to the Edinburgh control groups. I wanted
to test the hypothesis that the Dhaka population has higher IgA antibody against
0157: H7 LPS in the gut compared to the Edinburgh population and hence has
protection against 0157:H7 infection, possibly through cross-reactive R3 core-reactive
IgA.
Result
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Figure 5.12 illustrates the concentrations of IgA antibody against LPS of 0157:H7 in
WGLF from healthy volunteers from Edinburgh(n=12) and Dhaka (n=11). The median
concentration of IgA antibody in WGLF in the Edinburgh and Dhaka groups were 656
SAMI Unit/mL and 559 SAMI Unit/mL respectively. The levels thus tended to be higher
in the Dhaka groups but this was not statistically significant.
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Figure 5.12 Anti-LPS IgA antibody against E. coli 0157:H7 in WGLF between
two healthy control groups
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Discussion
In the present study, IgA antibody against E.coli 0157:H7 was detected in healthy
control groups both from Dhaka and Edinburgh. There was no significant difference in
antibody concentration between the groups. This may be due to small sample size in
both the groups. Despite the virtual absence of a problem of E.coli 0157:H7 infection
in Bangladesh, anti-LPS IgA antibody against E.coli 0157:H7 was found in healthy
volunteers from Dhaka. This may have been due to the fact that R3 core (present in
E.coli 0157:H7) which is present in Shigella might have stimulated the production of
cross-reactive antibody to the LPS of E.coli 0157:H7. Alternatively, there is evidence
that sera from patients with E.coli 0157:H7 infection react with the EPEC 055:H7 (an
E.coli strain associated world-wide with outbreaks of infantile diarrhoea) (Whittam et
al, 1993) but these strains may also have the R3 core. There is a close genetic
relationship between VTEC 0157:H7 and EPEC 055:H7 (Ludwig et al, 1996). Both
Shigella and EPEC infection are quite common in Bangladesh (Hoque et al
1992;1994).
The presence of anti-LPS IgA antibody against E.coli 0157:H7 in the Edinburgh
population is quite interesting. This finding has recently been replicated in an ongoing
study of E.coli 0157:H7 infection in Scotalnd (conducted in the Department of Medical
Microbiology by Professor Poxton and colleagues). The most logical explanation for
the presence of antibody against E.coli 0157:H7 in the gut of healthy Scottish people
is the presence of VT negative 0157 strains. This organism is widespread in Nature
and can easily be harboured by healthy people (Professor Poxton, personal
communication).
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This preliminary observation is fascinating and obviously warrants future studies. It is
to be hoped that an effective oral E.coli vaccine may be developed targeting a wide
range of pathogenic E.coli including E.coli 0157:H7 by using LPS core as an antigen.
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Chapter 6
Disease influences on intestinal humoral immunity
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Section 1: Inflammatory Bowel Disease
Introduction
The term inflammatory bowel disease (IBD) encompasses two major pathological
processes involving the human intestine, Crohn's disease (CD) and ulcerative colitis
(UC). Both of these diseases are characterized by a chronic relapsing course in which
there is recurrent tissue injury within the intestine mediated by the host's immune
response.
In UC, the inflammatory process almost always involves the rectum and then extends
proximally to a variable extent. Histologically, the abnormality is limited to the mucosa
and superficial submucosa, and is characterized by a dense infiltrate of both acute
and chronic inflammatory cells in the lamina propria. These cells can also localize to
crypts forming micro-abscesses. The deeper layers of the bowel wall are
characteristically not involved.
CD can present in a number of different ways, a reflection of its ability to involve any
part of the intestine from mouth to anus and the extensive nature of the inflammatory
process. This can include the deeper layers of the intestinal wall, with transmural
inflammation being common. The cellular infiltrate is predominantly made up of
lymphocytes and macrophages, and later can coalesce to form non-caseating
granulomas in 40-60% of patients. These pathological features can produce superficial
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and deep ulceration and can also lead to collagen deposition and fibrosis (Smith &
Jewell, 1996).
The aetiologies of UC and CD remain an enigma. Despite much research over
decades, no infectious agents have yet convincingly been associated with IBD
(Brandtzaeg,1995). Furthermore, the mechanisms of the spontaneous exacerbations
and remissions are also undefined.
There are a number of suggestions of possible environmental or genetic causes
including persistent infections, vasculitis, and immunological abnormalities, such as
autoimmunity. It is thought that UC and CD have different aetiologies on the basis of
differences in location, and the macroscopic and microscopic appearance of the
disorders. In addition, different cytokine and immunoglobulin isotype profiles are
thought to result from differences in mucosal immune activation (Sawyer and
Ferguson, 1994). Despite all of this the disorders may have very similar presentations
and precipitants of clinical relapse (Fiocchi,1998).
Much recent research has indicated the importance of the interaction between luminal
antigens and the mucosal immune system as the mechanism of relapse in IBD. The
suggestions were based on the findings: firstly, in postoperative recurrence of CD, the
histological and immunological evidence of mucosal inflammation occurs within 8 days
after exposing the neoterminal ileum to autologous luminal content ( D'Flaens et al,
1998); secondly, increased intestinal permeability heralds relapse in CD, while normal
permeability predicts a long-term remission (Arnott, 1998, Wyatt et al, 1993).
Intestinal infection, non-steroidal anti-inflammatory drug use, and dietary indiscretions
are known causes of relapse in CD. All of these cause increase in intestinal
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permeability across the epithelial cell layer or have the potential to do so (Bjarnason et
at, 1995). Thirdly, normal resident luminal bacteria provide the dominant stimulus for
experimental colitis, as demonstrated by absence of colonic inflammation in genetically
engineered rodents raised in germ-free conditions (Sadlack et at, 1993; Rath et at,
1996; Dianda et at, 1997). Further evidence to support this hypothesis was seen with
the rapid induction of colitis when adult HLA-B 27 transgenic rats (Rath et at, 1996) or
IL-10 deficient mice (Sator, 1998) were exposed to specific pathogen-free enteric
bacteria. Defined flora studies show that Bacteriodes species preferentially induce
colitis in HLA- B 27 transgenic rats (Rath et at, 1996); and finally, in some patients with
IBD, antibiotic treatment may be effective (Sator, 1998).
An earlier study of circulating antibodies in serum of IBD patients initially proposed that
there were high titres against enterobacteria. These antibodies were also cross-
reactive with colonic mucins (Thymer et at, 1969). Other studies showed that serum
titres of these antibodies were not significantly different from those of the controls
(Heddle & Shearman, 1979; Lanngercrantz et at, 1966; Carlsson et a/,1977). Similarly,
the theory of enterobacterial antigen specific activation of peripheral blood
lymphocytes (Bull & Ignaczak, 1973) was not confirmed (Bartnik et at, 1974). It is also
recognised that circulating immunoglobulin specificities may not be representative of
locally produced mucosal immunoglobulins. The main immunoglobulin produced in the
intestinal mucosa of normal subjects is IgA. It has been confirmed by
immunohistochemistry and cultured mucosal lymphocytes as well as with intestinal
lavage that in patients with active UC or CD, IgG production is dramatically increased
(O'Mahony, 1990; Brandtzaeg et al, 1974; Scott et at, 1986; Ruthlein et at, 1992)
reflecting an abnormal mucosal response.
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In this chapter I wanted to test the hypothesis that there is an abnormally increased
mucosal immune response against non-pathogenic commensal intestinal bacteria in
active CD and UC. This was to determine whether the increased IgG response was
specific for commensal bacteria hence, EndoCAb antibody was measured.
Furthermore, in contrast to IgG, the results of studies of IgA in IBD are conflicting. It
has been found in several studies that there is decreased synthesis of IgA in IBD
patients (McDermott et at, 1986; Verspaget et at, 1988). Conversely, Badr-el-Din et at
(1988) found a four-fold increase in IgA production by cultured colonic biopsies from
patients with UC compared to controls.
I therefore decided to study the humoral immunity in IBD. There is great deal of
literature to suggest that groups of cytokines play a key role in controlling local and
systemic immunity. Proinflammatory cytokines (IL-1 (3, IL-6, IL-8, and TNF-a) are
preferentially produced by monocyte-macrophages and production increases in gut
inflammation (Fiocchi, 1996). Accordingly, I tried to measure two cytokines (viz. I L-1 p,
IL-6) as well as cellular mediators [e.g. Granulocyte elastase (GE), a proxy marker of
luminal neutrophilia] in IBD with carefully selected, well-matched groups of patients
with active disease.
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Results
Immunoglobulins and anti-bacterial antibodies in WGLF
Figure 6.1 depicts the total IgA concentration in WGLF from patients with moderate to
severe IBD. The results showed that there was a significant difference in total IgA
concentration in WGLF between patients with active UC and CD. The median and
(range) values of total IgA in controls were 39 (18-82) pg/mL. In active CD, the
median value of total IgA was 28 (12-50) pg/mL, which was significantly lower than
that of controls (p<0.03). On the other hand, in active UC, the median value was 52
(29-100) pg/mL, which was higher than the controls but not significantly different
(p=0.15). When compared with active CD, the total IgA in WGLF was significantly
higher in active UC (p<0.003).
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Figure: 6.1 Total IgA in WGLF from patients with active IBD and controls
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The results of IgA antibody determinations against endotoxin core 'cocktail' antigens
are shown in Figure 6.2. There were significant differences in IgA EndoCAb levels
between active IBD and controls (Figure 6.2). In the control group, the median (and
range) concentration of IgA EndoCAb in WGLF was 1 (0.5-4) MU. The median values
of IgA EndoCAb were significantly higher in both UC and CD than that of controls.
These values were 3 (1-8) MU (p<0.004), and 7 (1-23) MU (p<0.005) respectively. As
can be seen from figure 6.2, the median value of IgA EndoCAb in CD is higher than
that in UC, but they are not statistically different (p=0.21). Flowever, there was good
correlation observed between total IgA and IgA EndoCAb in CD (r=0.68, p<0.021)
(Figure 6.3), but not in UC (r=0.5, p<0.13) (data not shown).
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Figure: 6.2 IgA EndoCAb in WGLF from patients with active IBD and healthy controls
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Figure:6.3 Correlation between IgA EndoCAb and total IgA in WGLF from patients
with active Crohn's disease.
The levels of IgG antibody against endotoxin core 'cocktail' antigens in WGLF were
similar to those for IgA EndoCAb. Unlike IgA EndoCAb, there was a significant
difference in IgG EndoCAb levels between active UC and CD (Figure 6.4). The median
(and range) concentration of IgG EndoCAb in WGLF in controls was 0.045 (0.019-
0.2) MU/mL. In active UC and CD, the levels of IgG EndoCAb significantly increased
(p<0.007 and p<0.001) when compared with controls, which were 0.14 (0.07- 0.47)
MU and 0.29 (0.02-0.79) MU/mL respectively.
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Figure: 6.4 IgG EndoCAb in WGLF from patients with active IBD and controls
A positive correlation was found between total IgG and IgG EndoCAb in WGLF from
patients with both UC (r=0.83, p<0.003) and CD (r=0.7, p<0.03) (Figures: 6.5 and 6.6).
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Figure: 6.5 Correlation between total IgG and IgG EndoCAb in WGLF from patients
with UC.
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Food antibodies
IgG antibody against ovalbumin in WGLF is undetectable in controls (Figure 6.7).
Levels were higher in patients with active IBD. There were significant differences in
anti-Ova IgG antibody between patients with active UC and CD (p<0.02).
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Figure:6.6 Correlation between total IgG and IgG EndoCAb in WGLF from patients
with Crohn's disease.
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Figure: 6.7 Anti-ovalbumin IgG antibody in WGLF from patients with active IBD.
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Serum antibodies:
The levels of IgG EndoCAb in serum are shown in figure 6.8. In the control group, the
median (and range) concentration of IgG EndoCAb in serum was found to be 200
(103-318) MU/mL. In CD, the levels of this antibody were significantly increased
(p<0.003), while in UC, the antibody levels were found to be significantly decreased
(p<0.004) when compared with controls. The antibody levels in CD and UC were 279
(148-595) and 79 (18-224) MU/mL respectively.
The serum level of IgG EndoCAb did not correlate with IgG EndoCAb in WGLF.
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Figure: 6.8 IgG EndoCAb in serum from patients with active IBD and controls.
Cytokines
Figure: 6.9, summarises the results of IL-1 p in WGLF. Out of 12 controls , 10 had no
IL-1 p detectable in WGLF. In the other 2 controls the IL-1 p levels were 11 and 13
pg/mL. These two cases have already been discussed in chapter 4. The median (and
range) value of IL-1 p in WGLF in CD and UC were 496 (184-1200) and 120 (22-1200)
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pg/mL. There was a significant difference in IL-1 (3 concentration between these two
patient groups (p<0.03).
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Figure: 6.9 I L-1 p concentration in WGLF from patients with active IBD and controls
Cellular mediators
Figure: 6.10 illustrates the correlation between granulocyte elastase (GE), a marker of
luminal neutrophilia and IgG in WGLF in patients with UC. There was no such
relationship observed in CD (data not shown).
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Figure 6.10 Correlation between IgG and GE in WGLF from patients with active UC
Serum IL-6 concentration was significantly higher in active CD when compared with
controls (p<0.04) (Figure: 6.11). The level was also higher than UC but did not reach
statistical significance at the 5% level (P<0.054). No difference was observed in serum
IL-6 level in UC when compared with controls.
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Figure:6.11 Serum IL-6 concentration in patients with active IBD and controls.
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Discussion
The intestinal mucosa has two opposing functions: as a barrier to exclude numerous
harmful antigens from micro-organisms and food, and to transfer antigens, a function
essential for evoking specific responses ( Sanderson and Walker, 1993). It is quite
possible that primary mucosal immunodeficiency is present in the intestines of IBD
patients, thus allowing agents to penetrate the intestinal mucosa, and subsequently
initiate both a local inflammation and a heightened systemic immune response
(MacDermott et al, 1981). The findings of heightened mucosal humoral responses
against bacterial and food antigens in CD and UC from this study lend further support
to the hypothesis.
Several earlier studies have indicated that local over production of IgG together with a
relative mucosal IgA deficiency may be essential for the tissue lesion in Crohn's
disease ( Baklien and Brandzaeg, 1976; MacDermott, 1988; Brandzaeg ef al, 1989).
The data on total IgA in this study substantiate that there is decreased IgA
concentration in WGLF from patients with active CD compared to controls or UC.
Clearly, this complex area needs further exploration. Whether primary mucosal
immunodeficency is responsible for the impaired barrier function, a credible factor in
the pathophysiology of CD, is not clear. Furthermore, the debate continues as to
whether the dysfunction is a primary aetiological factor in CD or merely an
epiphenomenon of the inflammatory process of the disease. There is evidence to
support the concept that the functional derangement of macromolecular uptake is due
to an intrinsic defect in the epithelial cells ( Hollander et a/, 1986; Katz et al, 1989 and
May et al, 1993), and consequently gut permeability tests might predict CD before the
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onset of serious symptoms. Conversely, other observations have suggested that the
barrier disorder is secondary to inflammation (Katz et al, 1989; Howden et at, 1991), in
which case its severity could be a useful indicator of clinical activity in CD and a
predictor of relapse (Howden et al, 1991; Wyatt et a/, 1993). However, some studies
found normal permeability in active CD (Howden et al, 1991; Ruttenberg et al, 1978). In
either case, this study has shown that there is abnormally high levels of both IgA
(Figure: 6.2) and IgG (Figure: 6.4) antibodies against enteric bacterial antigens. The
IgG antibody against a food antigen (Figure: 6.7) was also significantly higher in CD
than UC . The heightened systemic immune response in CD is clearly supported by
the findings of the high IgG EndoCAb (Figure:6.8) and IL-6 (Figure:6.10) levels in
serum. It is quite probable that a leaky gut would enable enteric antigens to penetrate
the mucosa to an increased extent, and the capacity for removal or degradation of this
antigenic load by the macrophage or neutrophil defences might then be exceeded.
The inability of macrophages to ingest the foreign material may result in a chronic
granulomatous inflammation (IL-ip result is supportive, Figure: 6.9). It has been
shown by culturing lamina propria mononuclear cells from patients with IBD that when
the mononuclear cell population was depleted of macrophages, IL-1 p activity was
appreciably reduced (Smith & Jewell, 1996). When the secretory immune
mechanisms are insufficient to exclude the antigen load from the gut lumen, a
compensatory mucosal IgG response ensues. This may cause a local inflammatory
reaction (Brandtzaeg,1987). This concept is supported by the following study findings:
a) restoration of gut immunological barrier by promotion of IgA immune response in
patients with CD by oral bacteriotherapy with Lactobacillus GG (Malin et al, 1996). b)
faecal stream diversion (which reduces bacterial antigenic load) may determine the
recurrence of CD (Rutgeerts et al, 1991); c) remission of CD by parenteral nutrition (
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Kushner et at, 1986)], or by elimination of dietary antigen when treating patients with
elemental diet (Saverymuttu et al, 1985) or exclusion diets (Jones et at, 1985).
As has already been mentioned, CD and UC both may have very similar presentations
and precipitants of clinical relapse but it is thought that they should be considered as
completely separate diseases (Ferguson, 1996). Several distinguishing features
between these diseases have been described elsewhere (Sawyerr & Ferguson, 1994;
Fiocchi, 1998); such as, the different subclasses of IgG secreted in CD (lgG1, lgG2)
and UC (IgG 1 and lgG3). In this study, there was a significantly higher IgG antibody
response against enteric bacterial antigens observed in both CD and UC compared to
controls (CD>UC, Figure:6.4). This antibody (IgG EndoCAb) correlated well with the
total IgG in WGLF (Figures: 6.5 and 6.6). Whether this antibody is the result of
increased mucosal production or merely a serum leakage, is not yet clear. I will
discuss more about this issue in chapter 7. However, it is of note that I have not
assayed the subclasses of IgG.
The observation of higher total IgA in WGLF and lower IgG EndoCAb in serum from
patients with UC compared to CD and controls ( Figures: 6.1 and 6.8) needs further
explanation. Previous studies showed that the production of IgA in the colonic mucosa
of patients with UC were substantially raised (Bader-el-Din,1988; Danis,1984). There
was a preferential increase in IgAI subtype secretion. That was supported by the
increased number of lgA1 cells in the colonic mucosa (Kett & Brandtzaeg,1987). There
is further evidence of defective immunoglobulin production and hyporesponsiveness
of peripheral blood lymphocytes in patients with UC (Danis & Heatley, 1983; Fiocchi,
1998). This evidence suggests that there is an unrestrained immune response in the
intestinal mucosa of CD directed against the normal flora. There is also an IgG-
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mediated immune response against normal colonic flora in the mucosa of patients with
UC, but at a relatively lower defence than that in CD. This may suggest that IgG
produced in UC is also directed against other antigens, such as epithelial cell proteins
(Das, 1977).
In UC, the inflammatory process is strictly limited to the superficial layer of colonic
mucosa. It has already been shown from this laboratory that luminal neutrophilia
(measured by GE) is a feature of active UC but not small bowel CD (Handy et al,
1996). This study confirms the previous findings (Figure:6.11).
Significantly increased IL-1 p in WGLF and IL-6 concentrations in serum were found in
IBD compared with controls. The increase is more pronounced in active CD compared
to active UC (Figures: 6.9 & 6.10). This is in accord with the findings of other studies
(Mahida et at, 1989; Smith & Jewell, 1996). IL-6 is osteopenic and thought to be
responsible for the reduced bone mineral density seen in CD (Pollak et al, 1998).
Therefore increased IL-6 levels may explain the finding of low bone mineral density in
Crohn's disease, which is not seen in UC, at diagnosis (Ghosh et al, 1994).
The impact of treatment with immunosuppresive drugs (for example prednisolone)
may affect antibody dynamics both systemically and mucosally. However, most of the
patients in both groups were on treatment. However, it has been found in a recent
study that treatment with immunosuppressive drugs did not have an impact on the
serological results in patients with IBD (Ruemmele et al, 1998). Further study should
be done to see whether IgG EndoCAb in serum could be used as a reliable serological
screening test which would have potential in identifying or predicting relapse in
patients with IBD, especially CD, as other tests (e.g. the dual sugar permeability test)
are cumbersome, time-consuming and lack specificity.
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Section Two
Ileal pouch-anal anastomosis (IPAA)
Introduction
Ileal pouch-anal anastomosis (IPAA) is the operation of first choice following
proctocolectomy in patients with UC and familial adenomatous polyposis (Merrett,
1997). These patients virtually have very little colon. At operation, the anus is retained
and a pouch is formed from the distal 40 cm of the terminal ileum. The pouch acts as a
storage reservoir for the output of the small bowel; it is joined to the top of the anal
canal and thus evacuation is possible by the normal route, eliminating the need for a
permanent ileostomy. In keeping with the same hypothesis discussed in section one of
this chapter, I was interested to see if the humoral antibody responses varied in
patients with UC and those who underwent surgery.
Up to 30% of patients with UC will require removal of their colon and rectum
(Thompson-Fawcett & Meadows, 1998). Soon after IPAA, 90% of these patients
reported an excellent quality of life; indeed, patients with pouches had the same quality
of life as matched controls who had undergone cholecystectomy (Tompson-Fawcett &
Meadows,1998). However, one of the long-term complications of IPAA is pouchitis
which is the most common cause of pouch dysfunction. The incidence is 15-20%
(Merrett, 1997) and the aetiology of pouchitis is unclear. Stasis and bacterial
overgrowth have been implicated because stasis is the main functional difference and
metronidazole, an anti-anaerobic bacterial agent is therapeutic in pouchitis. On the
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other hand, it has been postulated that pouchitis represents a recurrence of UC,
because pouchitis is seldom seen in patients who have a pouch for familial
adenomatous polyposis (Thompson-Fawcett & Meadows, 1998).
The bacteria associated with the colonic mucosa are predominantly anaerobic. The
majority belong to the genus Bacteroides (Poxton et al, 1997). In particular, B. fragilis
is one of the major components of the mucosal flora and is the most commonly
isolated species from patients with gut-associated abdominal sepsis (Poxton et at,
1997).
To test the hypothesis, I decided to measure EndoCAb and anti-B. fragilis LPS IgA
antibody responses in WGLF from patients with UC (without surgery ) and those who
had IPAA. The results were compared with those obtained from healthy controls from
Edinburgh and Dhaka. In view of identification of the enterotoxigenic B. fragilis as a
diarrhoeal pathogen in children in Bangladesh (Sack et al, 1994), the Dhaka control
group was included so that I could determine the variability of anti-B fragilis LPS
antibody levels in healthy controls from two geographically distinct populations in
Dhaka and Edinburgh.
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Results
EndoCAb antibodies
Figure: 6.12 illustrates the levels of IgA EndoCAb detected in WGLF from patients with
UC and IPAA. In UC patients, the concentration of IgA EndoCAb was significantly
higher than that of patients with IPAA (both Pouch and Pouchitis group) (p<0.003 and
p<0.004 respectively). There was also a significant difference in IgA EndoCAb levels
within the IPAA patients (p<0.008).
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Figure: 6.12 IgA EndoCAb in WGLF from patients with UC and IPAA.
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The serum IgA EndoCAb results are presented in figure 6.13. The results were similar
to those observed with WGLF. There was a significant difference in serum IgA
EndoCAb concentrations between patients with UC and IPAA (p<0.001). The
serological control values were similar to the values of UC patients. There were,
however, no differences observed within the IPAA patients (Figure 6.13).
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Figure: 6.13 IgA EndoCAb in serum from patients with UC and IPAA.
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Anti-Bacteroides fragilis (B.fragilis) LPS IgA antibodies in WGLF
Figure 6.14 shows the distribution of anti-B.fragilis IgA antibody in the healthy control
groups from Edinburgh and Dhaka. Both the median and range values of anti-B.fragilis
IgA antibody tended to be higher in the Dhaka controls than in the Edinburgh controls.
However, the difference was not statistically significant (P=0.16).
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Figure:6.14 Anti-B fragilis LPS IgA antibody in WGLF from healthy volunteers.
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The corresponding levels of B. fragilis antibody found in patients with UC and IPAA
are shown in (Figure:6.15). There was a significant difference in anti-B. fragilis IgA
concentration in patients with UC compared with pouch (P<0.004). Similarly, there was
also a significant difference observed between patients with pouch and pouchitis
(p<0.02). However, no significant difference was found between patients with UC and
pouchitis (p=0.35). The median and range values of anti-B. fragilis IgA in patients with
UC were higher than that of control groups from Edinburgh but this was not statistically
significant (p=0.23). Likewise, no significant difference was observed between controls
and patients with pouch (p=0.11).
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Figure: 6.15 Anti-B.fragilis LPS IgA antibody in WGLF from patients with UC, IPAA
and controls.
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Discussion
The higher IgA antibody responses against gut bacterial antigens in UC have already
been discussed in the previous section of this chapter. It is known that the production
of IgA, especially lgA2, increases along the intestinal tract with distance from the
stomach (Mestecky et at, 1989). The lower levels of IgA EndoCAb in patients with
pouch was an expected finding, because patients with pouch have virtually no colon
These factors may be responsible for the lower detection of IgA EndoCAb in a
normally functioning pouch. However, in pouchitis, the higher IgA EndoCAb response
supports the theory further that there is an abnormally increased mucosal immune
response against non-pathogenic commensal intestinal bacteria in UC. It also lends
support to the theory that pouchitis represents a recurrence of UC (Merrett,1997).
However, these results would have been more meaningful with more patients. In
addition, it would be informative to do other assays, such as total IgA, IgG EndoCAb
in WGLF and IgG EndoCAb in serum. However, due to paucity of sample size as well
as specimen I could not perform those assays.
The serological responses of IgA EndoCAb were similar both in UC and in control
groups and are significantly higher than those values for both the pouch and pouchitis
groups. This phenomenon has also been observed by others previously (Kilhamn et at,
1998). Kilhamn et at suggested that the weaker serum response seen in colectomized
patients may be due to depressed immune cells that present to the systemic immune
systems. These results lend further support to the idea of defective immunoglobulin
production and hyporesponsiveness of peripheral blood lymphocytes in patients with
UC (Danis & Heatley, 1983; Fiocchi, 1998).
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It is interesting to note that there was no significant difference observed in anti-
B.fragilis IgA antibody response between healthy controls from Dhaka and Edinburgh.
In the Dhaka group, however, the antibody response was somewhat higher than that
of Edinburgh groups. This may be due to higher incidence of diarrhoea caused by
toxigenic B.fragilis (Sack et al, 1994).
The anil-B. fragHis IgA antibody response was higher in UC patients when compared
with Edinburgh controls. The value did not reach statistical significance, probably due
to inadequate sample size. Significant differences were observed when antibody levels
were compared with those from patients with pouch. This result is quite expected as
pouch patients are colectomised and B.fragilis is predominantly a colonic bacterium.
The noteworthy finding was that there was a significant difference in anti-B.fragilis IgA
antibody responses between patients with pouch and pouchitis. In addition, there was
no difference in anti-B.fragilis IgA antibody responses between UC and pouchitis.
These results suggest the role of colonic bacterial flora in perpetuation of UC or
pouchitis. Alternatively, this may also mean that breakdown of tolerance towards these
organisms may be responsible for UC or pouchits. This concept is further supported by
the fact that metronidazole (a chemotherapeutic agents that is very effective against
Gram-negative anaerobic bacteria ) is the one effective mainstay therapy in pouchitis
(Thompson-Fawcett & Meadows, 1998).
In fact, pouch is a 'man-made' colonic reservoir. There are some studies suggesting
that in a pouch, there may an overgrowth of colonic bacteria due to stasis. It has also
been found that there is an increased ratio of anaerobes to aerobes with higher
concentrations of Bacteriodes and Bifidobacterium species(Merrett, 1998).
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The role of bacteroides bacteria in UC is not yet clearly defined. In a recent study, it
has been shown that Bacteroides thetaiotaomicron, was isolated from biopsy
specimens of all 3 patients with active UC but from only 4 of the other 18 samples from
non-inflamed colonic mucosa (Poxton et al, 1997). Whether this is a true association is
not yet known. However, the same research group had shown previously that the IgA
antibody responses to at least two of the most common Bacteroides (B.fragilis and
B.vulgatus) were directed largely toward a common epitope of the lipopolysaccharide
(Poxton et al, 1995) which may also be shared by other species of the genus. These
workers also suggested that this may be a mechanism for protecting the mucosa from
the potentially inflammatory molecules produced in the colon, thereby maintaining
homeostasis. It is quite probable that there may be breakdown of this homeostasis in
UC.
In conclusion, despite several limitations, some important pieces of information have
emerged from this study. It is recognised that the role of Bacteroides in UC warrants
further investigation. Apart from bacterial factors in the pathogenesis of pouchitis,
other factors for example short chain fatty acid deficiency or mucosal ischaemia may
have some role, and these also merit further study.
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Chapter 7
Evidence of Local Production of IgG
191
Introduction
The accurate assessment of activity and extent of disease in UC and CD is crucial in
the rational management of these conditions (Summers,1979). Objective parameters
of disease activity are necessary for the assessment of the effects of drug therapy
(Hodgson, 1997) and facilitate the comparison of data collected in multi-centre trials on
new therapeutic strategies in these conditions. Various scientific approaches to the
measurement of disease activity have been proposed (Singleton, 1987; Camilleri &
Proano,1989), although none could be considered as a 'gold standard'. Some are
heavily weighted towards subjective parameters which are variable. Laboratory tests
such as ESR, platelet count, and the estimation of acute phase proteins, are useful,
but may be normal in active IBD, particularly UC and small bowel CD (O'Mahony et
al, 1991). Studies from this unit have shown that total IgG in WGLF is an excellent
measure of disease activity in IBD (O'Mahony et al, 1991; Choudari et al, 1993). The
authors suggested that the high IgG value in WGLF is derived from plasma leakage
across the inflamed mucosa. The reasons for this conclusion were: firstly, there is a
high concentration of albumin in lavage fluid from patients with active IBD, and a
positive correlation between albumin and IgG levels was found. Secondly, there is no
mechanism as yet established for transport of IgG between the systemic and mucosal
compartments.
However, several studies have shown that the number of IgG-containing plasma cells
in the gut is greatly increased in IBD (Baklien & Brandtzaeg, 1976; Rosekrans et al,
1980). Also, intestinal mononuclear cells from isolated IBD patients spontaneously
secrete high amounts of IgG ( MacDermott et al, 1981; Verspaget et al, 1988).
Furthermore, as already discussed in chapter 6, I have found high IgG EndoCAb in
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WGLF from patients with IBD. It is relevant to know the source of the IgG antibody, as
this has inflammatory potential. It is well known that IgG can assist in the opsonisation
of antigen, and that it may be involved in triggering inflammation and enhancing
immune responses against infectious agents.
Therefore, I decided to study whether IgG in WGLF was plasma-derived or locally
produced. What proportion of the total IgG in WGLF is derived from plasma? In this
study, I used the results obtained from the study of patients with IBD presented in
chapter 6. I have tried to interpret these results to elucidate the source of IgG on the
basis of arithmetic calculations.
Calculation of plasma loss
Calculation of plasma loss per day was done using the formula used by Ferguson et
al (1996) for the calculation of blood loss. The original formula was:
WGLF Hb concentration (pg/mL) X Volume of lavage/d**
= mL of blood loss/d
Blood Hb concentration (g/L)
= mL of [blood - Haematocrit] = plasma lost Id
(** calculation based upon 'intake and output' data during lavage, 'd - day)
I have deducted the haematocrit value from the total volume of blood which gives the
total plasma lost per day.
It has been shown by a sequential lavage study that once the WGL specimens have
become clear, it is essentially a perfusate (Sallam, 1994). The perfusion rate was
generally 20 mL/min. The volume of lavage required for each patient was extrapolated
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to daily output. The specific antibody that can be lost per day through inflamed gut
was determined. Likewise, it was also possible to estimate the daily production of
antibody, assuming all antibodies are locally produced in the gut. Allowance was made
for reagents required for the processing of WGLF.
The following formula was used to calculate the relative coefficient of excretion (RCE)
of antibody:
RCE= (antibody in WGLF)/ (antibody in serum)
(albumin in WGLF)/(albumin in serum).
As transport of albumin in to the gut lumen is entirely passive (albumin is not produced
in the gut) (Jonard et al, 1984), the RCE is useful for expressing the secretion rate
independent of serum protein concentration and the net fluid transcolonic movement
(Delecourt et al, 1995; Jonard et al, 1984). If a protein is passively transported from
plasma to the colonic lumen, the RCE value for this protein is near 1 and inversely
related to its molecular weight. An RCE value of greater than 1 indicates partial or total
local gut synthesis and/ or facilitated transport (Delacroix et al, 1982).
I have used the results of two categories of specific antibody (EndoCAb and anti-
cholera toxin antibody) responses in both the serum and WGLF from patients with
active IBD as presented in chapter 6.
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Results
It is essential to determine whether the estimated plasma loss is well correlated with
the blood loss in patients with active IBD. Figure: 7.1 shows an excellent correlation
(r=0.98) between estimated plasma loss and haemoglobin in WGLF from patients with
active IBD.
WGL haemoglobin
Figure: 7.1 Correlation between estimated plasma loss/day and haemoglobin in
WGLF from patients with active IBD.
The estimated daily production and loss of IgG antibody against multiple gut bacterial
antigens (EndoCAb) and cholera toxin in active UC are presented in figures 7.2 and
7.3. These results show that there was more specific antibody produced within the gut
lumen than lost through the gut: 57% and 96% in cases of IgG EndoCAb and anti-CT
IgG respectively. When compared with albumin, the RCE values for IgG EndoCAb
and anti-CT IgG were 1.7 and 1.2 respectively (Figure: 7.4).
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Figure: 7.2 Estimated IgG EndoCAb production and loss/day in patients with active
UC.
c
3
5000000
3000000H
1000000
60000
50000 H
40000
30000
20000-
10000-
0
li_ M i II n n n
A. Production/D
MiiiiilM B. Loss/D
n
Individual patients
A vs B (p<0.002)
Figure:7.3 Estimated anti-CT IgG antibody production and loss/day in patients with
active UC.
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Figure: 7.4 Relative coefficient of excretion (ROE) of specific antibody in WGLF from
patients with active UC.
Similarly, in active CD, the local production of specific antibody was also increased
(Figures: 7.5 & 7.6). Both the IgG EndoCAb and anti-CT IgG were increased by 99%.
The RCE values for IgG EndoCAb and anti-CT IgG were higher in active CD than
active UC. These values were 1.8 and 2 respectively (Figure:7.7).
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Figure: 7.5 Estimated IgG EndoCAb production and loss/day in patients with active
Crohn's disease.
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Figure: 7.6 Estimated anti-CT IgG antibody production and loss/day in patients with
active Crohn's disease.
■o
o
£
C
TO |_L
O -J
o
° ^
a> >
CL c
if) ■-
<4-
o
LU
O
a:
Albumin Anti-CT IgG IgG Endo CAb
(n=11)
Figure: 7.7 relative coefficient of excretion (RCE) of specific antibody in WGLF from
patients with Crohn's disease.
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Discussion
This study demonstrates an increased local production of IgG antibody in the gut. It
has been shown histologically by several investigators (Soltoft,1969; Brandtzaeg et
al, 1974; Karen et a/, 1984; Rosekrans et at, 1980) that the number of IgG positive
lymphocytes are increased in the inflamed mucosa (Scott et a/, 1983). IgG-producing
cells constitute 3- 5% of the lymphocytes in the intestinal mucosa. In IBD, however,
there is a dramatic increase in intestinal Ig- producing cell populations, particularly,
IgG. It has been shown that the number of IgG-producing lymphocytes in IBD can be
increased by up to 200 -fold. This increase appears to be dependent on the degree of
inflammation (Brandtzaeg et al, 1985). In this study, the antigen-specific IgG antibody
levels were found to be increased by 56-99% over the estimated loss through gut
lumen (in patients with moderate to severe active IBD). The antibody production was
higher in CD than UC (Figures: 7.6 & 7.7) as has been previously described and
discussed in chapter 6. Macpherson et al (1996), found an increased IgG response
against normal colonic flora in endoscopically obtained mucosal washings from
patients with active IBD. The response was smaller in active UC than active CD. A
major disadvantage of the endoscopic mucosal wash technique, compared with
WGLF, is that the level of mucosal immunoglobulins only represents loss from an
isolated defined area which is not necessarily representative of the whole gut.
However, those investigators elegantly demonstrated a higher binding of mucosal IgG
to commensal bacterial protein in patients with CD and UC than that found in serum.
Furthermore, mucosal immunoglobin did not show significant binding to non-intestinal
commensal bacterial proteins, whereas there was strong binding by serum IgG.
Again, as has been discussed in chapter 4 of this thesis, despite higher serum IgG
and higher albumin loss through gut there was no evidence of higher IgG amounts in
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WGLF from the Dhaka control groups. These data all lend support to the postulated
local production of IgG in patients with IBD.
The higher antibody response in CD merits further explanation. It has been well
established that in CD there are activated T cells within the lamina propria (Breese et
al, 1993; Mullian et al, 1992). The increased production of IgG specific for commensal
bacterial antigens in active CD may reflect a Th1 (proinflammatory response) from
these activated cells (Liblau et al, 1995). It is thus conceivable that bacterial protein
antigens are recognised by the T cell receptors which might result in such a profound
immune activation leading to damage to epithelium. This may also explain the greater
response seen in active CD compared with active UC.
In the present study, the estimated plasma loss correlates well with blood loss through
the gut (Figure: 7.1). The results also show that there was greater plasma loss per day
in active CD compared with active UC. Although the estimated plasma loss in this
study is based on the formula for the calculation of daily blood loss through the gut,
these results are in accordance with those of other studies (Macpherson et al, 1996;
Saitoh et al, 1995).
Some important questions arise: firstly, what is the cause of increased mucosal
production ot IgG, or is there an increased population ot IgG-bearing lymphocytes in
IBD? Secondly, what are the implications of this increased local production of
antibody? It has been shown previously that the secretory Ig responses (e.g. secretory
IgA) apparently fail to cope with pathogenic agents in the diseased mucosa from
patients with CD (Baklein & Brandtzaeg, 1976). Due to the failure of this 'first line of
defence', an additional 'second line defence' seems to be established by local IgG
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production (Brandtzaeg, 1987). This phenomenon has already been observed; it is
recorded and discussed in chapter 6. It has been proposed that constant exposure of
Peyer's Patches to environmental antigen stimulates B cells to proliferate and switch
immunoglobulin isotypes in a vectorial manner (IgM -» IgG -»lgA) according to the
order of genes on the chromosomes (Cebra et al, 1982; Fuhrman & Cebra, 1981).
Basically, T cells control the quality as well as the quantity of the antibody response
(Elson,1985). It may be that continual antigen-driven division of B cells in the absence
of signals from helper T cells for the terminal differentiation may result in increased
IgG production instead of IgA in the gut. This 'compassionate' shift from IgA to IgG
might dominate the local humoral immunity in IBD. Although this may be beneficial as
a 'second line of defence', it may however, give rise to a deleterious reaction which
can induce and maintain chronic inflammation (Brandtzaeg, 1995). It has been shown
that increased IgG production is an early event in the pathogenesis of inflammation in
CD and UC, and that the IgG may contribute to ongoing inflammation by its
proinflammatory potency (Ruthlein et at, 1991). It is well recognised that IgG, in
particular IgG 1, is a potent complement activator. In fact, both lgG1 and activated
complement have been demonstrated in the epithelium in UC (Halstensen et al, 1990).
Thus it seems likely that IgG and complement may contribute to persistence of chronic
inflammation in IBD. As with IgG, it is unknown, whether complement components are
derived from plasma leakage or locally produced by the activated macrophage in the
gut. My results help to elucidate mechanisms that may be involved and this area
merits further study.
Recently, it has been reported from an in vitro study that IgG can be transported
across model human intestinal epithelial cells by the process of transcytosis (Christ et
al, 1997). By using the human cell line T84, the authors have demonstrated that there
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is a pathway involving the Fc receptor FcRn within human intestinal epithelia that
mediates the bi-directional transport of IgG across intestinal epithelia. The reported
work is fascinating but needs to be confirmed.
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Chapter 8
Intestinal Antibody Responses to Food Protein are Reduced in
Subjects Who Have High Levels of Gut Bacterial Antibodies
203
Introduction
The environmental antigens from food and the indigenous microbial flora are in
constant contact with mucosal surfaces and provide a continuous stimulus for the
entire immune system. Although a common result of such stimulation is the induction
of mucosal and systemic immunity, an alternative outcome is a state of
unresponsiveness or tolerance (Husby et al, 1994). In view of the high antigenic load
from the contaminated environment in healthy volunteers from Dhaka, the higher level
of IgA antibody in the gut of the Dhaka group compared to the Edinburgh group
(chapter 4) is of interest. Additionally, the higher IgA response may be related to non¬
specific immune activation resulting from the postulated high bacterial antigenic load.
Considering the above facts, I decided to test the hypothesis that, in developing
countries, the drive for production of a high humoral response to bacteria would have
the additional effect that antibodies to other gut antigens, such as foods, might be
absent or of low titre.
To address this question, I decided to measure antibody responses against a food
protein antigen in WGLF from healthy subjects both from Edinburgh and Dhaka. As
egg is one of the regular food items in both countries, I chose ovalbumin as the test
food antigen.
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Results
Antibodies in WGLF
Figure 8.1 depicts the anti-ovalbumin IgA concentration in WGLF from the healthy
subjects from Dhaka and Edinburgh. The median and (range) concentration of anti-
ovalbumin IgA concentrations in WGLF in the Dhaka and Edinburgh groups were 0.33
(0.05-1.28) Unit/mL and 7.5 (2-37) Unit/mL respectively. There was a significant
difference in anti-ovalbumin IgA concentrations between the Dhaka and Edinburgh
groups (p<0.001).
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Figure: 8.1 Anti-ovalbumin IgA antibody in WGLF from healthy controls.
Similarly, there were significantly higher levels of anti-ovalbumin IgM antibody found in
the Edinburgh groups (p<0.003) (figure 8.2). The median and (range) concentration of
anti-ovalbumin IgM antibody in WGLF from healthy subjects from Dhaka and
Edinburgh were 0.34 (0-4.2) Unit/mL and 3 (0-14) respectively.
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Figure 8.2 Anti-ovalbumin IgM antibody in WGLF from healthy subjects.
No anti-ovalbumin IgG antibody was detected in WGLF from either of the groups.
Serum antibodies
Figure 8.3 illustrates the anti-ovalbumin IgM antibody levels in serum from healthy
subjects in Dhaka and Edinburgh. The median and (range) concentrations of anti-
ovalbumin IgM antibody in controls from Dhaka and Edinburgh were 454 (83-620)
Unit/mL and 33.5 (11-100) Unit/mL respectively. There was a significant difference in
anti-ovalbumin IgM concentration between the two groups (p<0.002).
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Figure: 8.3 Anti-ovalbumin IgM antibody in serum from healthy subjects.
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The median and (range) values of anti-ovalbumin IgA in serum were similar in both of
the Dhaka and Edinburgh groups. These values were 13(7-42) Unit/mL and 11(5-22)
Unit/mL respectively (figure:8.4).
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Figure 8.4: Anti-ovalbumin IgA antibody in serum from healthy subjects.
Likewise, there was no significant difference in anti-ovalbumin IgG antibody in serum
in both the groups (figure:8.5). The median and (range) values of serum anti-
ovalbumin IgG antibody in the Dhaka and Edinburgh groups were 11 (4-19) Unit/mL
and 17(6-87) Unit/mL respectively.
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Figure: 8.5 Anti-ovalbumin IgG antibody in serum from healthy subjects.
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Discussion
Oral exposure to antigen has several potential outcomes, which include: a) induction of
systemic immunological hyporesponsiveness (tolerance), b) systemic priming, and/or
c) the induction of local secretory IgA responses in the absence of measurable
systemic immune responses . Mucosal exposure to living and multiplying pathogens
leads to local and systemic priming, whereas the most frequent outcome of an oral
encounter with soluble antigen is systemic tolerance (Strobel & Mowat, 1998).
The results of the present study were interesting. The increased IgA and IgM antibody
responses against ovalbumin in WGLF from Edinburgh control groups compared with
Dhaka groups merit consideration. Lymphocytes in Peyer's patches (PP), the
lymphoid follicles in the intestinal wall, are exposed to a wide variety of dietary and
bacterial antigens from the gut lumen (MacDonald, 1983). Studies have shown that
exposure of PP B cells to specific environmental antigens results in these B cells
becoming committed to giving rise to progeny capable of making secretory IgA
(Gearhart & Cebra, 1979; 1981; Fuhrman & Cebra, 1981). On the other hand, the
influence of environmental antigens on T cells in PP is not well described. T cells
capable of suppressing anti-lipopolysaccharide (LPS) B ceil responses can be found in
the PP of normal mice but not in germ-free mice. Thus suggests that they are
generated by the exposure of PP T cells to LPS from the normal intestinal flora
(McGhee et at, 1980).
After the oral administration of a single large dose (40mg) of ovalbumin to mice, it has
been reported that the PP not only contains T cells capable of helping anti-ovalbumin
IgA responses, but also contain T cells which can suppress anti-ovalbumin IgG
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responses (Richman et al, 1981). Conversely, it has also been shown that chronic low
levels of antigenic stimulation, which is probably the way in which most antigens are
presented at the mucosal surfaces, down-regulate the secretory IgA response in the
PP. This effect via the Ts (Suppressor T cell), may be a means of preventing
excessive mucosal immune responses to antigens of little or no pathogenic
significance (MacDonald,1983).
It is well recognised that the outcome of oral exposure to antigen depends on the
nature of the antigen, and the dosage and the frequency of antigen administration. In
addition, host factors such as genetic background, host immaturity and the role of the
gut flora are important factors modulating antigen responses (Strobel & Mowat, 1998).
It was not possible to ascertain the dose and frequency of intake of ovalbumin from
chicken egg between the two heterogeneous population groups tested. The higher
anti-ovalbumin IgA and IgM responses in WGLF in Edinburgh subjects or lower
responses in the Dhaka groups might have been due to the variation in dosage and
frequency of antigen. It is also quite probable that the lower antibody responses
against ovalbumin in Dhaka control groups may be due to 'antigen-driven bystander
suppression'. This is the mechanism by which CD 8+ T cells, generated after induction
of oral tolerance, are triggered in an antigen-specific fashion and release cytokines
(e.g. TGF-p) that mediate suppression (Miller et al, 1991). It has been shown in murine
models that LPS combined with oral ovalbumin suppressed anti-ovalbumin antibody
responses (Kim & Ohsawa, 1995). This is similar to the finding that LPS given orally to
rats in conjunction with myelin basic protein (MBP) promotes their hyposensitization to
MBP (Khoury et al, 1990). The mechanism for this phenomenon has been suggested
as competition at the level of antigen-presenting cells (APC) binding between
multideterminant antigens and immunogenic fragments of food proteins (Herrmann et
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a/, 1990). It is, therefore, likely that a higher bacterial antigenic load in Dhaka subjects
may be responsible for their lower antibody responses against ovalbumin.
Anti-ovalbumin IgG antibody was not detected in WGLF from either of the test groups.
This result is in accordance with others which suggest that locally produced food-
specific IgG is generally absent in normal individuals (Strobel & Mowat, 1998).
Regarding the data of serum antibodies against ovalbumin, the IgM antibody response
in Dhaka subjects indicates that there was systemic priming in the Dhaka group. In a
recent review by Strobel & Mowat, they suggested that, under certain conditions
depending on the nature of the antigen and poorly understood host factors, systemic
priming after oral antigen may also result (Strobel & Mowat, 1998).
Nevertheless, the distribution of anti-ovalbumin IgA and IgG antibodies in serum were
similar in both of the test groups. Since antigen-specific subcutaneous immunisation
was not done in either of the groups, it is difficult to comment on this aspect of the
results. With hindsight, if both groups had been subcutaneously re-challenged with
ovalbumin, and if subsequent follow up serum and proliferation studies had been done
and if the subclass of IgG antibodies against ovalbumin had been measured, we would
be to speculate. These results would have provided the different responses of T
helper subpopulations (lgG2 subclass is Th1 dependent, IgG 1 is Th2 dependent) .
Studies suggested that sensitivity to tolerance induction varies among T cell subsets.
CD4+T cell can be divided into two major subgroups based on their production of
cytokines. CD4+ Th1 cells produce IL-2 and IFN-y and mediate cellular immunity such
as delayed hypersensitivity. CD4+Th2 cells produce IL-4, IL-5, IL-6, IL-10 and provide
help for B cell antibody responses (Mosmann & Coffman, 1989, Husby et al, 1994). It
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has been shown in mice that parenteral injection of soluble protein antigen tolerized
Th1 but not Th2 cells (Burstein et al, 1989); the hyporesponsiveness in Th1 cells was
mediated by IL-4 production by Th2 cells (Burstein & Abbas, 1993). There seems to be
a gradient of sensitivity to tolerance induction, with Th1 cells >Th2 cells> B cells
(Husby et al, 1994).
It is certain that humans ingest food antigens daily in quantities that should result in
tolerance, and a small fraction is known to be absorbed into the circulation (Husby et
al, 1985). Despite the apparent occurrence of tolerance to food antigens, secretory
and serum antibodies to them are readily detectable in humans (Gunther et al, 1960,
Scott et al, 1985). The gradient of sensitivity of T cell subsets and B cells may explain
this apparent paradox. It is worth mentioning that an increasing body of evidence
supports the concept that 'certain systemic infections in early life may reverse the Th
response type by upregulating the Th1 and depressing the Th2 type
response'(Hertzen,1998). The higher incidence of infectious disease in Bangladesh
may be seen as relevant to the above statement
It is generally agreed that most studies related to antigens and 'tolerance' are in
animal models. Human studies are few in number. Despite certain limitations, this
present study has provided some useful information that may underpin future
research. There are possibilities to exploit orally induced tolerance in the treatment of
human disease such as allergy or autoimmunity. In addition, these results have other
implications, especially related to the strategies for oral vaccines against infectious
diseases.
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Chapter 9
Cell Migration: Eosinophils and the Gut
213
Introduction
It was known to the pathologists of the last century that leukocytes migrate from the
blood across the walls of microvessels and accumulate in inflamed tissue. The
purpose of this migration and the process (called 'diapedesis') was unknown until Elias
Metchnikoff showed that leukocytes engulf and kill bacteria and recognised
diapedesis as a fundamental mechanism of host defence (Metchnikoff, 1901). After
the discovery of interleukin 8 (IL-8) in the late 1980's, chemokines were seen as the
stimuli that largely control leukocyte migration (Baggiolini, 1998).
As already discussed in the literature review section of chapter 1, the granulocytes,
unlike lymphocytes cannot re-circulate. Eosinophils are granulocytes that originate in
the bone marrow and migrate to the tissue. It is a commonly held belief that they have
specialised roles in the host defence against non-phagocytosable multicellular
parasites (Weiler,1991). Their anti-parasitic host defence action is mediated by
release of cationic granule proteins which are toxic to parasites and may sometimes
be detrimental to the host's own cells.
The histology of the intestinal mucosa in IBD is characterized by epithelial cell damage
and tissue infiltration by lymphocytes, monocytes and neutrophils ( Lowes & Jewell,
1990). The role of some of these cells, such as eosinophils and mast cells, is less
clear, although there is increasing evidence that both cell populations are functional in
the pathophysiology of IBD ( Sarin et at, 1987; Bischoff et al, 1996). Activated
eosinophils release specific cationic proteins, such as major basic protein and
eosinophilic cationic protein (ECP), which are cytotoxic to a variety of target cells,
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including intestinal epithelial cells ( Gleich et al, 1979; Motojima et at, 1989). ECP levels
in serum and other body fluids, such as sputum, nasal secretions and bronchoalveolar
lavage fluid, are elevated in some allergic and inflammatory conditions, and may
provide information regarding involvement of eosinophils in the pathological process of
inflammation (Martin et at, 1996).
The mechanism of intestinal recruitment of eosinophils is not clearly known. However,
three main cytokines namely, IL-3, granulocyte-macrophage colony-stimulating factor
(GM-CSF), and IL-5 are known to be responsible for recruitment and activation of
eosinophils (Dvorak, 1980). Immunohistochemical studies showed that IL-3, GM-CSF
and IL-5 could be found in biopsy tissues from patients with eosinophilic gastro¬
enteritis (Desreumaux et al, 1996). In addition, it has been demonstrated that activated
eosinophils possess the capacity to synthesise these cytokines and can regulate their
own proliferation and differentiation perhaps by autocrine and /or paracrine activities
(Desreumaux et al, 1996; Kita et al, 1991; Moqbel et al, 1991; Deseumaux et al,
1992). IL-5 is considered an eosinophil-specific haemopoetic growth factor in
humans (Bagley et al, 1997). Studies with in situ hybridisation techniques on surgical
specimens from paediatric patients with active CD, IL-5 mRNA was detected within
the infiltrating cells in the mucosa. Most of the labelled cells were eosinophils. The
number of IL-5 -expressing cells correlated with the histological grade of inflammation
(Hankard et al, 1997).
Recently a new chemokine was identified and isolated in the bronchoalveolar lavage
(BAL) of guinea pigs after aerosol challenge with ovalbumin (Jose et al, 1994).
Intradermal injection of this BAL was followed by the accumulation of guinea pig
eosinophils into the dermis (Jose et al, 1994). Purification of BAL fluid revealed a new
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protein, termed Eotaxin. It has been demonstrated that the Guinea pig Eotaxin was
able to induce [Ca 2+] transients and chemotaxis in guinea pig and human eosinophils
(Jose et a/, 1994; Rothenberg eta/, 1995; Collins et al, 1995). Recently cloned human
Eotaxin has been shown to be a 8.4 kDa, 74 amino acid residue polypeptide. Cells
known to produce eotaxin include eosinophils themselves, macrophages,
lymphocytes, pseudostratified ciliated columnar epithelium, endothelium, and thymic
epithelium (Gonzalo et al, 1996) . Human Eotaxin was found exclusively to induce
chemotaxis of human eosinophils, with no effect on lymphocytes, monocytes and
neutrophils (Ponath et al, 1996). It has also been demonstrated In vitro that eotaxin
is a potent activator of eosinophil 'effector' function by means of activating the
respiratory burst (Eisner et al, 1996).
An interesting clinical case (described below) prompted me to ask the following
questions:
a) How do eosinophils accumulate selectively in certain diseases and contribute to
mucosal damage?
b) How do they accumulate in high numbers despite being a minority cell type in the
circulation?
Index Case:
D.R. (Date of birth: 24.10.81) was referred to the Gl unit on March 1995 with persistent
bloody mucoid diarrhoea. He first became unwell in April 1994 with sore throat,
malaise and a fine rash over his trunk. His general practitioner had made a clinical
diagnosis of glandular fever, but subsequent tests (monospot and antibody titre
against EBV) confirmed past infection only. He also complained of abdominal pain
which was mainly epigastric, and diarrhoea. Since that time he had suffered from
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recurrent episodes of epigastric pain and diarrhoea. He lost weight and was crossing
centiles for weight. Since October 1994, he continued to have persistent diarrhoea, up
to 5-6 motions per day with urgency. The diarrhoea was explosive in nature and very
watery, often containing bright red blood. His initial investigations showed a total white
cell count of 12.4/ mm 3 with an eosinophilia of 25%. Platelets were 530 and ESR was
50. IgG level was slightly raised at 15.6 g and IgA and IgM levels were normal.
Among liver enzymes, y-GT was slightly raised at 66 units (normal, 8-49) and other
investigations gave normal results. No enteric pathogens including ova and parasites
were isolated from stool. Very low levels of specific IgE against egg and wheat, and no
IgE antibody against milk, were found in his serum.
D. R.'s mother suffers from irritable bowel syndrome. D.R.'s elder brother suffered
from asthma when he was younger but there was no other family history of atopy.
There were two cats and a guinea pig at home and his grandmother has a dog. D.R.
was treated with Mebendazole for possible worm infestation.
Investigations done at the Royal Hospital for Sick Children, Edinburgh, showed
persistent eosinophilia. A barium enema showed a very fine granular appearance in
the mid-transverse colon but no ulceration was identified. His colonoscopy and
subsequent biopsy results showed severe active colitis with a prominent eosinophil
component (Figure: 9.1, Eosinophils are pink in colour with Carbol Chromotrope
staining). Ulcerative colitis was thought to be the likeliest diagnosis in view of the
disruption of crypt architecture, goblet cell depletion and crypt abscess formation,
which are not usual features of eosinophilic colitis.
The subsequent investigations conducted in the Gl unit showed: WGLF IgG 20 pg/mL,
IgA 123 pg/mL, and WGLF cytology analysis showed an abundance of eosinophils.
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His upper Gl endoscopy and biopsies were normal. He was treated with
Prednisonlone. In view of his persistent eosinophilia, a bone marrow examination was
performed and the report suggested reactive peripheral eosinophilia, but with no
evidence of eosinophilic leukaemia or a primary bone marrow problem. There was no
evidence of eosinophil infiltration in any other organs. A diagnosis of 'Enteropathy
hypereosinophilic syndrome' was made. He continued to receive a low dose of
Prednisolone to reduce his blood eosinophil counts which returned to within the normal
range after three months. He remained well when last seen in November 1998.
In the following section, I record IL-8, IL-ip, granulocyte elastase (GE) and IgA
EndoCAb determinations done relevant to my interests in eosinophil migration to the
gut mucosa. These results were discussed in chapters 4 and 6.
218
*A .*
*
^
f/# i - •
t < HV «V '
> *- 2?i
MM 4 ,*m.
f, •«•«»
f fc / • * l^y
I *L * . V.% §".
e
, # >3r&a^V^»
1^. flBb
Figure: 9.1. Colonic biopsies from the index case, carbol chromotrope staining.
A&B - original magnification: x 25; C - original magnification: x 40.
Results:
ECP in WGLF
Figure 9.2 illustrates the ECP concentration in WGLF from the index case. During the
active stage of his disease, the ECP concentration was found to be as high as 1193
pg/L, while in remission this value came down to 50.3 pg/L.
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Figure: 9.2 ECP concentration in WGLF from the index case during active and
remission stage of the disease.
Figure 9.3 depicts the concentration of ECP in WGLF from IBD patients and healthy
controls. The median and (range) values for ECP in WGLF from Dhaka and Edinburgh
controls were 70 (12-98) pg/L and 12 (6-29) pg/L respectively. There was a significant
difference (p<0.002) in ECP concentration in WGLF between Dhaka and Edinburgh
control groups. In IBD patients, the median and (range) concentrations of ECP in
WGLF from UC and CD were 69 (42-153) pg/L and 74(29-443) pg/L respectively.
These values were significantly higher than the values from the Edinburgh controls
(p<0.006 for UC and p<0.0001 for CD). No significant differences in ECP
concentration were observed between patients with UC and CD.
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Figure: 9.3 ECP concentration in WGLF from patients with active IBD and healthy
controls.
A significant positive correlation (r=0.8, p<0.03 for UC and r=0.75, p<0.001 for CD)
was noted between total IgG (an established objective marker of gut inflammation) and
ECP in WGLF from patients with active IBD (figures: 9.4 and 9.5).
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Figure: 9.4 Correlation between total IgG and ECP in WGLF from patients with active
UC.
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Figure: 9.5 Correlation between total IgG and ECP in WGLF from patients with active
CD.
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In active CD, a significant positive correlation was found between ECP, total IgA and
IgA EndoCAb (Figures: 9.6 and 9.7). No such correlation was found in patients with
active UC.
Total IgA in WGLF
Figure: 9.6 Correlation between ECP and total IgA in WGLF from patients with Crohn's
disease.
IgA EndoCAb in WGLF
Figure: 9.7 Correlation between ECP and IgA EndoCAb in WGLF from patients with
active Crohn's disease.
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IL- 5 in WGLF
There was no IL-5 detected in WGLF either from patients or from healthy controls by
the standard ELISA techniques.
The compiled results of GE, IL-8 and IL-1 (3 are presented in figures 9.8 a,b, and c.
The reason for presenting these compiled results is to show that despite the virtual
absence of GE, IL-1 (3 and IL-8 in WGLF, there were high ECP and eotaxin levels in
the Dhaka control group. In addition, there was no correlation noted between GE, IL-
1 p, IL-8 and ECP or eotaxin in WGLF from patients with active IBD.
Figure: 9.8a
Granulocyte elastase (GE) in WGLF
from patients with active IBD and
healthy controls
X.
DHAKA EDINBURGH CD UC
Patients and control groups
Figure:9.8b
IL-8 in WGLF from patients with active
IBD and healthy controls
CD UC DHAKA EDINBURGH
Patients and Control groups
Figure:9.8c
IL-1 p in WGLF from patients with
active IBD and controls
CD UC DHAKA EDINBURGH
Patients and Control groups
Figure: 9.8 a,b,c. Compiled results of GE, IL-8 and IL-1 (3 of patients with IBD and
healthy controls.
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Eotaxin in WGLF
The results of the eosinophil specific chemokine eotaxin levels in WGLF are presented
in Figure 9.9. The median and (range) concentrations of eotaxin in WGLF from the
healthy control groups from Dhaka and Edinburgh are 20 (15-28) pg/mL and 14 (12-
17) pg/mL respectively. There was a significant difference in eotaxin concentrations in
WGLF from the control groups of Dhaka and Edinburgh (p<0.004). in active IBD
patients, the median and (range) concentrations of Eotaxin in WGLF from UC and CD
were similar. These values were 17(15-24) pg/mL and 18(17-19) pg/mL respectively
and were significantly higher than the values of Edinburgh controls (p<0.002 for UC,
and p<0.007 for CD).
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Figure: 9.9 Eotaxin concentration in WGLF from patients with active IBD and controls.
A significantly positive correlation (r=0.8, p<0.03) was found between levels of eotaxin
and ECP in WGLF from patients with active UC (figure: 9.10). There was no such
correlation found in patients with active CD nor in healthy control groups from Dhaka
and Edinburgh.
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Figure: 9.10 Correlation between ECP and eotaxin in WGLF from patients with active
UC.
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Discussion
Gastrointestinal mucosa, unlike healthy skin and respiratory mucosa, normally
contains eosinophils. The constitutive presence of eosinophils in the gut is probably
very important in host defence, but also in the pathogenesis of diseases such as
eosinophilic gastroenteritis and coeliac disease (Talley et al, 1992). In fact, normally,
the level of eosinophils in the body is tightly regulated and accounts for only a small
minority of peripheral-blood leukocytes. A marked accumulation of eosinophils has
been found in several important disorders, including allergic disorders, parasitic
infections and cancer (Weller, 1991). The aim of the study was to identify signals of
eosinophils migration and their role in the genesis of mucosal damage in IBD.
Previous studies of the bowel mucosa in IBD have focused on the involvement of
neutrophils but have given little consideration to the eosinophil population. Rectal
biopsy specimens from patients with UC (Lumb & Protheroe, 1955; Truelove &
Richards, 1956) and surgical CD specimens (Dvorak, 1980) have been reported to
have an increased amount of eosinophil granule proteins. Increased levels of ECP
have also been shown in faeces from patients with IBD (Berstad et a/, 1993; Bischoff
et al, 1997). However, it has recently been suggested that measurement of secretory
proteins in faecal extracts may be highly misleading, since they are not representative
of the total amount of proteins secreted into the gut lumen (Ferguson et al, 1995). In
addition, degranulation of eosinophils may occur by the trauma during colonoscopic
biopsy as well as processing of the specimen ( Talley et al, 1992). Therefore,
measurement of eosinophil proteins in WGLF was considered a better approach for
investigating the role of eosinophils in IBD.
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In this study, the ECP concentration in WGLF from patients with active IBD was found
to be significantly higher than that from control groups (figure:9.3). It was also
observed from the index case that the ECP level decreased when the patient was in
clinical remission (figure 9.2). However, it is pertinent to question whether the ECP
detected in WGLF from patients with active IBD originated from the gut or whether it
could have resulted from plasma leakage through the inflamed bowel. An elegant
study was done by Croft (1996), who measured ECP concentrations in WGLF and
serum collected at the time of lavage. During the WGL procedure, lavage fluid is
taken at a rate of 20mL/minute (1200 mL/hour) in adults. Considering the ECP values
found in WGLF from patients with IBD, for serum to be the source of the ECP, in
excess of 1.2 litres per hour would have to have been secreted into the Gl tract. This is
not possible since such a high volume of fluid loss would have resulted in patients
becoming rapidly hypotensive (Croft, 1996). In addition, WGLF is a perfusate and is
considered more valid than faecal examination for the estimation of the total amount of
mediators released into the gut lumen (Ferguson et at, 1995).
It is recognised that the IgG levels in WGLF are an excellent objective marker of gut
inflammation and can be correlated with clinical disease activity score in active IBD
(Choudari et at, 1993). Data have also been presented in chapter 7 of this thesis to
support the view that there is local production of IgG in the gut. The significantly
positive correlation between ECP and IgG in WGLF from patients with active IBD
(Figures: 9.4 & 9.5) suggests that the level of ECP is related to the degree of mucosal
inflammation. Furthermore, it has been shown that activated eosinophils are capable
of secreting pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-a (Weller, 1992;
Costa et at, 1993). These findings may suggest that IBD is accompanied by eosinophil
activation and degranulation in the gut. However, whether activation and degranulation
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of eosinophils in IBD is a spontaneous phenomenon or induced by other factors in the
gut is not yet clear. Studies of immunoglobulin-mediated eosinophil degranulation
indicated that IgE (Capron et al, 1981;Capron & Dessaint, 1990) and especially
secretory IgA and IgG are potent stimuli of eosinophil degranulation ( Abu-Ghazaleh et
al, 1989). It is possible that increased local production of IgG in the gut induces
eosinophil degranulation in the lamina propria of inflamed mucosa in patients with
active IBD.
It is reasonable to raise several questions regarding mechanisms behind the activation
and local accumulation of eosinophils in the gut. What is the initial stimulus for gut
inflammation that results in expansion and activation of the eosinophil population in the
lamina propria and which cell responds initially to the stimulus? Do eosinophils follow
lymphocytic signals or signals from other granulocytes, such as neutrophils? Are there
any local mechanisms involved in the recruitment of eosinophils? In addition, what
role do they play in the pathogenesis of disease; are they effector, director or
collaborator?
It has been shown that the eosinophil receptor for IgA binds secretory IgA more
potently than other forms of IgA and hence induces degranulation (Abu-Ghazaleh et
al, 1989). As eosinophils usually localise to mucosal surfaces in the gut, their IgA
receptors can engage secretory IgA at this site and help in degranulation. The index
case had a very high level of IgA and ECP in WGLF. In addition, ECP concentrations
in WGLF from the Dhaka control group were significantly higher than for the
Edinburgh control group (figure: 9.3). As already discussed in chapter 4 the total IgA in
WGLF from Dhaka healthy controls was also significantly higher than in the Edinburgh
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control group. These results clearly support the hypothesis that IgA may have some
role in induction and degranulation of eosinophils.
Beeken et al, (1987) showed that intestinal eosinophils are capable of phagocytosis
and play a role in the defence against bacterial invasion in the gut. In view of the
higher microbial antigenic load in the gut of the Dhaka population (Albert et al, 1991), it
does seem that microbial antigens might be an additional aetiological factor for the
high ECP values in this population. In active CD, a positive correlation between ECP
and total IgA (figure: 9.6) as well as IgA EndoCAb (figure:9.7) lends further support to
these statements. The roles of non-pathogenic intestinal bacteria and IgA in CD have
already been discussed in chapter 6. However, there was no such correlation noted in
patients with active UC. Possible immunological differences in disease pathogenesis
exist between CD and UC (as discussed in chapter 6, CD is Th1 and UC is Th2
mediated). In addition, sites of inflammation (small bowel or colon: apart from
anatomical structure, bacterial populations are also different in these two sites) are
likely to determine this discrepancy.
In most well studied examples of gut inflammation such as IBD, activated T cells and
macrophages are considered to be the primary co-ordinators and it is generally
believed that eosinophils are recruited into the inflammatory lesion secondary to the
activation of primary immunoregulatory cells ( Levy & Kita, 1996). The summarised
results of IL-1 p, IL-8 and GE assays (figure: 9.8 a, b, c) showed that despite the virtual
absence of IL-1 p, IL-8 and GE there were high ECP levels in the WGLF of the Dhaka
control groups. These results clearly suggest that eosinophils are not just fellow
travellers with granulocytes, neutrophils, or macrophages. Whether eosinophils follow
lymphocytes in the event of inflammation is not known. On the other hand, it has been
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found that tissue lymphocytes are increased in eosinophilic gastroenteritis (EG) ( Levy
& Kita, 1996). This area needs further study.
In an excellent study conducted in patients with EG it is suggested that local
mechanisms must be involved in recruitment and activation of eosinophils in the gut
(Desreumaux et al, 1996). EG is a rare disorder defined by three criteria: the presence
of gastrointestinal symptoms, an eosinophilic infiltration of one or more areas of the
gastrointestinal tract from oesophagus to colon, and no evidence of parasitic or
extraintestinal disease (Cello, 1979). Unlike the idiopathic hypereosinophilic syndrome,
eosinophil infiltration in EG is limited to the gut without extension to other organs and
frequently occurs independently of blood eosinophilia (Spry, 1988). This suggests that
local mechanisms must be involved in recruitment and activation of eosinophils in the
gut. These mechanisms could involve key regulatory cytokines that control the
production and function of eosinophils. In this study, IL-5 was not detected in WGLF
from either patients or control groups. I have not undertaken 'spiking' experiments with
IL-5 in WGLF. However, in-house experiments with other cytokines showed that IL-6
and TNF-a were also not detected in WGLF (Hazel Drummond, personal
communication). 'Spiking' experiments with these cytokines suggest that IL-6 and
TNF-a are very labile. In addition, perhaps other unknown factors present in WGLF
are detrimental to the detection of these cytokines. IL-5 is a homodimeric glycoprotein
of 25 to 40 Kd, held together by two interchain disulphide bonds (Bagley et al, 1997). It
is probable that the reason for undetectable IL-5 in WGLF might be similar to that for
the apparent absence of IL-6 and TNF-a. This would need to be confirmed.
For the first time, it has been shown in this study that eotaxin is secreted into the gut
lumen in both health and disease. Higher eotaxin concentrations in WGLF from the
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Dhaka control group (figure: 9.9) may be the reason for higher ECP concentration in
that group compared to the Edinburgh controls. A significantly positive correlation was
found between eotaxin and ECP in WGLF from patients with active UC (figure: 9.10).
There was no such correlation noted in patients with CD and in either healthy control
groups from Dhaka or Edinburgh. These interesting results merit further clarification.
Eosinophils are predominantly tissue-dwelling cells; there are normally several
hundred times as many eosinophils in tissues as in blood (Weller,1991). Their actual
life span is unknown, but they live longer than neutrophils and may survive for weeks
within tissues (Spry, 1988). However, in disease states, where the process of activation
and degranulation of eosinophils leading to inflammation and tissue damage is rather
rapid, this cell turnover may be responsible for the positive correlation between
'eotaxin' and ECP in patients with active UC. Due to the paucity of sample size (in five
CD cases only), it is very difficult to comment on the lack of correlation between
eotaxin and ECP in CD patients. In addition, as already discussed, other non-specific
factors may be involved in activation and degranulation of eosinophils in patients with
CD.
In summary, this study demonstrates that eosinophils may contribute to mucosal
damage in active IBD. ECP in WGLF may represent another marker of inflammation in
IBD. Eosinophils are not fellow travellers, they actively migrate to tissues. Eotaxin
plays a key role in attracting eosinophils to the site of inflammation leading to tissue
damage by releasing ECP and perhaps some other reactive oxygen species. The
identification of molecules specifically involved in eosinophil- induced disease
pathogenesis offers hope for the development of new therapeutic agents that
specifically target eosinophil pathways.
232
Discussion
233
Chapter 10
General Discussion, Overview, and Future Directions
Infectious disease continues to be a major cause of mortality and morbidity throughout
the world and especially in developing countries. Despite the existence of multiple
mechanisms which control microbial populations at mucosal surfaces, the mucous
membranes remain the most important portal of entry for microbial infections. The
ability, therefore, to enhance mucosal resistance to infection has enormous clinical
importance. My long-term research objectives are to investigate the gut immune
system in the context of health and disease of people in the developing world,
especially in the fields of diarrhoeal disease and undernutrition. In this treatise, the
major aim was to develop antibody tests which could be used as tools to examine the
gut humoral immune responses to bacteria of the gut flora. Combined with studies of
other facets of gut immunity for which study methods are already available, these tools
should facilitate further investigations into active immunity and tolerance in the
mucosal and systemic compartments.
The technical developments related to measuring antibody in WGLF have been
presented in section 2 of chapter 2. The WGL technique has been established
recently as a clinical tool for studying various humoral immune functions and
inflammatory parameters in the gut. In chapter 3, evidence has been presented to
support the view that antibody tests with WGLF are essentially reproducible. The
techniques that I have described offer much hope in the further exploration of gut
immunopathogenicity and the pathophysiology of intestinal disease.
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The intestine is considered the largest lymphoepithelial organ in the body with a
surface that is exposed to the heaviest burden of environmental antigens. In view of
the higher microbial antigenic load from the contaminated environment in Dhaka
population, I hypothesized that there would be evidence of gut damage and
inflammation in healthy people of Dhaka. In addition, there may be higher levels of IgA
antibody in the intestine due to humoral responses to bacteria. The results presented
in chapter 4 suggest that there was no evidence of gut damage or inflammation in the
healthy Dhaka population. However, the results support the second part of the
hypothesis, demonstrating a higher IgA antibody production in the gut of the healthy
people of Dhaka. The reason for the increased total IgA in WGLF from healthy
controls from Dhaka may be due to non-specific immune activation. Furthermore, to
prevent gut inflammation or bacterial translocation, it is probable that there may be an
increased drive in the production of S-lgA.
As discussed in the literature review, lgA1 and lgA2 subclasses are present in the gut
and these have subtle structural and functional differences, including sensitivity to
bacterial proteases. Recently, it has been shown in a murine model that two
functionally distinct types of S-lgA antibodies exist. These antibodies are produced by
two separate B cell populations, B-1 and B-2 (Mestecky et a/, 1999). The B-1
lymphocytes (formerly Ly1+ or CD5+), make an important contribution to the lamina
propria IgA plasma cells. These produce less specific, perhaps polyreactive 'natural'
antibodies. These antibodies actually play a role in the maintenance of the normal
intestinal bacterial flora (Mestecky et al, 1999). However, pathogenic micro-organisms
stimulate the immune systems after invasion through Peyer's patch M cells (Owen &
Davis, 1997). These stimulate locally present conventional B-2 cells which are then
disseminated to the lamina propria of the gut, and mature into IgA plasma cells.
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These plasma cells then produce specific IgA antibodies with high affinity for the
pathogen which they exclude (Mestecky et at, 1999). These murine studies should not
be extrapolated to Man without caution, for the existence of such functional dichotomy
of S-lgA antibodies in human is unknown. Certainly this is a fertile area for future
studies. An immunology honours student placed in the Gl lab is currently setting up
studies to investigate this area. Knowledge from such studies will hopefully be helpful
for developing oral vaccines for enteric infections, especially for developing countries.
The immune system of the gut is separate and distinct from the systemic immune
system. It differs in many respects: in the cells and immunoglobulin isotypes involved,
in the various effector functions, and in its immunoregulation (Ferguson et at, 1994).
There are complex interrelationships between the normal gut flora, intestinal infection,
invasion of the tissues by gut bacteria or their products, sepsis syndrome, shock, and
multi-organ failure. Gram-negative sepsis and endotoxic shock are complicated
pathophysiological entities which have evaded effective medical treatment for
centuries. This sepsis syndrome is a major cause of mortality and morbidity in the
immunocompromised, especially in the neonate, elderly and in post-operative patients.
Estimated mortality in patients with severe sepsis and related haemodynamic
compromise ranges from 40-90% depending upon various settings and the time of
intervention. It is one of the leading cause of death in children hospitalised for
diarrhoeal diseases in developing countries (Strulence et at, 1985).
In the field of sepsis, the source of endotoxin (LPS) is debated (gut versus
bacteraemia). It has been shown that low serum anti-EndoCAb antibody is an
independent predictor of adverse outcome following cardiac surgery ( Bennett -
Guerrero et at, 1997). Antibodies to LPS are often protective (Poxton, 1995).
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Nevertheless, systemic immunisation is essentially ineffective for induction of mucosal
immune responses. Since the majority of infectious micro-organisms are encountered
through mucosal surface areas, it is logical to consider the induction of protective
antibodies and T cell responses in mucosal tissues. Various core types of LPS of E.
coli (a prototype of Gram-negative bacteria) were well studied in the Department of
Medical Microbiology, University of Edinburgh. The results are presented in chapter 5.
The study demonstrated for the first time that there are mucosal IgA antibody
responses present against the specific LPS core types of E.coli in the gut. There are
some important potential implications of this study. However, little is known of how
LPS epitopes, especially in the core /lipid A regions, are presented to the inductive arm
of mucosal immune systems, and notably the roles of T cells and immunological
memory are unclear. It is necessary to investigate the relationship between LPS core
types and O types and pathogenicity. In addition, it is worthwhile to study the
protective capabilities of specific monoclonal IgA antibodies against LPS core types,
especially whether antibodies recognising a single epitope on the target organism can
provide protection against colonisation or invasion of the gut mucosa. Immunoblot
study (figure 5.8 in chapter 5) clearly demonstrated that mucosally presented vaccine
against infectious diarrhoea is an avatar. It seems quite probable now, a vital
question, which could be answered using this study technique, is whether patients
with sepsis syndrome and multiorgan failure have adequate intestinal mucosal
antibody to LPS or whether there is transient or prolonged mucosal antibody failure in
this situation. However, my study underpinned several other studies which are
currently being undertaken in the Department of Microbiology under the supervision of
Professor Ian Poxton. If he precise mechanisms causing septic shock are determined,
the prospect of the development of effective therapy becomes more likely. It might not
even be necessary to use human antibodies for this purpose. Passive administration of
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heterogenous antibody via gut could theoretically be an attractive and economic
option.
Immune phenomena are believed to play a key role in the pathogenesis of tissue
damage in IBD. Results of studies on intestinal humoral immunity in this chronic
condition are conflicting. Genetic factors predispose to IBD but a contribution of the
gut flora cannot be ignored. The results presented in chapter 6 suggest that aberrant
immune responses to non-pathogenic luminal bacteria or bacterial products may be
responsible for initiation and perpetuation of chronic intestinal inflammation in IBD. In
addition, it is possible that primary mucosal immunodeficiency is present in IBD
patients, thus allowing agents to penetrate the intestinal mucosa and subsequently
initiate both a local inflammation and heightened systemic immune response against
bacterial and food antigens.
In CD, whether a primary mucosal immunodeficency is responsible for the impaired
barrier function, a plausible factor in the postulated pathophysiology, is not clear.
Furthermore, whether the dysfunction is a primary aetiological factor in CD or is merely
an 'epiphenomenon' of the inflammatory process of the disease, merits further study.
The results of serum IgG EndoCAb estimation in CD are fascinating and it suggest
that this could be used as a reliable serological screening test. Further studies are
needed to identify the sensitivity and specificity of this test in identifying and predicting
relapse in patients with IBD, especially CD, as other tests (i.e. the dual sugar
permeability test) are cumbersome, time-consuming and lack specificity.
Although some immunological features seem to be shared by CD and UC, there are
important distinguishing features, possibly reflecting different loops of immune-
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mediated intestinal inflammation. Evidence indicates that macrophage and T cell
derived cytokines play a key role in the amplification and perpetuation of the
inflammatory response in both disorders (Sator,1994). A number of quantitative
changes in the secretion (i.e. lgG1 & lgG2 in CD, lgG1 & lgG3 in UC) and /or activities
of both proinflammatory and regulatory cytokines have been reported in CD and UC.
Considering the variation in the magnitude of these changes, there seem to be
different cytokine profiles into which the inflammatory process may fall during the
course of the disease. Studies from murine models indicate that two T lymphocyte
subsets may be defined depending on their cytokine secretion profiles: Th1
lymphocytes producing interleukin (IL)- 2 and interferon y (IFN-y), and Th2-
lymphocytes producing IL-4, IL-5, and IL-10. Combined data from both human and
experimental studies suggest that in CD the local immune response tends to be
predominantly Th1, whereas in UC Th2 mediated phenomena tend to predominate.
Recently, it has been shown that IL-12 plays an important role in the generation of Th1
type cell clones and was found in increased concentration in the intestinal mucosal
sample of patients with CD (rarely detected in normal intestinal mucosa and in
unstimulated lamina propria mononuclear cells from patients with UC) (Pallone &
Monteleone, 1998). The IL-12 induces synthesis of IFN-y by lamina propria T
lymphocytes and this process is further enhanced by other cytokines produced in the
human intestine, such as IL-7 and IL-15 (Pallone & Monteleone, 1998). Driven by IL-
12, IL-7 and IL-15 may thus promote Th1 cell expansion and contribute to the
breakdown of tolerance towards the resident luminal antigens (Duchmann et al,
1995; 1996).
However, several questions are still unanswered. What induces IL-12 production in
CD? Is there any disease-specific stimulus for this or does it reflect macrophage
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activation by T cell derived cytokines or luminal bacteria or both? Nevertheless, it
seems clear that IL-12 may be involved in mediating the immune response in CD, and
the inhibition or blocking of its biological effects may be a promising way to control the
inflammatory process in CD.
The results on studies of bacteroides organisms UC and pouchitis are compelling.
Whether any particular species of Bacteroides is associated with UC [ B.
thetaiotaomicron (Poxton et at, 1997), B. vulgatus (Onderdonk et at, 1981)], or whether
the breakdown of tolerance towards predominant anaerobic resident colonic bacteria is
responsible for UC, is currently unknown. Avenues for further studies are thus clear.
In the field of IBD, the source of gut antibodies is debated. One of my research aims
was to establish, by studying patients with active IBD, whether the gut antibodies are
serum- derived or locally produced. I have already discussed the limitations of the
various methods of studying gut antibodies. For example, measurement of secretory
proteins in faecal extract may be highly misleading, since they are not representative
of the total amount of proteins secreted into the gut (Ferguson et at, 1995).
Endoscopic biopsy are susceptible to trauma and only represent isolated areas which
are not necessarily representative of the whole gut. In addition, cell culture in an
artificial medium is necessary. Most of the in vitro studies using cultured cells are rely
on stimulation by an antigen which may be inappropriate or dissimilar to luminal
antigens. The WGL technique is an excellent non-invasive tool for the study of gut
antibodies without trauma. To study the source of gut antibodies, an attractive
arithmetic model has been contrived in chapter 7. The study demonstrates an
increased local production of IgG antibody in the gut. It has been shown for the first
time that depending upon the nature, quality and number of antigens (single or
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multiple), local production of antigen-specific IgG antibody in the gut mucosa was
increased by 56-99% in active IBD. As mentioned earlier, it is quite probable that due
to the failure of the 'first line defence' ( S-lgA considered as a first line defence in the
gut mucosa), an additional second line defence seems to be established by local IgG
production. It does seem that in IBD, continual antigen-driven division of B cells in the
absence of signals from helper T cells for the terminal differentiation may result in
increased IgG production instead of IgA in the gut. Although this may be beneficial as
a second line defence, it may give rise to a deleterious reaction as IgG antibody has
'phlogistic' potential. Using my arithmetic model, others in this lab have recently shown
that there is increased local production of complement in the gut of patients with active
IBD (Kenneth Humphreyes, personal communicaton). It is now conceivable that locally
produced IgG ( a potent complement activator) and complement are contributing to the
persistence of chronic inflammation in IBD. What initiates complement attack, and the
identification of the antigens or autoantigens will be a 'Holy grail' in IBD research.
Initially I hypothesized that in developing countries, the drive of production of a high
humoral response to bacteria would have an additional effect, and that antibodies to
other luminal antigens, such as food, would be absent or of low titre. The hypothesis
has been tested and the results presented in chapter 8. The induction of
immunological unresponsiveness by feeding soluble antigens, termed 'oral tolerance'
is a well-known phenomenon. However, most of the data generated related to this
topic have come from studies on murine models. The literature on oral tolerance in the
human remains scanty, partly because of the difficulties in identifying safe,
immunogenic neoantigens in humans to be used in research on the induction of
tolerance. However, my study on systemic and humoral immunity to antigens regularly
encountered, such as gut bacteria or food antigens, supports the concept of a degree
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of down-regulation of systemic immunity to gut luminal antigens. A study conducted by
a colleague in this lab, feeding neo-antigen keyhole limpet haemocyanin (KLH) to
human volunteers, demonstrated that oral tolerance does occur in humans. The
mechanisms leading to oral tolerance include clonal deletion, anergy and active
suppression. The determining factor in this process is the dose of fed antigen. It is
recognised that low dose favours active suppression, whereas high dose favours
clonal deletion and anergy (Strobel & Mowat,1998, Husby et al, 1994). Nevertheless,
oral tolerance is an important physiological phenomenon and is likely to be relevant to
the understanding of pathogenesis, and the development of new forms of therapy in
several inflammatory gut diseases.
Recently the 'hygiene hypothesis' has gained wide acceptance. The key element of
the hypothesis is the Th1/Th2 paradigm. This hypothesis suggests that infection in
early life by micro-organisms that elicit a vigorous cell-mediated immunity (Th1 type
response, e.g. Mycobacterium tuberculosis) may prevent the development of atopy or
atopic diseases ( e.g. asthma, Th2 type response). It is possible that the higher
incidence of infectious disease (Th1 response) in Bangladesh may be a cause for low
antibody against food antigen (Th2 response) in the gut. In addition, lately, it has been
shown that the B subunit of cholera toxin is an immunomodulator. Coupling of antigen
to the B subunit prior to oral delivery can dramatically decrease the dose required to
stimulate tolerance (Williams et al, 1999). This may be a reason for low food antibody
in the gut in a population where cholera is endemic. These results have certain
implications in the strategies for oral vaccines against infectious disease.
Eosinophils have been implicated in a number of gastrointestinal diseases including
parasitic infestations, allergies and coeliac disease. There is some scepticism
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regarding the participation of eosinophils in mucosal inflammation in IBD, perhaps
related to the fact that eosinophils are terminally differentiated, minority, end stage
leukocytes. In addition, the discharge of potentially toxic, proinflammatory granule
proteins may make the cells less readily identified by routine histology (Levy and Kita,
1996). Thus, eosinophils which have not been identified may already have
participated in the inflammatory processes. However, the results presented in chapter
9 suggest that eosinophils contribute to the mucosal damage in active IBD. Their
granular protein ECP can be used as a marker of inflammation in IBD. Evidence has
been presented to support that eosinophils are not fellow travellers, but migrate to the
tissue by independent mechanisms. In fact, recently, mechanisms involved in
eosinophil migration and related chemoattraction have been described (Williams,
1998). In addition, eotaxin receptor CCR3 which is highly expressed on eosinophils
has been identified. Thus, eotaxin and its receptors emerge as prime targets for
potential therapeutic intervention. Blockade of the receptor with an antagonist may
render the circulating eosinophils insensitive to the attractant action of locally
produced chemokines and may be effective in preventing the pathogenesis
associated with eosinophil accumulation.
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Appendix: Reagents and
Instrumentation
WGLF Processing Methods and Reagents
1. Collect two Universal (2x30 mL)containers of clear lavage fluid
2. If the collected samples do not appear very clear or do not filter relatively quickly
then centrifuge the samples at 1500g for 5 minutes.
3. Dispense 3x1 mL unfiltered and untreated lavage fluid into sample tubes. Add 20 pi
sodium azide (1%). Label with Laboratory no. and UF+UP (Unfiltered and
Unprocessed).
4. Filter approximately 10 mL into a Universal or a flask, use Whatman GF/A 12.5 filter
paper.
5. Transfer 5 mL into a Universal A. Transfer 5 mL unfiltered lavage into a Universal B.
6. Treat both the Universal aliquots as follows:
Add 0.5mL SBTI (Soya bean trysin inhibitor), and mix.
Add 0.28 mL EDTA (BDH Cat No: 10093), and mix
Add 0.12mL PMSF (Phenylmethylsulphonylfluoride, Sigma Cat No P-7626)
Add 0.06 mL Na Azide and mix.
Leave for 2 minutes
Add 0.3 mL NBCS (Newborn calf serum, sigma Cat No N 4762 heat-
inactivated)
7. Dispense 10x250pl and 1x1 mL from A into microcentrifuge tubes and lab freezer
tubes respectively, labelled with approprite lab no.
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8. Dispense 2x1 mL from B into freezer tube labelled with lab no, and UF +UP.
9. Dispense 2x1 mL untreated filtered lavage into freezer tube, add 20 pi Sodium
azide, label with lab no and F+UP (Filtered and Processed).
10. Strore 1 of each F/P, F/UP, UF/P and UF/UP at -700 C.
In-House ELISA reagents
Plates
• Immulon 1 129 A (Dynatech) were used for total immunoglobulin assay.
• Immulon 2 129 B (Dynatech) were used for antibody ELISA's.
Coating antibodies
• Goat antihuman IgG: Fc specific, Sigma Chemical Co. (Cat No 2136)
• Goat antihuman IgM: p chain specific, Sigma Chemical Co, (Cat No I-2386)
• Goat antihuman IgA: a chain specific, DAKO Chemical Co (Cat No A-0262)
• Ovalbumin: (Sigma Cat No A-5503).
• Monosialoganglioside (GlVh): (Sigma) 1mg/mL in 2:1 chloroform:methanol
• Cholera Toxin: (List Biologicals)
Conjugated antibodies-alkaline phosphatase conjugate
All made up in the appropriate diluent
• Goat antihuman IgA, Sigma Chemical Co (Cat No A-3063)
• Goat antihuman IgM, Sigma Chemical Co (Cat No I-2386)
• Goat antihuman IgG, sigma Chemical Co (Cat No A-3187)
Other Reagents
• Sterile water
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1 litre sterile water containers (Baxter Healthcare Code F 7124)
• Coating buffer
Carbonate-bicarbonate coating buffer, 0.05 M, pH 9.6 at 25°C. Dissolve the contents
of 10 capsules (Sigma Chemical Co. Cat No C-304) in 1 litre water.
• Sodium chloride
0.9% sodium chloride in 1 litre sterile containers (Baxter Healthcare Code F7124)
• Wash solution
0.9% saline + 0.05% Tween 20 (Polyoxyethylene-Sorbitan Monolaurate, Sigma
Chemical, Cat No P-1379)
• Adult Bovine serum
Adult bovine serum (filtered through 22 pm filter) (SAPU, Law Hospital, Carluke,
Lanarkshire, ML8 5ES (Product No S026-220)
• Diluent
0.9% saline +0.05% Tween 20+ 1% adult bovine serum.
• Diluent for CT assay
0.9% saline +0.05% Tween 20+ 1% bovine serum albumin
• Diluent for EndoCAb and E.coli LPS cores
I litre freshly-distilled water + 1 vial powdered Dulbecco Phosphate Buffered saline + 1
mL Tween 20+ 5 mL 10% Na azide +40g PEG 800 (final cone 4%) + 10g serum
albumin (endotoxin free BSA, Sigma Cat No A-1933).
• DEA (diethanolamine) substrate
To make 5 litres of DEA substrate:
1. Add 500 mL diethanolamine-concentrated liquid (BDH Laboratory Supplies, Analar
Reagent Product No 10393 4J)
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0.51 g magnesium chloride (Mg CI26H20)
1 0g sodium azide (NaN3)
4 litre sterile water
2. Adjust the pH to 9.8 with 6M hydrochloric acid (HCI)
• P-nitrophenyl phosphate
5 mg phosphatase substrate tablets-disodium p-nitrophenyl phosphate hexahydrate
(Sigma Chemical Co. Product No 104-105)
• Alkaline phosphatase substrate
Fresh substrate is constituted approximately 30 minutes before required. Dissolve 1
tablet phosphatase substrate per 5 ml_ DEA buffer; mix thoroughly.
Haemoglobin Reagents
All reagents are analar grade and obtained from Merk (BDH) unless otherwise stated
• Oxalic acid Reagent: 4.0 g oxalic acid (Analar) is made up to a 10mL volume with
distilled water, and dissolved in a water bath at 100°C. 0.10 g uric acid and 0.11g
mannitol are then added, and the reagent left at 100 °C for 5 minutes. Any
undissolved reagent is left to settle out. The supernatant is pipetted off while hot in
the fume cupboard and this is the test reagent. The reagent is prepared fresh
before use.
• Ethyl acetate/acetic acid 10/1 v/v: Add 50 ml_ glacial acetic acid to 500 mL
ethylacetate in a fume cupboard.
• 3.3M Potassium Acetate (294g/L): Dissolve 29.4g potassium acetate(BDH GPR) in
100 mL distilled water. Store at room temparature.
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• 4.3M Potassium Acetate in 1M Potassium Hydroxide (56g/L): Dissolve 147g
potassium acetate in 300 ml_ distilled water, add 28g potassium hydroxide (fume
cupboard), dissolve with stirring and make up to 500 ml_ with distilled water.
• N-butanol (Rathburn Chemicals Ltd, Walkerburn)
• 6.2M H3PQ4/Acetic acid 9/1 v/v): Dissolve 68 ml_ orthophosphoric acid in 300 mL
water and add 58 mL glacial acetic acid.
• PEG 4000 reagent: Dissolve 60g PEG 3350, 9g NaCI, and 0.2 g sodium azide in 1
litre of distilled water. Use to make Drabkins reagent.
• Drabkin's Reagent: (Sigma Cat No. 525-2) 6 vials.
Each vial contains 1 g sodium bicarbonate, 0.2g potassium ferricyanide, and 0.05g
sodium cyanide. Take 1 vial and reconstitute to 1 litre with PEG 4000 reagent.
[ Caution: this is a dangerous solution and must be appropriately labelled, handled and
stored.]
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LPS extraction reagents :
• PCP reagent, 90% w/v aqueous phenol, chloroform and petroleum spirit in the
ratio of 2:5:8 by volume. (Use pyrogen-free glassware throughout)
• w/v aqueous phenol (add 1 part of pyrogen-free water to 8 parts of 90% w/v
aqueous phenol solution. Diethyl ether/acetone in the ratio of 1:5 by volume.
PAGE reagents:
1. 40% w/v aqueous acrylamide solution
100g acrylamide (BDH Electran), 2.7g methylenebisacrylamide (BDH Electran),
Pyrogen-free water to 250 mL
2. 15 g/L w/v ammonium persulphate solution.
300 mg ammonium persulphate (BDH Analar) in 20 mL of pyrogen-free water.
3. 0.05% w/v aqueous bromophenol blue solution. 10 mg of bromophenol blue
(BDH water soluble) in 20 mL of pyrogen-free water.
4. Water saturated butan -2-ol. Place 60mL butan-2-ol (BDH Analar) into a 100 mL
screw-capped bottle. Add pyrogen-free water, 10 mL at a time, mix thoroughly.
5 Electrode buffer. 0.025 M Tris, 0.192 M glycine, 0.1% SDS, pH 8.3.
6.057g Tris (hydroxymethyl) methylamine (BDH Analar), 28.827g glycine (BDH
chromatographically homogeneous). 2g sodium lauryl sulphate (SDS) (BDH especially
pure). Pyrogen-free water to 2000mL.
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6. Separating gel buffer (double strength). 0.75 M Tris/HCI pH 8.8, 0.2% SDS.
90.885 g Tris (hydroxymethyl) methylamine (BDH Analar)
2g sodium lauryl sulphate (SDS) (BDH especially pure)
5 M and 1M hydrochloric acid (BDH Analar)
Pyrogen-free water to 500 ml_.
7. Stacking gel buffer (double strength). 0.25M Tris/HCI pH 6.8, 0.2% SDS.
15.142g Tris (hydroxymethyl) methylamine (BDH Analar)
1 g sodium lauryl sulphate (SDS) (BDH especially pure)
5 M and 1M hydrochloric acid (BDH Analar)
Pyrogen-free water to 500 ml_.
8 Sample buffer (single strength). 0.0625 M Tris/HCI pH 6.8, 2% SDS, 10%
glycerol, 1% 2-mercaptoethanol, 0.001% bromophenol blue.
0.757g Tris (hydroxymethyl) methylamine (BDH analar), 2g Sodium lauryl sulphate
(SDS) (BDH especially pure), 12.6g glycerol (BDH analar) (=10% v/v glycerol)
1 ml_ 2 mercaptoethanol (BDH), 2ml_ Bromophenol blue (0.05% aqueous solution)
(BDH water soluble), 1 M HCI. Pyrogen-free water to 100mL.
[ SDS-free gel buffer is prepared as above but omitting the SDS]
9 Sample buffer (double strength). 0.125 M Tris/HCI pH 6.8, 4% SDS, 20%
glycerol, 2% 2-mercaptoethanol, 0.002% bromophenol blue.
1.514g Tris (hydroxymethyl) methylamine (BDH Analar).
4g sodium lauryl sulphate (SDS) (BDH especially pure). 25.2 g Glycerol (BDH analar)
(=20% v/v glycerol). 2 mL 2-mercaptoethanol (BDH). 4mL Bromophenol blue (0.05%
aqueous solution) (BDH water soluble). 1 M HCI. Pyrogen-free water to 100mL.
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Silver stain reagents
1. Fixative. 25% propan-2-ol, 7% acetic acid.
500mL propan-2-ol (BDH GPR)
140 mL glacial acetic acid (BDH Analar)
1360 mL distilled water.
2. Oxidizer. 0.7% periodic acid in dilute fixative.
1.05g periodic acid (BDH Analar)
4mL of fixative and 150mL of distilled water.
Dissolve the periodic acid in the water and add the fixative.
3 Silver stain (Ammoniacal silver nitrate).
a) Ammonia solution (BDH Analar, SG 0.88).
b) 0.36% sodium hydroxide solution (BDH Analar)
3.6g NaOH, lOOOmL distilled water. Dissolve the NaOH in the water in a glass screw-
capped bottle.
c) 19.4% silver nitrate solution
19.4g silver nitrate (BDH Analar)
Distilled water to 100mL
Dissolve the AgN03 in about 70 mL distilled water and make up to 100 mL with
distilled water.
Complete stain (Ammoniacal silver nitrate) (work in a fume cupboard). In a 100mL
flask kept specifically for this reagent, mix 21 mL 0.36% NaOH and 1.4 mL ammonia
solution. Then add dropwise with continual mixing 4mL 19.4% silver nitrate solution. A
dense brown precipitate forms on adding the silver nitrate, but the mixture becomes
colourless on mixing.
4. Developer. 0.005% citric acid in 0.019% formaldehyde solution.
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1mL of formaldehyde solution (BDH Analar, 38-40%)
2000 mL distilled water.
The complete developer is made up as follows:
10mg citric acid (BDH)
200 mL 0.19% formaldehyde solution.
Reagents for Coomassie blue staining
Reagent No Coomassie
brilliant R-250
1
2
3
4
ig
100mg
48 mg
Propan-2-ol Methanol
(GPR) (GPR)
500 mL
200 mL
Acetic acid Distilled
(Analar) water
200 mL
200 mL
200 mL
800 mL 200 mL
1300 mL
1600 mL
1800 mL
1000mL
200 mL 1800 mL
ECP Reagents
Included in the kit
• ECP (human) Standards 0,2,5,15,100,200 pg/L
• ECP 1251
• Anti-ECP
• Decanting suspension (Sepharose R anti-rabbit IgG raised in sheep)
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The Lavage solution
Commercially available as " Klean- Prep" from Norgine Ltd, Oxford, UK.
One sachet to be made up to one litre by adding tap water which contains:
• Polyethylene glycol (PEG), molecular weight of 3350 - 59g/L tap water (Osmolality
260 mosm/L)
• Sodium chloride (BP 1,4g)
• Sodium bicarbonate (BP 1.63g)
• Sodium bisulphate (BP 5.68g)
• Potassium chloride (BP 0.75g)
2. Instrumentation
• Centrifuge:
Mistral 3000I (MSE.UK)
• ELISA Reader:
Dynatech MR 500 (Dynatech)
• Freeze Dryer:
Heto CT 60E (HETO Lab Equipment)
• Shaker:
Denley Wellmix 1
• Spectrophotometer:
Pye Unicam PU 8610 UV/VIS (Philips)
• Vortex Mixer:
Rotamixer Deluxe (Hook & Tucker)
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